<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Oncotarget</journal-id>
<journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id>
<journal-id journal-id-type="publisher-id">Oncotarget</journal-id>
<journal-id journal-id-type="publisher-id">ImpactJ</journal-id>
<journal-title-group>
<journal-title>Oncotarget</journal-title>
</journal-title-group>
<issn pub-type="epub">1949-2553</issn>
<publisher>
<publisher-name>Impact Journals LLC</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29467963</article-id>
<article-id pub-id-type="pmc">5805549</article-id>
<article-id pub-id-type="publisher-id">24102</article-id>
<article-id pub-id-type="doi">10.18632/oncotarget.24102</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Korbecki</surname>
<given-names>Jan</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="A2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutowska</surname>
<given-names>Izabela</given-names>
</name>
<xref ref-type="aff" rid="A3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kojder</surname>
<given-names>Ireneusz</given-names>
</name>
<xref ref-type="aff" rid="A4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="A5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jeżewski</surname>
<given-names>Dariusz</given-names>
</name>
<xref ref-type="aff" rid="A4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="A5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goschorska</surname>
<given-names>Marta</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Łukomska</surname>
<given-names>Agnieszka</given-names>
</name>
<xref ref-type="aff" rid="A3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lubkowska</surname>
<given-names>Anna</given-names>
</name>
<xref ref-type="aff" rid="A6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chlubek</surname>
<given-names>Dariusz</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baranowska-Bosiacka</surname>
<given-names>Irena</given-names>
</name>
<xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="A1"><sup>1</sup> Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland</aff>
<aff id="A2"><sup>2</sup> Department of Biochemistry and Molecular Biology, Faculty of Health Sciences, University of Bielsko-Biała, 43-309 Bielsko-Biała, Poland</aff>
<aff id="A3"><sup>3</sup> Department of Biochemistry and Human Nutrition, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland</aff>
<aff id="A4"><sup>4</sup> Department of Applied Neurocognitivistics, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland</aff>
<aff id="A5"><sup>5</sup> Department of Neurosurgery, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland</aff>
<aff id="A6"><sup>6</sup> Department of Functional Diagnostics and Physical Medicine, Pomeranian Medical University in Szczecin, 71-210 Szczecin, Poland</aff>
<author-notes>
<corresp id="cor1">
<bold>
<italic>Correspondence to:</italic>
</bold>
<italic>Irena Baranowska-Bosiacka,</italic>
<email>irena.bosiacka@pum.edu.pl</email>
</corresp>
</author-notes>
<pub-date pub-type="collection">
<day>23</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>9</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>9</volume>
<issue>6</issue>
<fpage>7219</fpage>
<lpage>7270</lpage>
<history>
<date date-type="received">
<day>12</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2018 Korbecki et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License 3.0</ext-link> (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<abstract>
<p>Recent years have seen considerable progress in understanding the biochemistry of cancer. For example, more significance is now assigned to the tumor microenvironment, especially with regard to intercellular signaling in the tumor niche which depends on many factors secreted by tumor cells. In addition, great progress has been made in understanding the influence of factors such as neurotensin, growth differentiation factor-15 (GDF-15), sphingosine-1-phosphate (S1P), and infection with cytomegalovirus (CMV) on the ‘hallmarks of cancer’ in glioblastoma multiforme.</p>
<p>Therefore, in the present work we describe the influence of these factors on the proliferation and apoptosis of neoplastic cells, cancer stem cells, angiogenesis, migration and invasion, and cancer immune evasion in a glioblastoma multiforme tumor. In particular, we discuss the effect of neurotensin, GDF-15, S1P (including the drug FTY720), and infection with CMV on tumor-associated macrophages (TAM), microglial cells, neutrophil and regulatory T cells (T<sub>reg</sub>), on the tumor microenvironment. In order to better understand the role of the aforementioned factors in tumoral processes, we outline the latest models of intratumoral heterogeneity in glioblastoma multiforme. Based on the most recent reports, we discuss the problems of multi-drug therapy in treating glioblastoma multiforme.</p>
</abstract>
<kwd-group>
<kwd>glioblastoma multiforme</kwd>
<kwd>cytomegalovirus</kwd>
<kwd>neurotensin</kwd>
<kwd>growth differentiation factor-15</kwd>
<kwd>sphingosine-1-phosphate</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>INTRODUCTION</title>
<p>One of the most lethal cancers, glioblastoma multiforme (GBM) is the most common cancer of the glial cells, with an incidence of about 3/100,000 persons per year [<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R2">2</xref>]. The basic procedure for GBM patients with clinical symptoms caused by the mass effect is surgical treatment (cytoreduction), which is also used to obtain material for histopathological examination. It should be combined with other methods such as radiotherapy, or in another variant chemotherapy with fotemustine or cyclically administered temozolomide (TMZ) or angiogenesis-inhibiting bevacizumab. Other methods, including immunotherapy, continue to be studied [<xref ref-type="bibr" rid="R3">3</xref>].</p>
<p>GBM has been subject to highly intense research due to the very low five-year post-operative survival rate, estimated to be only 9.8% [<xref ref-type="bibr" rid="R4">4</xref>]. In particular, researchers focus on intercellular signaling in the GBM tumor, i.e. autocrine influence of factors secreted by the GBM cells on themselves and the remaining cells in the niche. This has resulted in significant progress over the last 4 years in the understanding of the previously little known secretory factors such as neurotensin (NT), growth differentiation factor-15 (GDF-15), sphingosine-1-phosphate S1P, and of infection with cytomegalovirus (CMV). In this paper, we begin the discussion of these factors with the issue of intratumoral heterogeneity.</p>
</sec>
<sec id="s2">
<title>INTRATUMORAL HETEROGENEITY OF GLIOBLASTOMA</title>
<p>The population of tumor cells is not homogenous. It consists of genetically and epigenetically diverse tumor cells [<xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R6">6</xref>] with different expressions of mRNA [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R7">7</xref>] and proteins [<xref ref-type="bibr" rid="R8">8</xref>]. This intratumoral heterogeneity in GBM was first reported in the 1980s [<xref ref-type="bibr" rid="R9">9</xref>]. Thanks to increasingly precise and sensitive research methods in which proteome, transcriptome and genome analysis can be performed on single cells, recent research shows in detail the differentiation of cancer cells in a GBM tumor [<xref ref-type="bibr" rid="R10">10</xref>].</p>
<sec id="s2_1">
<title>Formation of intratumoral heterogeneity</title>
<p>Due to the uncontrolled division of cancer cells, a tumor has a much larger number of changed cells at the onset of neoplasm. The divisions result in the accumulation of genetic changes, and over time the environment within the tumor becomes increasingly diverse. In particular, selection pressure is exerted by the distribution of necrotic areas, different concentrations of oxygen including hypoxia [<xref ref-type="bibr" rid="R11">11</xref>], metabolic compounds, and tissue hormones, and the placement of unaltered tumor-building cells. Selected in a Darwinian-like manner [<xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R12">12</xref>], different tumor cell lines are formed with various mechanisms of bypassing cancer resistance mechanisms, exhibiting properties described as the ‘hallmarks of cancer’ [<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref>].</p>
<p>Intratumoral heterogeneity seems to depend primarily on cancer stem cells, forming a small and rarely dividing population in a tumor [<xref ref-type="bibr" rid="R15">15</xref>]. During division they form a stem cell and a rapidly dividing cancer cell. The latter cells have a limited number of divisions and by definition do not form tumors in animals inoculated with them. However, according to most recent research, the differentiated GBM cells are able to dedifferentiate into glioblastoma stem cells (GSC) [<xref ref-type="bibr" rid="R16">16</xref>]. This partly refutes the theory of intratumoral heterogeneity based solely on cancer stem cells, and indicates that both stem and differentiated cells are responsible for the diversity of tumor cell lines [<xref ref-type="bibr" rid="R16">16</xref>].</p>
</sec>
<sec id="s2_2">
<title>Intratumoral heterogeneity in the development of glioblastoma</title>
<p>Mutations in the development of individual GBM lines are not haphazard. Sottoriva et al. show that they can be organized into three stages [<xref ref-type="bibr" rid="R10">10</xref>]. First, very characteristic changes occur on chromosome 7, with the amplification of the fragment with epidermal growth factor receptor (<italic>EGFR)</italic>, cyclin-dependent kinase (<italic>CDK)6</italic>, and <italic>MET</italic> genes. It is also highly likely that deletion occurs on chromosome 10 with the <italic>PTEN</italic> gene. This stage is also characterized by deletion of the chromosome 9 fragment with the cyclin-dependent kinase inhibitor 2A and 2B (<italic>CDKN2A/B</italic>) gene.</p>
<p>The next stages of tumor growth include very different mutations on different chromosomes, which results in a very large diversity of tumor cell lines within a single tumor. These include changes on chromosome 17 with <italic>P53</italic> and neurofibromin 1 (<italic>NF1)</italic> genes, or on chromosome 4 with solute carrier family 2 member 9 (<italic>SLC2A9/GLUT9)</italic> gene, and platelet-derived growth factor (<italic>PDGFR)A</italic> amplification [<xref ref-type="bibr" rid="R10">10</xref>]. Also mutations of this type occur later in GBM recurrences, resulting in considerable genetic differences between the GBM cells in the relapse sites and the parent tumor [<xref ref-type="bibr" rid="R8">8</xref>].</p>
<p>The probability of each mutation depends on the tumor microenvironment and the selection of individual clones by anti-cancer mechanisms. Of particular significance is the location of the tumor in the brain; e.g. periventricularly located GBM has a higher expression of factors such as vascular endothelial growth factor (VEGF)-C or hepatocyte growth factor (HGF) than at cortical locations [<xref ref-type="bibr" rid="R17">17</xref>].</p>
<p>Intratumoral heterogeneity results in the creation of a tumor with a specific cell distribution pattern. GBM cells with amplified <italic>PDGFRA</italic> form a compact population surrounded by cells with amplified <italic>EGFR</italic> [<xref ref-type="bibr" rid="R18">18</xref>]. The accumulation of changes results in the formation of specific GBM subtypes: classical, mesenchymal, neural, and proneural [<xref ref-type="bibr" rid="R5">5</xref>]. In each GBM tumor there is a proneural cell population [<xref ref-type="bibr" rid="R5">5</xref>], while the other subtypes may occur in very low numbers or not at all. However, there have been no studies showing the detailed structures formed by cancer cells.</p>
</sec>
<sec id="s2_3">
<title>Functional domains of the tumor</title>
<p>Experiments on neurospheres derived from stabilized GBM cell lines demonstrate that these tumor cells are interdependent and specialized in specific functions [<xref ref-type="bibr" rid="R19">19</xref>]. In particular, tumor cells co-operate with each other for specific purposes in cancer development [<xref ref-type="bibr" rid="R20">20</xref>]. An example of this are the mesenchymal GBM cells, which contain many more proteins associated with immunosuppression [<xref ref-type="bibr" rid="R21">21</xref>]. Thanks to this they can participate in cancer immune evasion. However, intratumoral functional domains require further research which could open new possibilities for effective antitumor therapies.</p>
</sec>
<sec id="s2_4">
<title>Impact on therapy</title>
<p>GBM cell differentiation in a single tumor in terms of resistance to anti-cancer drugs has very negative consequences for therapy. It is estimated that 1/4 of tumor clones are resistant to TMZ and only 1/10 are very susceptible to the drug [<xref ref-type="bibr" rid="R22">22</xref>]. Such a scope of resistance in a GBM tumor is similar for other anti-cancer drugs [<xref ref-type="bibr" rid="R22">22</xref>] This has important implications for therapy, because the use of an anti-cancer drug, including TMZ, destroys only those cells which are susceptible to the drug, but leaves other cells that are resistant to it [<xref ref-type="bibr" rid="R22">22</xref>]. Within a few months of chemotherapy, new tumors in relapse sites are formed by GBM cells which survive treatment [<xref ref-type="bibr" rid="R4">4</xref>]. This results in a five-year survival rate of 10% in patients after chemotherapy with TMZ.</p>
<p>Some hope lies in studying the cancer microenvironment, in particular interactions between the tumor niche and cancer cells, and the intercellular signaling in the tumor microenvironment. These processes depend on many secretion factors (Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Secretory factors in normal tissue and in the tumor microenvironment</title>
<p>Secretory factors responsible for the ‘hallmarks of cancer’ occur in low concentrations in non-cancerous tissue. However, the development of a tumor increases the concentration of these factors. This process is non-specific and so the combinations and levels of secretory factors vary among tumors and even within a single tumor.</p>
</caption>
<graphic xlink:href="oncotarget-09-7219-g001"></graphic>
</fig>
<p>GBM has been studied extensively for NT, GDF-15, S1P, and infection with CMV, which play important roles in tumor processes, in particular the viability, migration and invasion of tumor cells, GSC, angiogenesis, and tumor immune escape (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>The influence of secretory factors on the ‘hallmarks of cancer’</title>
<p>Cancer cells secrete various secretory factors into the tumor microenvironment. The total pool of these secretory factors affects the hallmarks of cancer, in particular via autocrine stimulation of tumor cell proliferation, angiogenesis, migration and invasion, and tumor immune escape.</p>
</caption>
<graphic xlink:href="oncotarget-09-7219-g002"></graphic>
</fig>
</sec>
</sec>
<sec id="s3">
<title>CYTOMEGALOVIRUS</title>
<sec id="s3_1">
<title>Cytomegalovirus as a carcinogenic factor in glioblastoma</title>
<p>CMV is a DNA virus of the β-herpesvirinae subfamily, carried by more than half the global population [<xref ref-type="bibr" rid="R23">23</xref>]. Since Cobbs et al. demonstrated the expression of CMV in all GBMs [<xref ref-type="bibr" rid="R24">24</xref>], the incidence of CMV infection in the tumor has been widely discussed. Several research groups have confirmed the occurrence of CMV DNA and the expression of antigens of the proteins encoded by its genome in almost 100% GBMs [<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R32">32</xref>].</p>
<p>Other research groups have also confirmed the presence of CMV in GBM, although only in 36% (27/75) [<xref ref-type="bibr" rid="R33">33</xref>], 51% (25/49) [<xref ref-type="bibr" rid="R34">34</xref>] and 75% (12/16) [<xref ref-type="bibr" rid="R35">35</xref>] of the tumors studied. In addition, other research groups have shown a lack of CMV infection in samples of brain slices affected by GBM [<xref ref-type="bibr" rid="R36">36</xref>–<xref ref-type="bibr" rid="R39">39</xref>]. They also postulate a false positive in other research groups due to the cross-reactivity of antibodies with non-viral proteins such as myelin basic protein or human serum albumin [<xref ref-type="bibr" rid="R38">38</xref>]. Some also postulate a false positive caused by non-specific immunocytochemistry staining of glial cells with gemistocytic morphology [<xref ref-type="bibr" rid="R36">36</xref>].</p>
</sec>
<sec id="s3_2">
<title>Epidemiology of the cytomegalovirus</title>
<p>CMV infection occurs in more than a half of the global population, with the likelihood of infection increasing with age [<xref ref-type="bibr" rid="R40">40</xref>–<xref ref-type="bibr" rid="R44">44</xref>]. Forty percent of people under 10 years of age are carriers of this virus. Higher age is associated with a higher likelihood of contracting and carrying this virus. In older people, the virus is estimated to have infected 70%-90% of the population, depending on the population studied. Although this high number of CMV carriers is not reflected in the incidence of GBM (3/100,000 persons/year [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>]), numerous studies show that the virus does increase the aggressiveness of GBM [<xref ref-type="bibr" rid="R45">45</xref>–<xref ref-type="bibr" rid="R51">51</xref>].</p>
</sec>
<sec id="s3_3">
<title>Tumor microenvironment and cytomegalovirus</title>
<p>The appearance of CMV in GBM may be caused by an immunosuppressive microenvironment of the tumor, as CMV infection is completely controlled by a healthy immune system [<xref ref-type="bibr" rid="R52">52</xref>–<xref ref-type="bibr" rid="R55">55</xref>]. Particularly crucial here is the NK cell response [<xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R53">53</xref>, <xref ref-type="bibr" rid="R55">55</xref>]. As a result, the virus exists in the body in a latent form and is reactivated when immunity reduces, e.g. as a result of the action of immunosuppressive drugs after transplantation [<xref ref-type="bibr" rid="R56">56</xref>, <xref ref-type="bibr" rid="R57">57</xref>]. The tumor microenvironment, in particular in GBM, also involves intensive immunosuppression processes that cause the immune evasion of cancer cells (Figure <xref ref-type="fig" rid="F3">3</xref>) [<xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R59">59</xref>]. This allows an intensive replication of CMV in GBM [<xref ref-type="bibr" rid="R60">60</xref>].</p>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<title>The carcinogenic effect of CMV on different cells</title>
<p>CMV affects cells in the tumor niche, particularly macrophages and astrocytes which affects the tumor immune escape. CMV also affects cancer cells. It stimulates migration and invasion GSC, stimulates divisions and disturbs apoptosis. CMV in the tumor cell is responsible for the tumor immune escape via the production of vIL-10.</p>
</caption>
<graphic xlink:href="oncotarget-09-7219-g003"></graphic>
</fig>
</sec>
<sec id="s3_4">
<title>Effect of cytomegalovirus on the tumor niche and tumor immune escape</title>
<p>Due to the lack of appropriate research models, little is known about the direct influence of CMV on processes occurring in the GBM tumor niche. Nevertheless, <italic>in vitro</italic> experiments with CMV infection of various cell types have made it possible to develop a model of the interaction between this factor and processes occurring in the tumor niche.</p>
</sec>
<sec id="s3_5">
<title>From monocytes with latent infection to lytic infection in the tumor</title>
<p>CMV is present in CD34<sup>+</sup> bone-marrow progenitors, and consequently it also occurs in peripheral blood mononuclear cells during differentiation of the progenitors into monocytes [<xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R62">62</xref>]. CMV does not cause lytic infection of monocytes; it is latent in these cells [<xref ref-type="bibr" rid="R63">63</xref>]. However, even during latent infections, the CMV reprograms the expression profile of some of the genes in the monocytes. In this state, only a small number of viral genes [<xref ref-type="bibr" rid="R64">64</xref>] are expressed.</p>
<p>Studies have shown increased expression of viral chemokine scavenger receptor US28 that stimulates the migration of infected cells in response to a wide spectrum of chemokines [<xref ref-type="bibr" rid="R65">65</xref>, <xref ref-type="bibr" rid="R66">66</xref>]. US28 increases migration especially in response to C-X3-C motif chemokine ligand (CX3CL)1/fractalkine [<xref ref-type="bibr" rid="R67">67</xref>] and to a lesser extent in response to chemokines such as CC motif chemokine ligand (CCL)2/monocyte chemoattractant protein 1 (MCP-1), CCL3/macrophage inflammatory protein (MIP)-1α, CCL4/MIP-1β and CCL5/regulated on activation, normal T-cell expression and secretion (RANTES) [<xref ref-type="bibr" rid="R65">65</xref>, <xref ref-type="bibr" rid="R67">67</xref>].</p>
<p>The effect of individual chemokines is cell-specific and depends on the type of cell where the expression of US28 has taken place [<xref ref-type="bibr" rid="R67">67</xref>]. Also, simultaneous activation of CX3CL1/fractalkine together with CCL2/MCP-1 or CCL5/RANTES on US28 results in no migration of monocytes or macrophages that are expressing this receptor [<xref ref-type="bibr" rid="R67">67</xref>, <xref ref-type="bibr" rid="R68">68</xref>]. If in the tumor microenvironment there are also other chemokines (i.e. in addition to CX3CL1/fractalkine), then it results in the inhibition of US28-dependent monocyte and macrophage migration.</p>
<p>CX3CL1/fractalkine is mainly secreted by neurons [<xref ref-type="bibr" rid="R69">69</xref>]. In physiological conditions it shows a neuroprotective action, suppressing excessive activation of microglial cells by proinflammatory agents, e.g., LPS or CMV [<xref ref-type="bibr" rid="R70">70</xref>, <xref ref-type="bibr" rid="R71">71</xref>]. CX3CL1/fractalkine is also produced by GSC [<xref ref-type="bibr" rid="R72">72</xref>] and TAM in the GBM niche [<xref ref-type="bibr" rid="R73">73</xref>], which may result in the recruitment of monocytes with latent CMV infection expressing US28. The action of this chemokine may also affect the location of infected TAM and other cells throughout the tumor niche [<xref ref-type="bibr" rid="R66">66</xref>, <xref ref-type="bibr" rid="R67">67</xref>].</p>
<p>The use of antibodies neutralizing CX3CL1/fractalkine results in a decrease in the intensity of the migration of TAM and microglia isolated from GBM tumors. Nevertheless, the use of CX3CR1-neutralizing antibodies, which are the specific receptor for this chemokine, causes the same decrease in the intensity of migration of these cells [<xref ref-type="bibr" rid="R74">74</xref>]. This demonstrates that in the tumor microenvironment in these cells, it is CX3CL1/fractalkine with CX3CR1, but not viral US28, that are responsible for the migration of TAM and microglial cells. The effect of CX3CL1/fractalkine-dependent TAM and microglial cells in the context of CMV infection requires further research, especially with regard to the recruitment of monocytes with latent CMV infection.</p>
<p>After the migration into the tumor niche, monocytes differentiate into macrophages [<xref ref-type="bibr" rid="R75">75</xref>]. This differentiation of monocytes with latent infection into macrophages often causes CMV reactivation [<xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R62">62</xref>]. CMV reactivation can also be caused by granulocyte-colony stimulating factor (G-CSF) [<xref ref-type="bibr" rid="R76">76</xref>], a cytokine produced in the GBM tumor [<xref ref-type="bibr" rid="R77">77</xref>]. These facts may explain the presence of active CMV infection in GBM.</p>
</sec>
<sec id="s3_6">
<title>Cytomegalovirus as a oncogenic factor: effect on apoptosis and proliferation</title>
<p>Some researchers suggest that CMV occurs in almost all GBMs and the incidence of CMV in GBM tumors is positively correlated with the grade of the tumor. Indeed, almost all GBM samples with the highest grades have been reported to contain the antigens or DNA of this virus [<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R32">32</xref>]. This indicates that CMV plays an important role in the development of GBM. As demonstrated by <italic>in vitro</italic> experiments, the virus enters GBM cells through EGFR [<xref ref-type="bibr" rid="R78">78</xref>] or PDGFR-α (Figure <xref ref-type="fig" rid="F4">4</xref>) [<xref ref-type="bibr" rid="R79">79</xref>]. These receptors are important for GBM cells and are often amplified and overexpressed [<xref ref-type="bibr" rid="R80">80</xref>, <xref ref-type="bibr" rid="R81">81</xref>]. CMV has a particular tropism to GSC in which it enhances the stem cell phenotype [<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R50">50</xref>]. CMV in tumor cells disrupts apoptosis in many ways, especially via the viral proteins, such as activation of the viral inhibitor caspase-8 and the viral mitochondria-localized inhibitor of apoptosis, homolog of anti-apoptotic Bcl-2 [<xref ref-type="bibr" rid="R82">82</xref>]. In addition, the immediate early 86 (IE86) viral protein initiates activating transcription factor 5 (ATF5), an anti-apoptotic protein commonly found in GBM [<xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R83">83</xref>]. The IE86 protein also causes changes in the level of histone acetylation, which changes the expression of many genes in GBM cells [<xref ref-type="bibr" rid="R31">31</xref>]. In addition to its effect on apoptosis, CMV also affects cell division. It enhances the expression of telomerase, an enzyme essential for unlimited cancer cell divisions [<xref ref-type="bibr" rid="R84">84</xref>]. Viral proteins also reduce the expression of Rb and p53 proteins, which are important for regulating cell division [<xref ref-type="bibr" rid="R45">45</xref>, <xref ref-type="bibr" rid="R85">85</xref>–<xref ref-type="bibr" rid="R87">87</xref>]. In addition, CMV proteins alter the expression of cell cycle cyclins, halting the division of normal cells and favoring viral DNA replication [<xref ref-type="bibr" rid="R88">88</xref>, <xref ref-type="bibr" rid="R89">89</xref>]. However, as a result of tumor changes, this mechanism is impaired and CMV in some GBM cell lines induces cell division [<xref ref-type="bibr" rid="R45">45</xref>]. Another mechanism in which viral proteins promote GBM growth is the activation of the PDGFR-α and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (PKB) pathways, i.e., pathways crucial for the stimulation of GBM proliferation [<xref ref-type="bibr" rid="R45">45</xref>, <xref ref-type="bibr" rid="R90">90</xref>, <xref ref-type="bibr" rid="R91">91</xref>].</p>
<fig id="F4" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<title>The cytoplasmic effect of CMV infection</title>
<p>CMV virions enter cells via the PDGFR-α or EGFR receptors. The viral proteins transmit the signal that causes changes characteristic for cancer. In particular, the US28 viral receptor is involved in angiogenesis, migration and invasion. vIL-10 is involved in tumor immune escape.</p>
</caption>
<graphic xlink:href="oncotarget-09-7219-g004"></graphic>
</fig>
</sec>
<sec id="s3_7">
<title>Effect on angiogenesis and tumor dissemination</title>
<p>In addition to the effect on replication, CMV increases angiogenesis and GBM dissemination. The CMV genome encodes the US28 receptor, a homolog of the receptor for the CC chemokine family, responsible for the disruption of the immune response against CMV [<xref ref-type="bibr" rid="R23">23</xref>]. US28 increases the expression of VEGF by increasing interleukin (IL)-6 expression and activating the hypoxia inducible factor (HIF)-1α/pyruvate kinase M2 (PKM2) pathway [<xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R92">92</xref>–<xref ref-type="bibr" rid="R94">94</xref>]. IL-6 activates its receptor and signal transducer and activator of transcription (STAT)3, which then expresses VEGF. In addition to the effects on VEGF, CMV also reduces the expression of thrombospondin-1, an angiogenesis inhibitor [<xref ref-type="bibr" rid="R87">87</xref>]. CMV infection of the GBM cells also results in increased expression of endocan, a compound associated with the remodeling of the blood vessels and angiogenesis [<xref ref-type="bibr" rid="R95">95</xref>].</p>
<p>CMV also participates in a very characteristic sign of GBM, i.e., early cancer dissemination. US28 activates focal adhesion kinase (FAK) via phospholipase C-β (PLC-β), an enzyme reducing the adhesion of cells, which results in the migration of GBM [<xref ref-type="bibr" rid="R93">93</xref>, <xref ref-type="bibr" rid="R94">94</xref>, <xref ref-type="bibr" rid="R96">96</xref>, <xref ref-type="bibr" rid="R97">97</xref>]. Another way of dissemination is in increased expression of matrix metalloproteinase (MMP)2 [<xref ref-type="bibr" rid="R35">35</xref>]. However, the mechanisms of CMV's influence on GBM cells requires further research and more detailed understanding, in particular regarding the activation of the human endogenous retrovirus [<xref ref-type="bibr" rid="R98">98</xref>].</p>
<p>Another mechanism of CMV-induced angiogenesis in GBM is intensification of the stem cell phenotype [<xref ref-type="bibr" rid="R48">48</xref>]. Finally, the CMV genome contains a UL7 protein, similar to the N-terminal V-like domain of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), inducing vasculogenesis and migration of endothelial cells [<xref ref-type="bibr" rid="R99">99</xref>].</p>
</sec>
<sec id="s3_8">
<title>Effect on cancer cells in cancer immune evasion</title>
<p>CMV affects the communication between the tumor cell and the cell of the tumor microenvironment. In particular, the virus causes immune evasion of the infected cancer cell, especially GSC [<xref ref-type="bibr" rid="R46">46</xref>]. It disrupts major histocompatibility complex (MHC) I: human leukocyte antigen (HLA)-A, HLA-B and HLA-C, expression of which makes it impossible to recognize the altered antigens on the tumor cell by immune cells [<xref ref-type="bibr" rid="R100">100</xref>–<xref ref-type="bibr" rid="R104">104</xref>].</p>
<p>In infected cells CMV also reduces the expression of surface HLA-G and increases the levels of soluble HLA-G, as evidenced by experiments on U-373 MG astrocytoma cells [<xref ref-type="bibr" rid="R105">105</xref>, <xref ref-type="bibr" rid="R106">106</xref>]. HLA-G is a non-classical molecule of MHC I that plays an important role in maternal-fetal tolerance [<xref ref-type="bibr" rid="R107">107</xref>] but is also a carcinogenic factor [<xref ref-type="bibr" rid="R108">108</xref>]. Lowering surface HLA-G expression and increasing the expression of soluble HLA-G by CMV is a mechanism of viral attack on the host immune response.</p>
<p>There are cytotoxic T cells in the human body that recognize CMV antigens response restricted by HLA-G [<xref ref-type="bibr" rid="R109">109</xref>]. However, in the tumor microenvironment, the increased amount of soluble HLA-G has an immunosuppressive effect [<xref ref-type="bibr" rid="R108">108</xref>, <xref ref-type="bibr" rid="R110">110</xref>]. Although the degradation of surface HLA-G may stimulate an antitumor immune response, at the same time numerous cancer immune evasion mechanisms occur in the tumor microenvironment.</p>
<p>CMV infection of GBM cells also results in increased expression of arginase-2 [<xref ref-type="bibr" rid="R111">111</xref>] and FasL [<xref ref-type="bibr" rid="R112">112</xref>], which interfere with cancer-related immunosuppression. In an infected cell, CMV also induces the production of viral interleukin-10 (vIL-10) with an immunosuppressive action [<xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R113">113</xref>, <xref ref-type="bibr" rid="R114">114</xref>]. Infected cells also produce various chemokines that cause chemotaxis of various cells to the site of the CMV infection. If a CMV infection focus is present in the GBM tumor, then these infected cells maybe be recruited into the tumor niche.</p>
</sec>
<sec id="s3_9">
<title>Effect of cytomegalovirus on astrocytes</title>
<p>CMV has a high tropism for astrocytes and therefore these cells play an important role in CMV infection of the brain [<xref ref-type="bibr" rid="R115">115</xref>]. CMV has tropism for neural stem cells and immature glia cells in the subventricular zone [<xref ref-type="bibr" rid="R116">116</xref>, <xref ref-type="bibr" rid="R117">117</xref>], and for GSC in the tumor niche [<xref ref-type="bibr" rid="R46">46</xref>]. CMV is also replicated in other cells, including nerve cells [<xref ref-type="bibr" rid="R118">118</xref>]. Infection in the brain is followed by chronic inflammation in this organ. Viral processes and the fight against CMV crucially depend on the production of chemokines, i.e. cytokines with chemotactic activity.</p>
<p>In the first stage of infection, astrocytes increase the expression of chemokines such as CCL2/MCP-1, CCL3/MIP-1α and IL-8/CXC motif chemokine ligand (CXCL)8, but not CCL5/RANTES. However, the infected astrocytes do not produce an increased amount of proinflammatory cytokines such as IL-1β, IL-6 or tumor necrosis factor α (TNF-α) [<xref ref-type="bibr" rid="R119">119</xref>]. Chemokines enable the chemotaxis of immune cells responsible for the fight against CMV infection. In combination with pro-inflammatory cytokines [<xref ref-type="bibr" rid="R120">120</xref>, <xref ref-type="bibr" rid="R121">121</xref>] produced by other immune system cells such as NK cells, NKT cells, microglial cells [<xref ref-type="bibr" rid="R89">89</xref>, <xref ref-type="bibr" rid="R122">122</xref>], CD4<sup>+</sup> T-cells [<xref ref-type="bibr" rid="R123">123</xref>] and CD8<sup>+</sup> T-cells [<xref ref-type="bibr" rid="R124">124</xref>], the fight against CMV infection can proceed. CMV also causes a decrease in the expression of CCR5, which interferes with the chemotaxis of these cells in response to chemokines [<xref ref-type="bibr" rid="R125">125</xref>]. This effect is dependent on viral protein UL128, which is included in the envelope of the CMV virion [<xref ref-type="bibr" rid="R126">126</xref>]. During cell infection, this protein degrades several chemokine receptors, not just CCR5, to interfere with chemo-dependent migration of infected cells.</p>
<p>Chemokines which play an important role in fighting CMV infection in an immunosuppressive cancer microenvironment can support tumor processes. Secreted by cells infected with CMV, chemokines act as chemoattractants for regulatory T cells (T<sub>reg</sub>), microglia, neutrophils and monocytes. These cells are recruited into the GBM tumor niche where they participate in tumor processes [<xref ref-type="bibr" rid="R59">59</xref>, <xref ref-type="bibr" rid="R127">127</xref>–<xref ref-type="bibr" rid="R129">129</xref>]. CMV infection results in increased expression and secretion of cytokines that may contribute to the formation of the immunosuppressive cancer microenvironment. In particular, expression of vIL-10 in astrocytes plays a crucial role in immunosuppressive mechanisms [<xref ref-type="bibr" rid="R122">122</xref>, <xref ref-type="bibr" rid="R130">130</xref>]. This cytokine reduces the production of CXCL10/IP-10 chemokine in infected microglial cells and thus reduces recruitment of lymphocytes that fight against CMV and tumor cells [<xref ref-type="bibr" rid="R122">122</xref>]. vIL-10 also causes differentiation of monocytes into immunosuppressive macrophages with a M2c phenotype [<xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R130">130</xref>]. In the infected astrocytes transforming growth factor β (TGF-β) is expressed, an immunosuppressive cytokine having a key function in the development of GBM [<xref ref-type="bibr" rid="R131">131</xref>].</p>
<p>In addition to the effects on immune responses, CMV in astrocytes disrupts the uptake of glutamate [<xref ref-type="bibr" rid="R132">132</xref>]. This results in an increase in the concentration of this amino acid and cell toxicity in the CMV infection microenvironment [<xref ref-type="bibr" rid="R132">132</xref>]. This feature is shared with GBM [<xref ref-type="bibr" rid="R133">133</xref>]. However, there are no studies on CMV dependence on cytotoxic concentrations of glutamate in the GBM microenvironment.</p>
</sec>
<sec id="s3_10">
<title>Effect of cytomegalovirus on microglial cells</title>
<p>CMV infection causes major changes in microglial function. CCL2/MCP-1 and CCL5/RANTES chemokines produced in infected astrocytes cause migration of microglial cells to the site of CMV infection [<xref ref-type="bibr" rid="R119">119</xref>, <xref ref-type="bibr" rid="R134">134</xref>, <xref ref-type="bibr" rid="R135">135</xref>]. Influenced by CMV, microglia produce pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, which help to control CMV infection. Infected microglial cells also produce chemokines such as CCL2/MCP-1, CCL3/MIP-1α, CCL5/RANTES, IL-8/CXCL8 [<xref ref-type="bibr" rid="R119">119</xref>] and CXCL10/IP-10 [<xref ref-type="bibr" rid="R122">122</xref>]. CMV infection also results in the degradation of CCR5 and CXCR4 in microglia [<xref ref-type="bibr" rid="R125">125</xref>], as well as other chemokine receptors, which interferes with chemokine-dependent chemotaxis of infected cells [<xref ref-type="bibr" rid="R126">126</xref>]. This process depends on the aforementioned CMV virion envelope protein: UL128.</p>
<p>CCL2/MCP-1 and CCL5/RANTES cause monocyte migration, which results in the accumulation of these cells in the site of CMV infection [<xref ref-type="bibr" rid="R136">136</xref>]. In turn, CXCL10/IP-10 induces migration of T and NK cells [<xref ref-type="bibr" rid="R122">122</xref>], which results in the accumulation of CD8<sup>+</sup> T-cells, responsible for chronic activation of microglial cells via the production of interferon gamma (IFN)-γ [<xref ref-type="bibr" rid="R124">124</xref>] which helps to control CMV infection. However, chronic inflammation is toxic to the cells in the brain, and one of the mechanisms that protects the brain from damage are immunosuppressive reactions involving T<sub>reg</sub> [<xref ref-type="bibr" rid="R124">124</xref>].</p>
<p>Chronic inflammation can assist in the development of many cancers, including GBM. Prolonged inflammation activates immunosuppressive mechanisms. In particular, the effect of IFN-γ changes to oncogenic [<xref ref-type="bibr" rid="R137">137</xref>]. Chronic inflammation is also accompanied by the recruitment of T<sub>reg</sub> [<xref ref-type="bibr" rid="R138">138</xref>] and an increase in the expression of immunosuppressive IL-10 [<xref ref-type="bibr" rid="R139">139</xref>]. In addition to the inflammatory effect, infected cells produce chemokines: CCL2/MCP-1 and CCL5/RANTES and also chemokines encoded by the CMV genome, that help in recruiting various GBM-associated cells, including neutrophils [<xref ref-type="bibr" rid="R139">139</xref>–<xref ref-type="bibr" rid="R144">144</xref>], macrophages [<xref ref-type="bibr" rid="R135">135</xref>, <xref ref-type="bibr" rid="R136">136</xref>, <xref ref-type="bibr" rid="R145">145</xref>, <xref ref-type="bibr" rid="R146">146</xref>], microglial cells [<xref ref-type="bibr" rid="R119">119</xref>, <xref ref-type="bibr" rid="R134">134</xref>, <xref ref-type="bibr" rid="R135">135</xref>] and T<sub>reg</sub> [<xref ref-type="bibr" rid="R129">129</xref>]. After migration, these cells are included in the carcinogenic mechanisms.</p>
<p>In particular, this refers to the presence of anti-inflammatory cytokines in GBM, such as IL-10 and TGF-β, and also vIL-10 expression during CMV infection. The latter cytokine reduces expression of CXCL10/IP-10 in microglial cells and thus reduces recruitment of lymphocytes fighting against CMV infection and responsible for tumor destruction [<xref ref-type="bibr" rid="R122">122</xref>]. Also, vIL-10 causes monocyte differentiation into immunosuppressive macrophages with M2c phenotype [<xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R130">130</xref>]. The anti-inflammatory cytokines, in particular vIL-10, are responsible for the expression of programmed death ligand-1 (PD-L1)/B7-H1 in microglia [<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R147">147</xref>]. This is an immunosuppressive molecule that reduces the antiviral response of CD8<sup>+</sup> T-cells but also the antiviral activity of other immune cells. This mechanism also contributes to GBM tumor immune evasion. However, due to the lack of appropriate research models, this requires confirmation, just as the other CMV activities in GBM.</p>
</sec>
<sec id="s3_11">
<title>Influence of infection in tumor niche on monocytes and macrophages</title>
<p>In addition to CX3CL1/fractalkine, other chemokines also affect monocyte chemotaxis into the GBM tumor. In particular, CMV-infected GSC cells [<xref ref-type="bibr" rid="R46">46</xref>], astrocytes [<xref ref-type="bibr" rid="R119">119</xref>], macrophages [<xref ref-type="bibr" rid="R63">63</xref>, <xref ref-type="bibr" rid="R148">148</xref>, <xref ref-type="bibr" rid="R149">149</xref>] and microglia [<xref ref-type="bibr" rid="R119">119</xref>] secrete increased amounts of CCL2/MCP-1 and CCL5/RANTES. It seems that expression of these chemokines, at least with regard to CCL2/MCP-1, is highest in the early phase of cell infection and is dependent on the pp71 viral protein [<xref ref-type="bibr" rid="R63">63</xref>, <xref ref-type="bibr" rid="R150">150</xref>, <xref ref-type="bibr" rid="R151">151</xref>]. The expression of some chemokines is then reduced by other viral proteins at a later stage of infection [<xref ref-type="bibr" rid="R63">63</xref>, <xref ref-type="bibr" rid="R150">150</xref>, <xref ref-type="bibr" rid="R151">151</xref>].</p>
<p>CCL2/MCP-1 and CCL5/RANTES are chemokines that cause chemotaxis of monocytes from the blood and the subsequent accumulation of these cells in the focus of CMV infection. These chemokines also play an important role in the recruitment of monocytes into the cancer niche [<xref ref-type="bibr" rid="R135">135</xref>, <xref ref-type="bibr" rid="R136">136</xref>, <xref ref-type="bibr" rid="R145">145</xref>, <xref ref-type="bibr" rid="R146">146</xref>]. Also, the CMV genome encodes viral chemokines that affect monocytes and macrophages. In particular, the murine CMV genome encodes murine cytomegalovirus chemokine (MCK)-1 and MCK-2 [<xref ref-type="bibr" rid="R152">152</xref>, <xref ref-type="bibr" rid="R153">153</xref>]. This shows the identical mechanisms of CMV and GBM on blood monocytes. However, further studies are required to understand the effects of the aforementioned chemokines secreted during CMV infection on the recruitment of monocytes into the GBM niche.</p>
<p>After chemotaxis of monocytes into the tumor niche, they differentiate into macrophages. This process is induced by IL-10 and vIL-10, encoded by the CMV genome. These cytokines, in particular vIL-10, induce differentiation of monocytes into macrophages with phenotype M2c [<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R113">113</xref>, <xref ref-type="bibr" rid="R114">114</xref>]. Differentiation of monocytes by vIL-10 results in the activation of the PI3K and STAT3 pathways resulting in the increased expression of heme oxygenase-1 (HO-1) [<xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R130">130</xref>]. Expression of this enzyme maintains this state of macrophage polarization.</p>
<p>These cells exhibit increased expression of IL-10 [<xref ref-type="bibr" rid="R130">130</xref>] TGF-β [<xref ref-type="bibr" rid="R46">46</xref>] and VEGF [<xref ref-type="bibr" rid="R46">46</xref>] and increased expression of immunosuppressive protein PD-L1/B7-H1 [<xref ref-type="bibr" rid="R46">46</xref>]. This is also accompanied by reduced expression of TNF-α [<xref ref-type="bibr" rid="R154">154</xref>] and a reduction in the expression of MHC II components [<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R101">101</xref>, <xref ref-type="bibr" rid="R102">102</xref>, <xref ref-type="bibr" rid="R155">155</xref>, <xref ref-type="bibr" rid="R156">156</xref>]. As a result, the impaired MHC II presentation of antigens interferes with the antiviral response and also disrupts the antitumor response of the immune system [<xref ref-type="bibr" rid="R104">104</xref>].</p>
<p>One should not forget that CMV infection is not the only factor causing monocyte differentiation into macrophages. In GBM there are other factors that are produced by GBM cells and cells that accompany this tumor. In particular, these are factors such as M-CSF [<xref ref-type="bibr" rid="R157">157</xref>] or IL-10 [<xref ref-type="bibr" rid="R158">158</xref>]. However, further research is required to understand this problem.</p>
</sec>
<sec id="s3_12">
<title>Influence of direct infection on monocytes and macrophages</title>
<p>Direct infection with CMV affects monocytes [<xref ref-type="bibr" rid="R159">159</xref>]. CMV does not replicate in infected monocytes, but these cells are subject to latent infection with this virus [<xref ref-type="bibr" rid="R63">63</xref>]. After the infection of monocytes, CMV inhibits the apoptosis of these short-lived cells [<xref ref-type="bibr" rid="R160">160</xref>, <xref ref-type="bibr" rid="R161">161</xref>]. This virus disrupts the expression of antigens by the infected monocytes; in particular it lowers the expression of MHC II components, in particular HLA-DR [<xref ref-type="bibr" rid="R62">62</xref>, <xref ref-type="bibr" rid="R162">162</xref>].</p>
<p>During direct infection with this virus, monocytes dependent on NF-κB and PI3K differentiate into macrophages that simultaneously secrete cytokines and chemokines of M1 and M2 macrophages [<xref ref-type="bibr" rid="R148">148</xref>, <xref ref-type="bibr" rid="R149">149</xref>, <xref ref-type="bibr" rid="R163">163</xref>]. The gene expression profile is more similar to M1 than to M2 polarization [<xref ref-type="bibr" rid="R148">148</xref>, <xref ref-type="bibr" rid="R159">159</xref>]. There is an increase in the expression of cytokines associated with M1 polarization, i.e. IL-1β, IL-6, IL-15, TNF-α, and an increase in the expression of M1 marker: CD80. However, infected monocytes also secrete factors associated with M2 polarity, such as IL-10 [<xref ref-type="bibr" rid="R148">148</xref>].</p>
<p>Infected monocytes begin to produce larger amounts of chemokines, in particular CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES but also large amounts of CCL8/MCP-2, CCL19/ELC, CCL20/MIP-3α, CCL23/MPIF-1, with a reduced secretion of CXCL1/GROα [<xref ref-type="bibr" rid="R63">63</xref>, <xref ref-type="bibr" rid="R148">148</xref>]. They also secrete CXCL10/IP-10 and CXCL11/I-TAC, causing T-cell and NK cell migration with a possible antiviral effect. Expression of CCL2/MCP-1, CCL4/MIP-1β and CCL8/MCP-2 is highest at the onset of monocyte infection and decreases with time [<xref ref-type="bibr" rid="R63">63</xref>, <xref ref-type="bibr" rid="R150">150</xref>, <xref ref-type="bibr" rid="R151">151</xref>]. CMV also causes an increase in cyclooxygenase-2 (COX-2) expression in infected monocytes, but also a decrease in VEGF expression [<xref ref-type="bibr" rid="R148">148</xref>].</p>
<p>Infection of monocytes with CMV virions results in reduced expression of many receptors for chemokines such as CCR1, CCR2, CCR5 and CXCR4 [<xref ref-type="bibr" rid="R148">148</xref>, <xref ref-type="bibr" rid="R164">164</xref>], which interferes with the action of chemokines directly after CMV infection. CMV does not affect the expression of CCR7 and CX3CR, which is already low in monocytes [<xref ref-type="bibr" rid="R164">164</xref>]. This effect is dependent on viral protein UL128, which is included in the CMV envelope complexes [<xref ref-type="bibr" rid="R126">126</xref>]. During infection, this protein causes the degradation of many chemokine receptors, which may be very important in the GBM tumor, where CMV is intensely replicated.</p>
<p>CMV infects the already polarized macrophages M1 and M2, with a higher tropism for M2 macrophages [<xref ref-type="bibr" rid="R149">149</xref>, <xref ref-type="bibr" rid="R165">165</xref>]. After macrophage infection, CMV inhibits apoptosis in these cells [<xref ref-type="bibr" rid="R166">166</xref>]. In infected macrophages CMV further increases the expression of surface and soluble HLA-G, which impairs the immune response in the microenvironment of the infected cells. [<xref ref-type="bibr" rid="R105">105</xref>]. This may explain HLA-G expression in TAM and microglial cells in GBM tumor sections [<xref ref-type="bibr" rid="R167">167</xref>].</p>
<p>Soluble HLA-G also causes monocyte differentiation to immunosuppressive M2 macrophages, which may be significant in a tumor microenvironment with active CMV infection [<xref ref-type="bibr" rid="R108">108</xref>, <xref ref-type="bibr" rid="R110">110</xref>]. The infection of macrophages is pro-inflammatory, which stimulates the immune system and thus may have an antitumor effect. The increased expression of MHC I components (HLA-A, HLA-B and HLA-C) and CD80 and CD86 helps in the presentation of antigens by these cells. However, it appears that the effect of CMV on the amount of MHC I is cell-specific because in the U-373 MG astrocytoma cells [<xref ref-type="bibr" rid="R105">105</xref>, <xref ref-type="bibr" rid="R106">106</xref>] or primary murine fibroblasts [<xref ref-type="bibr" rid="R168">168</xref>], CMV causes MHC I degradation. In M2 macrophages, CMV reduces the expression of their markers: CD163 and CD206 [<xref ref-type="bibr" rid="R149">149</xref>].</p>
<p>Cytokine expression also changes in infected macrophages. In M1 there is an increase in the expression of chemokines and pro-inflammatory cytokines [<xref ref-type="bibr" rid="R149">149</xref>]. The same effect is exerted by CMV infection of M2 macrophages. There is an increase in the expression of chemokines such as CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES but not CXCL10/IP-10 [<xref ref-type="bibr" rid="R149">149</xref>]. This helps in recruiting monocytes from the blood to the CMV infection focus, but this mechanism is also common in cancer, not just GBM [<xref ref-type="bibr" rid="R136">136</xref>].</p>
<p>Infection of M2 macrophages results in increased secretion of pro-inflammatory cytokines such as IL-1β, IL-2, IL-6, IL-12, IL-15, TNF-α and IFN-γ and anti-inflammatory IL-10. Infected M2 macrophages secrete larger amounts of VEGF, which affects angiogenesis. It is also worth noting that the chemokines secreted by CMV-infected cells affect angiogenesis [<xref ref-type="bibr" rid="R169">169</xref>–<xref ref-type="bibr" rid="R171">171</xref>]. In particular, CCL2/MCP-1 and CCL5/RANTES cause vascular remodeling which may affect angiogenesis in GBM. Factors secreted by infected M2 macrophages are capable of enhancing immune responses in immune cells, which may have antiviral and antitumor effects.</p>
<p>In addition to the effects on the secretion of cytokines and chemokines, CMV interferes with chemotaxis in infected macrophages. In particular, it reduces the expression of CCR1 and CCR5 [<xref ref-type="bibr" rid="R172">172</xref>]. This effect is dependent on the expression of CMV genes. CMV replication also results in the expression and secretion of macrophage migration inhibitory factor (MIF) [<xref ref-type="bibr" rid="R172">172</xref>]. In this way, macrophages (also uninfected macrophages) are insensitive to many chemokines such as CCL2/MCP-1, CCL5/RANTES, CX3CL1/fractalkine, as well as to CCL19/MIP-3, CXCL1/GROα, CXCL12/SDF-IL-8/CXCL8 and macrophage-colony stimulating factor (M-CSF) [<xref ref-type="bibr" rid="R172">172</xref>]. Nevertheless, CX3CL1/fractalkine causes an <italic>in vitro</italic> increase in the migration of TAM and microglial cells isolated from GBM tumors [<xref ref-type="bibr" rid="R74">74</xref>].</p>
<p>The results of studies on the expression profile of different genes in TAM and microglia from a GBM tumor partially coincide with <italic>in vitro</italic> studies on the infection of macrophages. In particular, TAM and microglia isolated from GBM exhibit the expression of proinflammatory cytokines such as IL-1β, IL-6, and TNF-α at a level similar to M1 macrophages [<xref ref-type="bibr" rid="R73">73</xref>]. Similar observations in TAM from <italic>in vivo</italic> models in mice show a mixed gene expression profile. In these models TAM simultaneously express genes specific for different macrophage phenotypes, with a predominance of M1 phenotype [<xref ref-type="bibr" rid="R173">173</xref>, <xref ref-type="bibr" rid="R174">174</xref>]. However, TAM isolated from postoperative human GBM tumors do not express genes associated with immune activation [<xref ref-type="bibr" rid="R175">175</xref>].</p>
<p>TAM from GBM postoperative tumors are significantly different from CMV-infected and non-infected M2 macrophages. In particular, these TAM do not express TNF-α, although 20% of microglial cells and myeloid-derived suppressor cells (DMSC) isolated from GBM tumors do express this cytokine [<xref ref-type="bibr" rid="R176">176</xref>]. <italic>In vitro</italic> macrophage infection by CMV increases TNF-α expression [<xref ref-type="bibr" rid="R149">149</xref>] which indicates that CMV infection, if present in GBM tumors, does not affect TNF-α expression in TAM. But microglial cells infected <italic>in vitro</italic> by CMV do exhibit enhanced TNF-α expression, indicating the influence of CMV infection [<xref ref-type="bibr" rid="R119">119</xref>]. TAM have reduced expression of CD163 and CD206. In particular, these markers are expressed by a very small percentage of TAM isolated from proneural and neural GBM [<xref ref-type="bibr" rid="R176">176</xref>]. This is similar to the <italic>in vitro</italic> observation of CMV-infected M2 monocytes, in which CD163 and CD206 expression was reduced [<xref ref-type="bibr" rid="R149">149</xref>].</p>
<p>The effect of CMV monocyte infection on the differentiation of these cells in the GBM tumor, as well as the effect on infected TAM, still needs to be investigated further. Nevertheless, some of the findings on TAM isolated from postoperative GBM tumors were in contrast to those expected from <italic>in vitro</italic> studies on CMV-infected macrophages. On the other hand, studies on microglia and DMSC [<xref ref-type="bibr" rid="R176">176</xref>] have shown that inflammation caused by some factors match CMV infection. Research on CMV infection in GBM should be continued, with particular regard to the location of the infection in a particular type of cell in the tumor niche.</p>
<p>CMV has different tropisms for different cells. Also, the replication rate of this virus varies between cell types [<xref ref-type="bibr" rid="R177">177</xref>]. CMV lytic infection is destructive to the cells to which the virus has a particularly high tropism and a high rate of replication. However, in some cells, the virus immediately goes into a latent state and is activated only by some undiscovered factors. This results in a certain intratumoral heterogeneity in the CMV infection focus.</p>
</sec>
<sec id="s3_13">
<title>Effect of cytomegalovirus on regulatory T cells</title>
<p>Acute CMV infection results in inflammatory reactions and, in particular, chronic activation of microglial cells [<xref ref-type="bibr" rid="R124">124</xref>]. Immunosuppressive reactions, in particular recruitment of T<sub>reg</sub>, help to reduce excessive inflammatory response and thus protect against brain damage [<xref ref-type="bibr" rid="R138">138</xref>]. During cessation of the inflammatory response, the concentration of T<sub>reg</sub> in the inflammatory focus returns to physiological levels.</p>
<p>In a GBM tumor there is an increased number of T<sub>reg</sub> that have a role in cancer immune evasion [<xref ref-type="bibr" rid="R178">178</xref>]. Recruitment of these cells is accomplished via CCL2/MCP-1 [<xref ref-type="bibr" rid="R129">129</xref>], i.e. a chemokine that is produced by CMV-infected cells [<xref ref-type="bibr" rid="R89">89</xref>]. Further research is required to determine whether CMV affects the recruitment of T<sub>reg</sub> into the tumor niche or the expression of CCL2/MCP-1 is the result of CMV-independent cancer mechanisms. Further studies are also needed with regard to T<sub>reg</sub> populations in GBM tumors and how they are influenced by CMV. CMV carriers, particularly older adults, have increased numbers of cytomegalovirus-induced regulatory T cells (iT<sub>reg</sub>) [<xref ref-type="bibr" rid="R179">179</xref>–<xref ref-type="bibr" rid="R181">181</xref>]. These are T<sub>reg</sub> which alleviate inflammatory reactions. However, iT<sub>reg</sub> are specifically activated by CMV antigens, which causes them to only act in the focus of the CMV infection.</p>
<p>CMV has been shown to activate a certain T-cell subpopulation to produce IL-10 and thereby to alleviate the immune response. These cells do not express Foxp3, a T<sub>reg</sub> marker [<xref ref-type="bibr" rid="R182">182</xref>]. This T-cell subpopulation is activated in response to IL-27, which in turn is induced by type I IFN. These chemokines are produced by infected cells. In particular, IFN-α is produced in infected monocytes [<xref ref-type="bibr" rid="R148">148</xref>, <xref ref-type="bibr" rid="R183">183</xref>] and IFN-β in infected M2 macrophages [<xref ref-type="bibr" rid="R165">165</xref>]. Further studies on the effect of CMV on T<sub>reg</sub> and on other immune system cells in a GBM tumor are required.</p>
</sec>
<sec id="s3_14">
<title>Effect of cytomegalovirus on neutrophils</title>
<p>Neutrophils play an important role in reactions caused by CMV which infects these cells and thus is spread throughout the body [<xref ref-type="bibr" rid="R184">184</xref>]. They also play an important role in GBM. Neutrophils are recruited near CD133<sup>+</sup> GSC [<xref ref-type="bibr" rid="R185">185</xref>], i.e., near the same cells for which CMV has tropism [<xref ref-type="bibr" rid="R46">46</xref>]. The elevated number of neutrophils in the GBM tumor increases the aggressiveness of this tumor and, in addition, worsens the prognosis for the patient [<xref ref-type="bibr" rid="R186">186</xref>, <xref ref-type="bibr" rid="R187">187</xref>]. Neutrophils in tumors are involved in angiogenesis, migration and invasion of cancer cells, and cancer immune evasion [<xref ref-type="bibr" rid="R127">127</xref>]. However, very little research has been devoted to the relation between these cells and cancer.</p>
<p>Neutrophils have been shown to be recruited under the influence of chemokines which are expressed in CMV-infected cells. The chemokines that are important for neutrophils include IL-8/CXCL8 [<xref ref-type="bibr" rid="R140">140</xref>], CCL2/MCP-1 [<xref ref-type="bibr" rid="R139">139</xref>] and viral CXC motif chemokine ligand 1 (vCXCL1) [<xref ref-type="bibr" rid="R141">141</xref>–<xref ref-type="bibr" rid="R144">144</xref>]. The CMV genome contains the UL146 gene which encodes protein vCXCL1. This viral chemokine, which works specifically as a chemoattractant for neutrophils, allows CMV to infect neutrophils and spread throughout the body in these cells [<xref ref-type="bibr" rid="R184">184</xref>]. If CMV infection is present in the GBM tumor, then neutrophils may be recruited into the tumor niche. However, the exact effect of CMV on neutrophil recruitment, as well as the effect of this carcinogenic factor on already recruited neutrophils in GBM is poorly understood and requires further investigation [<xref ref-type="bibr" rid="R186">186</xref>].</p>
</sec>
<sec id="s3_15">
<title>Correlation between cytomegalovirus infection and glioblastoma epidemiology</title>
<p>All of the discussed mechanisms may play a crucial role in GBM growth, which may be confirmed by the fact that some research groups estimate that 100% of GBM are infected with CMV [<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R32">32</xref>]. This virus also very often causes congenital neuronal disorders. It is striking that CMV has tropism for neural stem cells and immature glia cells in the subventricular zone [<xref ref-type="bibr" rid="R116">116</xref>, <xref ref-type="bibr" rid="R117">117</xref>]. This region of the brain is considered to be the source of stem cells from which cancerous tumors such as gliomas (including GBM) are produced via carcinogenesis [<xref ref-type="bibr" rid="R188">188</xref>]. However, over 50% of the population has a latent CMV infection [<xref ref-type="bibr" rid="R40">40</xref>–<xref ref-type="bibr" rid="R43">43</xref>] and the number of GBM cases is only about 3/100,000 persons per year [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>], which shows a poor correlation between CMV infection and GBM epidemiology. CMV infection models in GBM in mice should answer further questions about the exact role of CMV in GBM development [<xref ref-type="bibr" rid="R189">189</xref>].</p>
</sec>
</sec>
<sec id="s4">
<title>NEUROTENSIN</title>
<sec id="s4_1">
<title>Neurotensin, receptors, functions</title>
<p>Neurotensin (NT) is a peptide hormone consisting of 13 amino acids. There are currently 4 known receptors of this hormone: NT receptor types 1-4 (NTSR<sub>1-4</sub>) [<xref ref-type="bibr" rid="R190">190</xref>]. NTSR<sub>1</sub> has a high (0.1-0.3nM) affinity for NT, and NTSR<sub>2</sub> has a low (3-10nM) affinity. Both these receptors are G-protein-coupled. Two other receptors, NTSR<sub>3</sub>/sortilin and NTSR<sub>4</sub>/SorLA, contain the Vps10p domain [<xref ref-type="bibr" rid="R191">191</xref>]. The extracellular domain of the NTSR<sub>3</sub>/sortilin can be released by its proteinase, and as a result can occur as soluble NT receptor type 3 (sNTSR<sub>3</sub>), performing biological functions without the involvement of NT [<xref ref-type="bibr" rid="R192">192</xref>, <xref ref-type="bibr" rid="R193">193</xref>].</p>
<p>NT regulates the function of the digestive tract [<xref ref-type="bibr" rid="R194">194</xref>, <xref ref-type="bibr" rid="R195">195</xref>]. In particular it stimulates the small bowel as well as colonic mucosa growth, and increases the production of digestive enzymes by the pancreas. NT is also produced in the brain where it influences the secretion and action of neurotransmitters [<xref ref-type="bibr" rid="R196">196</xref>–<xref ref-type="bibr" rid="R198">198</xref>]. In particular, NT reduces the effect of dopamine [<xref ref-type="bibr" rid="R197">197</xref>, <xref ref-type="bibr" rid="R198">198</xref>]. NT also causes an increase in extracellular glutamate levels, associated with neurotoxic effects in pathological conditions [<xref ref-type="bibr" rid="R199">199</xref>–<xref ref-type="bibr" rid="R201">201</xref>]. NT is therefore associated with neurodegenerative diseases, in particular Parkinson's disease as well as schizophrenia or drug abuse [<xref ref-type="bibr" rid="R197">197</xref>]. Finally, NT is also associated with cancer, which has been best researched in pancreatic, colorectal, breast, lung, prostate, and liver cancers [<xref ref-type="bibr" rid="R194">194</xref>]. Recent research shows that NT has important functions in gliomas, especially in GBM [<xref ref-type="bibr" rid="R202">202</xref>].</p>
</sec>
<sec id="s4_2">
<title>Neurotensin and cancer cell</title>
<p>Expression of NT and NTSR<sub>1</sub> in gliomas increases with increasing tumor grade [<xref ref-type="bibr" rid="R202">202</xref>]. Among the gliomas, the highest expression of NT and NTSR<sub>1</sub> occurs in GBM, which positively correlates with increased postoperative mortality [<xref ref-type="bibr" rid="R202">202</xref>]. In addition, different cell lines express different NT receptors. The GL261, U-87 MG, U-118 MG and A172 lines express NTSR<sub>1</sub> [<xref ref-type="bibr" rid="R202">202</xref>–<xref ref-type="bibr" rid="R204">204</xref>]. The C6 line does not express NTSR<sub>1</sub> but rather NTSR<sub>2</sub> [<xref ref-type="bibr" rid="R205">205</xref>]. The U-373 MG line expresses three different NT receptors: NTSR<sub>1</sub>, NTSR<sub>2</sub> and NTSR<sub>3</sub>/sortilin [<xref ref-type="bibr" rid="R206">206</xref>].</p>
</sec>
<sec id="s4_3">
<title>Effect on signal transduction in tumor cell</title>
<p>Exact NT signal transduction in GBM cells is not well known. Exact mechanisms have been established in other cancers, mainly lung, breast, colon and pancreatic adenocarcinoma cell lines [<xref ref-type="bibr" rid="R192">192</xref>, <xref ref-type="bibr" rid="R207">207</xref>–<xref ref-type="bibr" rid="R210">210</xref>]. Activation of the NTSR<sub>1</sub> receptor leads to activation of the EGFR family: in particular EGFR, ErbB2/HER2, and ErbB3/HER3, which in turn are responsible for signal transduction within the tumor cell [<xref ref-type="bibr" rid="R207">207</xref>, <xref ref-type="bibr" rid="R209">209</xref>]. The PI3K-PKB pathway and extracellular signal-regulated kinase 1 and 2 (ERK1/2) mitogen-activated protein kinase (MAPK) are activated, and are responsible for the all properties of NT described in the following sections of this article.</p>
<p>Activation of the EGFR family by NTSR<sub>1</sub> is dependent on the PLC-β-protein kinase C (PKC) pathway, which increases expression and activates MMP1 and MMP9 (Figure <xref ref-type="fig" rid="F5">5</xref>) [<xref ref-type="bibr" rid="R207">207</xref>, <xref ref-type="bibr" rid="R209">209</xref>–<xref ref-type="bibr" rid="R212">212</xref>]. In particular, the increase in MMP9 expression is responsible for PKC activation of the PI3K-PKB and ERK1/2 MAPK pathways [<xref ref-type="bibr" rid="R212">212</xref>]. MMP1 and MMP9 release epidermal growth factor (EGF)-like ligands, in particular heparin-binding EGF-like growth factor (HB-EGF), neuregulin 1 and neuregulin 2, which activate the EGFR family [<xref ref-type="bibr" rid="R209">209</xref>, <xref ref-type="bibr" rid="R210">210</xref>]. As a result, these receptors activate ERK1/2 MAPK and the PI3K-PKB pathway [<xref ref-type="bibr" rid="R207">207</xref>].</p>
<fig id="F5" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<title>Signal transduction in the tumor cell from the NTSR<sub>1</sub> receptor</title>
<p>In general, the activation of NTSR<sub>1</sub> leads to activation of ERK1/2 MAPK and PI3K-PKB cascades. The signal transmission involves EGFR, activated via c-Src. EGFR can also be activated by MMP1 and MMP9. These metalloproteins release the EGF-like ligands, thus activating these receptors. As a result, the ERK1/2 MAPK cascade and the PI3K-PKB pathway are activated. Nevertheless, the ERK1/2 MAPK cascade can be directly activated by the NTSR<sub>1</sub>-PLCβ-PKC pathway, without the involvement of other receptors. Similarly, the PI3K-PKB pathway can be activated by signal transduction to IGF-1R.</p>
</caption>
<graphic xlink:href="oncotarget-09-7219-g005"></graphic>
</fig>
<p>EGFR activation may occur in a different manner. In prostate tumor PC3 cells, NT causes EGFR activation via c-Src [<xref ref-type="bibr" rid="R213">213</xref>]. This kinase causes phosphorylation of Tyr<sup>845</sup> EGFR which results in STAT5b activation. Also, activated NTSR<sub>1</sub> causes NF-κB activation which results in the increased expression of miR-21 and miR-155 [<xref ref-type="bibr" rid="R214">214</xref>]. miR-21 inhibits PTEN expression, a phosphatase degrading the PKB activator, which allows NT to increase the activity of this kinase. miR-155 reduces expression of the protein phosphatase 2 catalytic subunit α (PPP2CA), the suppressor of PKB activity.</p>
<p>There is also an EGFR-independent mechanism of signal transduction from NTSR<sub>1</sub>, i.e. via the activation of the PLCβ-PKC-ERK1/2 MAPK pathway. PI3K-PKB is also activated [<xref ref-type="bibr" rid="R207">207</xref>], which may involve another receptor with tyrosine kinase activity. An example of this is the insulin-like growth factor 1 receptor (IGF-1R) activated by Src in human colonic epithelial NCM460 cells [<xref ref-type="bibr" rid="R215">215</xref>].</p>
<p>GBM cells have been shown to express ErbB/HER2 while ErbB3/HER3 is more abundant on GSC [<xref ref-type="bibr" rid="R216">216</xref>–<xref ref-type="bibr" rid="R218">218</xref>]. Expression of these receptors, as well as the importance of EGFR amplification [<xref ref-type="bibr" rid="R81">81</xref>] in tumor processes in GBM, gives strong evidence that NT also acts through these receptors in this type of tumor.</p>
</sec>
<sec id="s4_4">
<title>Neurotensin and glioblastoma stem cells</title>
<p>Expression of NT as well as receptors of this hormone in GBM occur mainly in GSC (Figure <xref ref-type="fig" rid="F6">6</xref>) [<xref ref-type="bibr" rid="R203">203</xref>, <xref ref-type="bibr" rid="R219">219</xref>]. NTSR<sub>1</sub> regulates the carcinogenic properties of GSC of various cells lines. The exact mechanism of NT effect on GSC is dependent on IL-8/CXCL8 [<xref ref-type="bibr" rid="R203">203</xref>]. NT after activation of NTSR<sub>1</sub> and EGFR increases expression of IL-8/CXCL8 in GSC. Following the secretion of IL-8/CXCL8, this chemokine activates the CXCR1 receptor in an autocrine manner, which activates the STAT3 transcriptional factor. As a consequence, the expression of stem cell markers increases, especially nestin and Sox2, and sphere-forming ability is increased [<xref ref-type="bibr" rid="R203">203</xref>]. IL-8/CXCL8 also supports proliferation, migration and invasion [<xref ref-type="bibr" rid="R220">220</xref>]. Also, this chemokine is involved in angiogenesis and tumor immunosuppression [<xref ref-type="bibr" rid="R221">221</xref>, <xref ref-type="bibr" rid="R222">222</xref>].</p>
<fig id="F6" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<title>The effect of NT on GSC markers</title>
<p>Activation of NTSR<sub>1</sub> results in signal transmission to IGF-1R or EGFR and increased IL-8/CXCL8 expression. Then, the activation of CXCR1, an IL-8/CXCL8 receptor, activates STAT3 and increases the expression of stem cell markers: nestin and Sox2.</p>
</caption>
<graphic xlink:href="oncotarget-09-7219-g006"></graphic>
</fig>
<p>The exact mechanism of increased expression of IL-8/CXCL8 by NT in GBM has not been well understood. Experiments on other types of cancer show that ERK1/2 MAPK cascade, in particular ERK1/2 and RAF-1, are important in signaling, as demonstrated by stem cells of hepatocellular carcinoma and HCT116 human colorectal cancer [<xref ref-type="bibr" rid="R208">208</xref>, <xref ref-type="bibr" rid="R223">223</xref>]. Also, the effect of NT on IL-8/CXCL8 expression may depend on NF-κB activation as demonstrated by transfected NCM460-line colonocytes and HCT116 human colorectal cancer [<xref ref-type="bibr" rid="R223">223</xref>, <xref ref-type="bibr" rid="R224">224</xref>]. Nevertheless, the expression of IL-8/CXCL8 may also be activated by other receptors other than the EGFR family. In particular, the Src activation of the IGF-1R receptor can activate PKB, which increases expression of IL-8/CXCL8 in the colonic epithelial NCM460 cells [<xref ref-type="bibr" rid="R215">215</xref>].</p>
</sec>
<sec id="s4_5">
<title>Effect on proliferation</title>
<p>NT stimulates the proliferation of GBM cells [<xref ref-type="bibr" rid="R202">202</xref>]. Activation of NTSR<sub>1</sub> enhances the expression of CDK4 and CDK6 [<xref ref-type="bibr" rid="R204">204</xref>]. This effect is associated with a decrease in miR-129-3p expression and a reduction in miR-29b-1 expression via the NTSR<sub>1</sub>-c-myc pathway. These miRNAs reduce the expression of CDK6. This makes NT proliferate via the increased expression of CDK6. Also, NTSR<sub>1</sub> via c-myc increases expression of CDK4 [<xref ref-type="bibr" rid="R204">204</xref>]. Thanks to these pathways, NT stimulates GBM cells to cross the G<sub>1</sub>/S checkpoint. In addition to the effects on proliferation, NT inhibits apoptosis by increasing Bcl-2 expression, as demonstrated on breast cancer MCF-7 cells [<xref ref-type="bibr" rid="R225">225</xref>].</p>
</sec>
<sec id="s4_6">
<title>Effect on glutamate concentration</title>
<p>One of the features of gliomas, including GBM, is increased glutamate concentrations in the tumor environment [<xref ref-type="bibr" rid="R133">133</xref>]. This causes a neurotoxic effect. However, the impact of NT in this process is controversial. In the brain, NT increases glutamate concentration [<xref ref-type="bibr" rid="R199">199</xref>–<xref ref-type="bibr" rid="R201">201</xref>]. However, the induction of expression and activation of NTSR<sub>1</sub> on GBM C6 cells results in an increase in the amount of excitatory amino acid carrier 1 (EAAC1) on the cell membrane, resulting in the uptake of aspartate and glutamate [<xref ref-type="bibr" rid="R226">226</xref>]. The involvement of NT in the neurotoxic effects of glutamate within GBM and gliomas requires further research.</p>
</sec>
<sec id="s4_7">
<title>Effect on dissemination</title>
<p>NT stimulates GBM cells to invasion [<xref ref-type="bibr" rid="R202">202</xref>]. NT causes changes in the cytoskeleton organization. In particular, by activating Rac1 and cell division cycle 42 (Cdc42) increases the motility of U373 cells on laminin substrate [<xref ref-type="bibr" rid="R206">206</xref>]. Cells cultured on a plastics-only medium had more fibrillar actin and filopodial protrusions, and so showed lower motility [<xref ref-type="bibr" rid="R206">206</xref>].</p>
<p>Information on the effect of NT on GBM dissemination is incomplete, as no specific inhibitor studies have been conducted. Studies on other types of cancer show that NT acts via NTSR<sub>1</sub> and NTSR<sub>3</sub>/sortilin which caused epithelial-mesenchymal transition [<xref ref-type="bibr" rid="R193">193</xref>, <xref ref-type="bibr" rid="R212">212</xref>, <xref ref-type="bibr" rid="R227">227</xref>, <xref ref-type="bibr" rid="R228">228</xref>]. NT via NTSR<sub>1</sub> in lung cancer cell lines NCI-H1299 activates FAK resulting in cell migration [<xref ref-type="bibr" rid="R229">229</xref>]. Also the migration of tumor cells is enhanced by sNTSR<sub>3</sub> [<xref ref-type="bibr" rid="R192">192</xref>, <xref ref-type="bibr" rid="R193">193</xref>]. Irrespective of NT or signal transduction from EGFR, NT increases FAK phosphorylation and activation [<xref ref-type="bibr" rid="R192">192</xref>]. Also, sNTSR<sub>3</sub> decreases the expression of integrins, E-cadherin localization disorder, and changes in the desmosome structure, resulting in tumor cell release and migration [<xref ref-type="bibr" rid="R193">193</xref>]. Importantly, sNTSR<sub>3</sub> does not affect tumor cell proliferation as it does not activate ERK1/2 MAPK [<xref ref-type="bibr" rid="R192">192</xref>].</p>
<p>In addition to FAK activation and changes in cytoskeleton organization and expression integration, NT also affects GBM dissemination by other means. In particular, NT induces an increase in IL-8/CXCL8 expression. By the action of this chemokine, the expression of MMP or activity of the uroplasminogen activation system is enhanced, as was the case in pancreatic adenocarcinoma BxPC-3 and PANC-1 lines [<xref ref-type="bibr" rid="R230">230</xref>].</p>
</sec>
<sec id="s4_8">
<title>Neurotensin and angiogenesis</title>
<p>To date, the effect of NT on angiogenesis has not been unambiguously determined. However, it may be inferred that – similar to immune evasion – it is cell-specific. In experiments on human umbilical vein endothelial cells (HUVEC) NT has not been reported to cause angiogenesis [<xref ref-type="bibr" rid="R231">231</xref>]. However, in experimental colitis of the large intestine, NTSR<sub>1</sub> is a factor that does enhance angiogenesis [<xref ref-type="bibr" rid="R232">232</xref>]. In particular, NTSR<sub>1</sub> activity stabilizes and increases HIF-1α expression. This results in increased expression of genes dependent on this protein, especially VEGF-A which is involved in angiogenesis [<xref ref-type="bibr" rid="R232">232</xref>].</p>
<p>NT can also indirectly influence tumor angiogenesis through IL-8/CXCL8. NT induces an increase in IL-8/CXCL8 expression in GSC [<xref ref-type="bibr" rid="R203">203</xref>]. This chemokine causes the recruitment of tumor-associated neutrophils which secrete various hormones involved in angiogenesis [<xref ref-type="bibr" rid="R222">222</xref>, <xref ref-type="bibr" rid="R233">233</xref>].</p>
</sec>
<sec id="s4_9">
<title>Neurotensin and tumor immune evasion</title>
<sec id="s4_9_1">
<title>Effect on macrophages</title>
<p>The effect of immunological processes is cell-specific. NT does not affect macrophages in tumor immune evasion but instead enhances the already induced immune response by increasing macrophage activation, although this effect is about 10 times smaller than at 100 U/ml IFN-γ [<xref ref-type="bibr" rid="R234">234</xref>–<xref ref-type="bibr" rid="R236">236</xref>]. In experiments on RAW 264.7, NT does not affect migration, expression of TNF-α, IL-10, nor IL-12 in macrophages [<xref ref-type="bibr" rid="R236">236</xref>]. In contrast, NT increases IL-1β and IL-6 expression [<xref ref-type="bibr" rid="R236">236</xref>]. NT also strengthens the immune response as demonstrated on lipopolysaccharide (LPS)-activated RAW 264.7 macrophages [<xref ref-type="bibr" rid="R236">236</xref>] and rat alveolar macrophages [<xref ref-type="bibr" rid="R237">237</xref>]. NT increases the production of TNF-α, IL-1β and IL-12 [<xref ref-type="bibr" rid="R236">236</xref>]. However, NT does not modify the expression of IL-1 caused by IFN-γ nor that caused by leukotriene B<sub>4</sub> [<xref ref-type="bibr" rid="R237">237</xref>]. NT also increases the migration and expression of COX-2 and inducible nitric oxide synthase (iNOS) in LPS and IFN-γ activated macrophages [<xref ref-type="bibr" rid="R235">235</xref>]. The NT effect on macrophages is associated with NTSR<sub>1</sub> activation, which affects LPS-activated NF-κB factor and the activated JAK2-STAT1 pathway [<xref ref-type="bibr" rid="R235">235</xref>]. However, due to immunosuppressive processes in tumors [<xref ref-type="bibr" rid="R238">238</xref>], NT does not directly play any direct role in the activation or migration of macrophages in GBM tumors.</p>
</sec>
<sec id="s4_9_2">
<title>Effect on microglial cells</title>
<p>In a similar way NT affects microglia. This is a heterogeneous population of cells; with only 8% of adult mouse brain cells and 13% of neonatal C57Bl/6 mouse brain reacting to NT [<xref ref-type="bibr" rid="R239">239</xref>]. Activation of microglial cells of these populations, especially in the neonatal brain of mice, may be impaired by the action of a previously anti-inflammatory cytokine such as IL-4 [<xref ref-type="bibr" rid="R239">239</xref>]. Nevertheless, the number of NT-responsive microglial cells may increase. If adult mouse brain microglial cells are activated with a proinflammatory cytokine such as IFN-γ, the number of NT-responsive cells increases 3 times [<xref ref-type="bibr" rid="R239">239</xref>]. This effect does not occur under the influence of LPS or IFN-γ on microglia isolated from a neonatal mouse brain.</p>
<p>Microglial cells express NTSR<sub>3</sub>/sortilin but not NTSR<sub>1</sub> [<xref ref-type="bibr" rid="R240">240</xref>–<xref ref-type="bibr" rid="R242">242</xref>]. Activation of this receptor causes migration of microglial cells. This effect is triggered by the activation of PI3K and MAPK cascades [<xref ref-type="bibr" rid="R240">240</xref>]. This results in changes in F-actin polymerization and filopodia formation. Via NTSR<sub>3</sub>/sortilin activation, NT induces an increase in the expression of IL-1, TNF-α, CCL2/MCP-1, CCL5/RANTES, IL-8/CXCL8, CXCL2/MIP-2 but not altering the expression of IL-6, CCL3/MIP-1α nor CCL4/MIP-1β [<xref ref-type="bibr" rid="R241">241</xref>, <xref ref-type="bibr" rid="R242">242</xref>]. The effect on the expression of these hormones is dependent on the activation of ERK1/2 MAPK and PI3K in microglial cells [<xref ref-type="bibr" rid="R241">241</xref>]. Chemokines produced by microglial cells participate in the migration and recruitment of other microglial cells (CCL2/MCP-1 and CCL5/RANTES) [<xref ref-type="bibr" rid="R134">134</xref>] as well as macrophages (CCL2/MCP-1 and CCL5/RANTES) [<xref ref-type="bibr" rid="R134">134</xref>, <xref ref-type="bibr" rid="R136">136</xref>, <xref ref-type="bibr" rid="R146">146</xref>], neutrophils (IL-8/CXCL8, CCL2/MCP-1 and CXCL2/MIP-2) [<xref ref-type="bibr" rid="R139">139</xref>, <xref ref-type="bibr" rid="R140">140</xref>] and T<sub>reg</sub> (CCL2/MCP-1) [<xref ref-type="bibr" rid="R129">129</xref>]. In contrast, pro-inflammatory cytokines enhance the immune response. Nevertheless, the immunosuppressive tumor microenvironment decreases the number of NT-responsive microglial cells [<xref ref-type="bibr" rid="R238">238</xref>].</p>
</sec>
<sec id="s4_9_3">
<title>Effect on neutrophils</title>
<p>NT also has an effect on neutrophils. However, this action is poorly understood and requires further investigation in GBM tumors. It has been shown that <italic>in vitro</italic> NT at a concentration as low as 0.1nM acts as a chemoattractant for neutrophils, increasing their targeted migration [<xref ref-type="bibr" rid="R243">243</xref>]. This effect is direct via NT receptors on these cells and also indirect via IL-8/CXCL8 [<xref ref-type="bibr" rid="R203">203</xref>, <xref ref-type="bibr" rid="R222">222</xref>]. NT expression, occurring predominantly in GSC [<xref ref-type="bibr" rid="R203">203</xref>, <xref ref-type="bibr" rid="R219">219</xref>], may explain the accumulation of neutrophils in the GBM tumor near the GSC [<xref ref-type="bibr" rid="R185">185</xref>]. Further studies on the effect of NT on the migration of neutrophils to the tumor niche and the location of these cells in the tumor are required.</p>
<p>After the migration of neutrophils near GBM, NT increases adherence and diapedesis of neutrophils, thereby increasing the infiltration of these cells within the tumor. This has been demonstrated by <italic>in vitro</italic> experiments in which NT caused adherence to bronchial epithelial cells [<xref ref-type="bibr" rid="R244">244</xref>]. It seems that NT induces neutrophil activation, in particular phagocytosis of these cells [<xref ref-type="bibr" rid="R243">243</xref>].</p>
</sec>
<sec id="s4_9_4">
<title>Effect on dendritic cells</title>
<p>NT has immunosuppressive properties on fetal-skin dendritic cells [<xref ref-type="bibr" rid="R245">245</xref>]. NT reduces the production of TNF-α, IL-10 and VEGF in these cells, which is anti-angiogenic [<xref ref-type="bibr" rid="R245">245</xref>]. On the other hand, NT enhances the synthesis of EGF in these cells, which may have a significant effect on GBM with amplified EGFR near dendritic cells. NT also interferes with LPS activity in dendritic cells. Incubation of NT together with LPS or pre-incubation of NT completely abolishes dendritic cell response to LPS, in particular the expression of TNF-α, IL-6 and IL-10 [<xref ref-type="bibr" rid="R245">245</xref>]. This shows that NT can interfere with the antitumor immune response.</p>
</sec>
</sec>
</sec>
<sec id="s5">
<title>GROWTH DIFFERENTIATION FACTOR-15 / MACROPHAGE INHIBITORY CYTOKINE-1</title>
<sec id="s5_1">
<title>Growth differentiation factor-15 as an antineoplastic agent</title>
<p>GDF-15/macrophage inhibitory cytokine-1 (MIC-1) is a member of a TGF-β superfamily hormone [<xref ref-type="bibr" rid="R246">246</xref>]. To date, no receptor for this extracellular protein has been identified [<xref ref-type="bibr" rid="R247">247</xref>, <xref ref-type="bibr" rid="R248">248</xref>]. GDF-15 seems to act via the TGF-β receptor type II (TGFβRII) [<xref ref-type="bibr" rid="R249">249</xref>, <xref ref-type="bibr" rid="R250">250</xref>]. Heterodimers of TGFβRI/activin receptor-like kinase (ALK-5) and TGFβRII are also important in the signal transduction. According to a recent study, the GDNF family receptor α-like (GFRAL) is a specific GDF-15 receptor [<xref ref-type="bibr" rid="R251">251</xref>–<xref ref-type="bibr" rid="R253">253</xref>]. Thanks to this, overexpression of GDF-15 results in decreased appetite and weight loss [<xref ref-type="bibr" rid="R254">254</xref>, <xref ref-type="bibr" rid="R255">255</xref>]. GDF-15 is also associated with the cachexia associated with cancer. This property of GDF-15 may explain the decreased appetite and drastic weight loss in some glioma and GBM patients [<xref ref-type="bibr" rid="R256">256</xref>].</p>
<p>GDF-15 plays a very important and diverse function in cancer processes. At the beginning, it has antitumor properties, as it inhibits tumor cell division (Table <xref ref-type="table" rid="T1">1</xref>). It induces phosphorylation of Smad3 (a protein that participates in tumor suppression) and apoptosis via the intrinsic mitochondrial pathway, as demonstrated on U-87 MG, U-118 MG, U-251 MG, U-373 MG and T98G cell lines [<xref ref-type="bibr" rid="R248">248</xref>, <xref ref-type="bibr" rid="R257">257</xref>]. GDF-15 also disrupts connective tissue growth factor (CTGF)-induced angiogenesis in HUVEC [<xref ref-type="bibr" rid="R258">258</xref>]. In particular, GDF-15 decreases FAK activation and decreases clustering of the α<sub>V</sub>β<sub>3</sub> integrin. Expression of GDF-15 is enhanced by the action of the p53 protein in an antitumor mechanism [<xref ref-type="bibr" rid="R259">259</xref>]. However, the resulting mutations in the <italic>P53</italic> gene and hypermethylation of the <italic>GDF15</italic> gene promoter result in reduced expression of this protein in cancer cells [<xref ref-type="bibr" rid="R257">257</xref>]. In GBM cells the epigenetic silencing of Egr-1 and Sp-1 transcription factors results in a decrease in expression of GDF-15, as demonstrated with the use of histone deacetylase inhibitor Trichostatin A [<xref ref-type="bibr" rid="R260">260</xref>].</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Anti- and pro-cancer properties of GDF-15</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="center" colspan="1" rowspan="1" valign="top">Anti-cancer properties</th>
<th align="center" colspan="1" rowspan="1" valign="top">Pro-cancer properties</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cell viability</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Inducted intrinsic mitochondrial apoptosis pathway</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased viability via increased activation of the PI3K-PKB pathway</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle">Neutralization of the cytotoxic action of TGF-β1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduction in CTGF-dependent angiogenesis</td>
<td align="center" colspan="1" rowspan="1" valign="middle">In hypoxia, an increased expression of HIF-1α and VEGF</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Migration and invasion</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Decreased FAK activity</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased expression of MMP2 and MMP9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle">Decreased intensity of integrin α<sub>V</sub>β<sub>3</sub>clustering</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Inducted epithelial-mesenchymal transition</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Tumor immune escape</td>
<td align="center" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced IL-2 synthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased IL-10 synthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced IL-12 synthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased TGF-β1 synthesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle">NK dysfunction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle"></td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced infiltration of macrophages and T cells.</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s5_2">
<title>Growth differentiation factor-15 as a progression of cancer</title>
<p>As cancer progresses, tumor cell resistance to GDF-15 and its elevated synthesis increases [<xref ref-type="bibr" rid="R261">261</xref>, <xref ref-type="bibr" rid="R262">262</xref>]. This is an indication of the progression of cancer; hence a high correlation of this hormone level and a reduction in survival of patients after GBM removal [<xref ref-type="bibr" rid="R262">262</xref>, <xref ref-type="bibr" rid="R263">263</xref>]. The expression of GDF-15 in secondary glioblastomas is much higher than in primary glioblastomas [<xref ref-type="bibr" rid="R261">261</xref>]. Nevertheless, expression of GDF-15 is not the same for all GBM cells in the tumor. The highest expression occurs in the mesenchymal subtype, with the lowest in the proneural subtype [<xref ref-type="bibr" rid="R262">262</xref>]. Another significant source of GDF-15 are TAM, as shown in esophageal squamous cell carcinomas [<xref ref-type="bibr" rid="R264">264</xref>].</p>
<p>Related to the progression of tumor formation, resistance to GDF-15 is associated with changes in the pathways activated by this hormone. In particular, GDF-15 no longer causes Smad3 phosphorylation [<xref ref-type="bibr" rid="R263">263</xref>]. As a result, the hormone no longer causes apoptosis of the GBM lines, particularly lines A172 and LN-229 [<xref ref-type="bibr" rid="R261">261</xref>–<xref ref-type="bibr" rid="R263">263</xref>, <xref ref-type="bibr" rid="R265">265</xref>]. These lines, unlike the U-87 MG and T98G lines (not-resistant to GDF-15), have a high expression of this protein [<xref ref-type="bibr" rid="R261">261</xref>, <xref ref-type="bibr" rid="R262">262</xref>, <xref ref-type="bibr" rid="R265">265</xref>].</p>
<p>It has also been shown that GDF-15 stimulates the intensity of proliferation not only of LN-229 and A172, but also of LN-319, U-87 MG, D-247 MG, LN-308, LN-428, LN-18 and U-373 MG [<xref ref-type="bibr" rid="R261">261</xref>]. On the other hand, studies by Kadowaki et al. and Zhang et al. show an opposite effect. GDF-15 reduces the proliferation of U-87 MG and U-373 MG cells lines [<xref ref-type="bibr" rid="R248">248</xref>, <xref ref-type="bibr" rid="R257">257</xref>]. In addition to Smad3 pathways, GDF-15 also increases the activation of the PI3K-PKB pathway which increases the viability of the cells [<xref ref-type="bibr" rid="R248">248</xref>]. Another pathway of GDF-15 proliferative activity is TGF-β1 dysfunction [<xref ref-type="bibr" rid="R266">266</xref>]. Accumulated in the cancer cell nucleus, GDF-15 causes a disorder in the expression of genes associated with Smad factors [<xref ref-type="bibr" rid="R266">266</xref>]. Smad factors are associated with the transduction of a signal from the TGF-β1 receptor. In this way, GDF-15 abolishes the inhibitory effect on cell division TGF-β1.</p>
<sec id="s5_2_1">
<title>Effect on angiogenesis</title>
<p>In addition to proliferation, GDF-15 also induces angiogenesis in advanced tumor processes. GDF-15 stimulates the proliferation of HUVEC via increased expression of cyclins D1 and E [<xref ref-type="bibr" rid="R267">267</xref>, <xref ref-type="bibr" rid="R268">268</xref>]. This effect depends on the activation of PI3K-PKB and ERK1/2 and JNK MAPK pathways. In anoxia, expression of GDF-15 increases in GBM cells independently of p53 and HIF-1, as demonstrated in the LN-Z308 cell line [<xref ref-type="bibr" rid="R269">269</xref>]. Then, this hormone causes angiogenesis in hypoxic conditions which corresponds to increasing peritumoral angiogenesis in region of raised regional tissue tension followed by regional cerebral blood flow failure causing hypoxia [<xref ref-type="bibr" rid="R270">270</xref>]. Through the stabilization of the p53-MDM2 complex, it disrupts the p53 function in vascular cells [<xref ref-type="bibr" rid="R271">271</xref>]. This is followed by an increase in HIF-1α expression and an increase in VEGF expression, as demonstrated in HUVEC [<xref ref-type="bibr" rid="R271">271</xref>]. In hypoxia, this causes angiogenesis in the tumor.</p>
</sec>
<sec id="s5_2_2">
<title>Effect on migration and invasion</title>
<p>GDF-15 also promotes migration and invasion of GBM cells [<xref ref-type="bibr" rid="R262">262</xref>]. Anti-GDF-15 antibodies induce a decrease in the invasive capabilities of lines such as U-373 MG and LN-308 while increasing the invasion capability of the LN-428 line [<xref ref-type="bibr" rid="R261">261</xref>]. This indicates that depending on tumor cell changes, GDF-15 inhibits or enhances the migration and invasion of GBM cells. Nevertheless, GBM is a tumor with high intratumoral heterogeneity. As a result, this cytokine can cause the migration of certain tumor lines sensitive to GDF-15 in the GBM tumor. Linking such changes in the cancer cell to the effect of GDM-15 requires further investigation. It is known that GDF-15 affects the activity of the uroplasminogen activation system in LNT-229 and LN-308 glioma cells. GDF-15 induces an increase in miRNA expression, silencing plasminogen activator inhibitor-1 (PAI-1), and a less pronounced silencing ofthe expression of urokinase-type plasminogen activator (uPAR) receptor [<xref ref-type="bibr" rid="R262">262</xref>]. More precise studies have shown that GDF-15 affects GBM cell migration independently of uroplasminogen activation system expression [<xref ref-type="bibr" rid="R262">262</xref>].</p>
<p>GDF-15 can have an affect on invasion by using other pathways as demonstrated in experiments using other cancers. GDF-15 causes epithelial-mesenchymal transition (EMT) of colorectal cancer in HT29 and SW480 cell lines [<xref ref-type="bibr" rid="R272">272</xref>] and carcinoma cell line HepG2 [<xref ref-type="bibr" rid="R273">273</xref>]. GDF-15 results in decreased expression of E-cadherin and increased expression of N-cadherin and vimentin.</p>
<p>The adhesion of GBM cells is performed by integrins [<xref ref-type="bibr" rid="R274">274</xref>]. GDF-15 may interfere with integrin activation [<xref ref-type="bibr" rid="R250">250</xref>, <xref ref-type="bibr" rid="R275">275</xref>]. However, the impact on GBM migration via this pathway still needs to be investigated further. This cytokine may also increase the expression of MMP2 and MMP9 by activation of the PI3K-mTOR pathway, as demonstrated in ovarian cancer cells [<xref ref-type="bibr" rid="R276">276</xref>]. However, the impact on GBM via this pathway is yet to be confirmed.</p>
</sec>
<sec id="s5_2_3">
<title>Effect on tumor immune escape</title>
<p>GDF-15 also causes tumor immune escape. In experiments on splenocytes, it reduced IL-2 synthesis and increased the synthesis of immunosuppressive IL-10 [<xref ref-type="bibr" rid="R265">265</xref>]. GDF-15 has been shown to impair NK function and reduce malignant infiltration of macrophages and T cells in tumors [<xref ref-type="bibr" rid="R265">265</xref>]. In addition, GDF-15 causes dendritic cell function abnormalities. It reduces the synthesis of IL-12 and increases the synthesis of TGF-β1, a cytokine that also strongly disrupts the immune function [<xref ref-type="bibr" rid="R277">277</xref>]. GDF-15 also decreases the expression on dendritic cell membrane proteins, particularly CD25, CD83, CD86 and HLA-DR [<xref ref-type="bibr" rid="R277">277</xref>, <xref ref-type="bibr" rid="R278">278</xref>]. These changes cause disorders in the stimulation of the antitumor immune response, in particular a reduction in the stimulation of cytotoxic T lymphocytes and other immune cells [<xref ref-type="bibr" rid="R277">277</xref>]. This causes immunosuppression in the tumor microenvironment.</p>
<p>In addition to silencing the antitumor immune response, GDF-15 affects cell migration to the tumor niche. In particular, it enhances expression of CCL2/MCP-1 chemokine via TGFβRII-SMAD-3, as demonstrated on RAW 264.7 macrophages [<xref ref-type="bibr" rid="R249">249</xref>]. GDF-15 action via TGFβRII differs from the activation of this receptor by TGF-β (which does not increase the expression of CCL2/MCP-1). In addition to its effects on chemokine expression, GDF-15 exhibits increased expression of CCL2/MCP-1 receptor (CCR2) in macrophages [<xref ref-type="bibr" rid="R249">249</xref>]. This cytokine also changes CCR2 phosphorylation, which increases the intensity of activation of this receptor [<xref ref-type="bibr" rid="R249">249</xref>].</p>
<p>GDF-15 may interfere with the recruitment of monocytes and neutrophils into the tumor niche. In particular, GDF-15 disrupts integrin activation on THP-1 monocytes and murine neutrophils [<xref ref-type="bibr" rid="R250">250</xref>, <xref ref-type="bibr" rid="R275">275</xref>]. This results in abnormal adherence and diapedesis of these cells and hence a decrease in infiltration of monocytes and neutrophils to other tissues. This effect is dependent on TGFβRI/ALK-5 and TGFβRII receptors [<xref ref-type="bibr" rid="R250">250</xref>].</p>
</sec>
</sec>
</sec>
<sec id="s6">
<title>SPHINGOSINE-1-PHOSPHATE</title>
<sec id="s6_1">
<title>Sphingosine-1-phosphate synthesis, degradation, and receptors</title>
<p>Sphingosine-1-phosphate (S1P) is a hormone; a sphingolipid synthesized from sphingosine by two sphingosine kinase isoforms: sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) [<xref ref-type="bibr" rid="R279">279</xref>, <xref ref-type="bibr" rid="R280">280</xref>]. These enzymes catalyze the same reaction but have different cellular locations and functions [<xref ref-type="bibr" rid="R280">280</xref>]. Activated SphK1 attaches to the cell membrane and catalyzes the formation of S1P; it is responsible for the concentration of S1P outside the cell. The activity and product of the reaction catalyzed by this enzyme have antiapoptotic and promitogenic properties. In contrast, SphK2 is primarily a nuclear enzyme. Its inactive form is attached to biological membranes (in particular to the cell membrane) and to the endoplasmic reticulum via the BH3 domain. SphK2 activity has proapoptotic properties and inhibits cell division.</p>
<p>S1P is inactivated in two ways. First, it can be dephosphorylated by S1P-catalyzed phosphohydrolase (SPP)1 or SPP2. Another way to inactivate this hormone is through breakdown by S1P lyase (SPL).</p>
<p>The synthesized S1P can act as a second messenger, as well in an autocrine or paracrine manner via S1P receptors on the surface of cells. As the second messenger, S1P activates peroxisome proliferator-activated receptor γ (PPARγ) and thus performs important functions in HUVEC physiology [<xref ref-type="bibr" rid="R281">281</xref>]. However, S1P is also secreted outside the cell. Then, in an autocrine or paracrine manner it activates five of its receptors (S1PR<sub>1-5</sub>), coupled with different small G proteins and thus differing in signal transduction and function [<xref ref-type="bibr" rid="R282">282</xref>].</p>
</sec>
<sec id="s6_2">
<title>Sphingosine-1-phosphate-related enzymes in the glioblastoma multiforme tumor</title>
<p>S1P plays a very important role in apoptosis [<xref ref-type="bibr" rid="R283">283</xref>–<xref ref-type="bibr" rid="R285">285</xref>], homeostasis of the immune system [<xref ref-type="bibr" rid="R284">284</xref>, <xref ref-type="bibr" rid="R286">286</xref>] and blood vessel physiology [<xref ref-type="bibr" rid="R287">287</xref>]. An increasing number of papers show that S1P plays a very important role in the pathogenesis of cancers, including the development of brain tumors. GBM is associated with the overexpression of S1PR<sub>1</sub>, S1PR<sub>2</sub>, S1PR<sub>3</sub> and S1PR<sub>5</sub> and higher S1P concentrations than in the rest of the brain [<xref ref-type="bibr" rid="R288">288</xref>, <xref ref-type="bibr" rid="R289">289</xref>]. At the same time, S1PR<sub>4</sub> is not expressed in this tumor or in normal brain tissue [<xref ref-type="bibr" rid="R288">288</xref>, <xref ref-type="bibr" rid="R289">289</xref>].</p>
<p>In contrast, SphK1 expression is higher in recurrent and secondary GBM, whereas SphK2 is higher in primary GBM [<xref ref-type="bibr" rid="R288">288</xref>]. Also, the expression of S1PRs differs in GBM. The expression of S1PR<sub>1</sub> and S1PR<sub>5</sub> is elevated in all types of GBM, mostly in secondary GBM [<xref ref-type="bibr" rid="R288">288</xref>]. In contrast, increased expression of S1PR<sub>2</sub> and S1PR<sub>3</sub> occurs only in secondary GBM [<xref ref-type="bibr" rid="R288">288</xref>].</p>
<p>A reduction in S1PR<sub>1</sub> expression is associated with a shorter postoperative survival time of patients [<xref ref-type="bibr" rid="R289">289</xref>–<xref ref-type="bibr" rid="R291">291</xref>]. Also the overexpression S1PR<sub>2</sub> [<xref ref-type="bibr" rid="R289">289</xref>], S1PR<sub>5</sub> [<xref ref-type="bibr" rid="R288">288</xref>] SphK1 [<xref ref-type="bibr" rid="R292">292</xref>–<xref ref-type="bibr" rid="R294">294</xref>] and SPP1 [<xref ref-type="bibr" rid="R289">289</xref>] is associated with short postoperative survival time. Nevertheless, different studies indicate different proteins related to the survival of patients. Research by Bien-Möller et al. shows that the expression of S1PR<sub>3</sub>, S1PR<sub>5</sub> and the enzymes SphK1, SphK2, SPP2 and SPL1 is not related to survival [<xref ref-type="bibr" rid="R289">289</xref>]. In contrast, Quint et al. show that S1PR<sub>1</sub>, S1PR<sub>2</sub>, S1PR<sub>3</sub>, SphK1 and SphK2 have no such effect [<xref ref-type="bibr" rid="R288">288</xref>].</p>
</sec>
<sec id="s6_3">
<title>Effect on glioblastoma cell viability</title>
<p><italic>In vitro</italic> experiments show that S1P and enzyme expression involved in the biochemistry of this hormone influence the viability and behavior of GBM cell lines. The induction of expression and activity of SphK1 are influenced by various factors, in particular activation of the receptors of PDGFR [<xref ref-type="bibr" rid="R295">295</xref>] EGFR [<xref ref-type="bibr" rid="R296">296</xref>], and the expression of variant III of EGFR mutation (EGFRvIII) [<xref ref-type="bibr" rid="R294">294</xref>]. These receptors are closely involved in the development of GBM [<xref ref-type="bibr" rid="R80">80</xref>, <xref ref-type="bibr" rid="R81">81</xref>, <xref ref-type="bibr" rid="R297">297</xref>].</p>
<p>In addition to growth factors, inflammatory reactions also increase the expression of SphK1. IL-1 enhances the expression of SphK1 in GBM cells via c-Jun terminal kinase (JNK) MAPK and AP-1, independently of NF-κB [<xref ref-type="bibr" rid="R298">298</xref>]. Hypoxic stress also increases the expression of SphK1 [<xref ref-type="bibr" rid="R299">299</xref>, <xref ref-type="bibr" rid="R300">300</xref>]. It increases the expression and activity of SphK1 and thus the extracellular concentration of S1P. SphK1 increases the rate of cell proliferation, increases migration and invasion, and inhibits multiple glioma cell lines, in particular LN-229, LN-382, U-87 MG, U-373 MG, U-1242 MG, and primary human non-established GBM GBM6 cells [<xref ref-type="bibr" rid="R292">292</xref>, <xref ref-type="bibr" rid="R301">301</xref>, <xref ref-type="bibr" rid="R302">302</xref>]. In particular, the activation of PKB by S1PRs results in inactivation of FOXO3a and consequently a decrease in the expression of proapoptotic Bcl-2-like protein 11 (Bim) [<xref ref-type="bibr" rid="R302">302</xref>]. The expression of S1PRs, mostly S1PR<sub>1</sub>, increases the rate of proliferation of U-118 MG and U-373 MG cells [<xref ref-type="bibr" rid="R303">303</xref>]. This effect is related to the activation of ERK1/2 MAPK. S1PR<sub>5</sub> has been shown to inhibit proliferation by inhibiting ERK1/2 MAPK activation [<xref ref-type="bibr" rid="R303">303</xref>]. Nevertheless, Yoshida et al. showed the opposite results, with S1PR<sub>1</sub> decreasing tumor cell proliferation rates in U-87 MG and U-251 MG cancer cell lines [<xref ref-type="bibr" rid="R291">291</xref>].</p>
<p>S1P has different effects on different cell lines. LN18 cell proliferation is not affected by signal transduction from any of the S1PRs [<xref ref-type="bibr" rid="R289">289</xref>]. This is due to mutations in the <italic>P53</italic> gene, which results in the independence of proliferation and apoptosis of cells with mutations in that gene from the level of S1P [<xref ref-type="bibr" rid="R304">304</xref>].</p>
</sec>
<sec id="s6_4">
<title>Effect on glioblastoma stem cells</title>
<p>The action of S1P differs according to the cell type. The greatest synthesis and secretion of S1P occurs in GSC [<xref ref-type="bibr" rid="R305">305</xref>]. The expression of S1PR<sub>1</sub>, S1PR<sub>2</sub> and S1PR<sub>4</sub> also occurs predominantly in these cells, which results in the fact that it is GSC that mainly react to S1P [<xref ref-type="bibr" rid="R306">306</xref>]. For example, S1P in an autocrine manner increases the life span of the GSC. It stimulates the expression of GSC markers [<xref ref-type="bibr" rid="R307">307</xref>]. S1P also stimulates GSC proliferation and has antiapoptotic and antinecrotic effects [<xref ref-type="bibr" rid="R307">307</xref>]. As a result of this action, S1P causes resistance of GSC to TMZ, which is independent of methylguanine-methyltransferase (MGMT) expression [<xref ref-type="bibr" rid="R305">305</xref>, <xref ref-type="bibr" rid="R308">308</xref>]. These S1P properties are due to the Notch pathway in GSC [<xref ref-type="bibr" rid="R309">309</xref>], crucial because of its role in promoting proliferation and self-renewal of these cells in the GBM tumor (Figure <xref ref-type="fig" rid="F7">7</xref>) [<xref ref-type="bibr" rid="R310">310</xref>]. Signal transduction from S1PR<sub>3</sub> induces the p38 MAPK-dependent ADAM17 activation in the signal transmission from Notch1. This ADAM17 activation mechanism is independent of Notch1 receptor activation.</p>
<fig id="F7" orientation="portrait" position="float">
<label>Figure 7</label>
<caption>
<title>Activation of Notch1 pathway by S1P</title>
<p>The activation of S1PR<sub>3</sub> activates the Notch1 pathway. This activation is independent of the Notch1 ligand and is dependent on the ADAM17 protein, which results in GSC self-renewal.</p>
</caption>
<graphic xlink:href="oncotarget-09-7219-g007"></graphic>
</fig>
</sec>
<sec id="s6_5">
<title>Hypoxia and angiogenesis</title>
<p>S1P also participates in angiogenesis. In the model of hypoxia using CoCl<sub>2</sub> in GBM cells, the expression of SphK2 decreased and expression of SphK1 increased [<xref ref-type="bibr" rid="R299">299</xref>, <xref ref-type="bibr" rid="R300">300</xref>]. This results in an increase in the synthesis and concentration of S1P in the tumor microenvironment [<xref ref-type="bibr" rid="R299">299</xref>]. The increase in SphK1 expression was due to an increase in HIF-2α activity that binds to the promoter of the SphK1 gene [<xref ref-type="bibr" rid="R299">299</xref>]. HIF-1α likewise has this effect. Increasing S1P concentrations stimulates GBM cells to proliferate and inhibit apoptosis by ERK1/2 MAPK and PKB activation [<xref ref-type="bibr" rid="R300">300</xref>, <xref ref-type="bibr" rid="R302">302</xref>, <xref ref-type="bibr" rid="R303">303</xref>].</p>
<p>S1P not only affects tumor cells in an autocrine manner but also blood vessel cells. In particular, it initiates endothelial cell sprouting and migration, and formation of ‘tubes’ as shown on HUVEC, human dermal microvascular endothelial cells, and mouse embryonic fibroblasts [<xref ref-type="bibr" rid="R299">299</xref>, <xref ref-type="bibr" rid="R311">311</xref>, <xref ref-type="bibr" rid="R312">312</xref>]. This process is mainly triggered by S1PR<sub>1</sub> activation under hypoxic conditions [<xref ref-type="bibr" rid="R299">299</xref>].</p>
<p>However, in HUVEC, S1P may participate in angiogenesis independently of its specific receptors. S1P in these cells directly activates PPARγ, resulting in an increase in PAI-1 expression [<xref ref-type="bibr" rid="R281">281</xref>]. Importantly, S1P does not affect the expression of proteins involved in lipid metabolism. A consequence of PAI-1 expression is the stimulation of angiogenesis [<xref ref-type="bibr" rid="R313">313</xref>].</p>
<p>The endothelial structures formed by cells are not stable, and so S1P is not a sufficient factor for the entire course of angiogenesis. It is other proangiogenic factors that support the formation of new vessels in the tumor [<xref ref-type="bibr" rid="R311">311</xref>]. That is why in hypoxia VEGF expression occurs later than SphK1 expression [<xref ref-type="bibr" rid="R299">299</xref>]. Nevertheless, it seems that VEGF and S1P work together in angiogenesis, mutually enhancing each other's action [<xref ref-type="bibr" rid="R299">299</xref>, <xref ref-type="bibr" rid="R314">314</xref>].</p>
</sec>
<sec id="s6_6">
<title>Effect on migration and invasion</title>
<p>GBM is a tumor that always recurs after surgery. The migration and invasion of GBM cells depends on several factors, including S1P and the proteins involved in the biochemistry of this hormone. The expression of S1PR<sub>1</sub> and S1PR<sub>3</sub> is responsible for the migration and invasion of U-118 MG and U-373 MG cells [<xref ref-type="bibr" rid="R303">303</xref>]. This process depends on the plasminogen activation system. In particular, in A172, U-118 MG, and U-373 MG cells, the overexpression of S1PR<sub>1</sub>, and to a lesser extent that of S1PR<sub>2</sub> and S1PR<sub>3</sub>, results in an increase in urokinase-type plasminogen activator (uPA) and uPAR activity, independently of S1P [<xref ref-type="bibr" rid="R293">293</xref>, <xref ref-type="bibr" rid="R315">315</xref>]. In contrast, in U-373 MG cells the overexpression of S1PR<sub>1</sub> and S1PR<sub>2</sub>, as well as activation of S1PR<sub>2</sub> by S1P, result in increased expression and activity of uPAR and PAI-1 [<xref ref-type="bibr" rid="R293">293</xref>, <xref ref-type="bibr" rid="R315">315</xref>, <xref ref-type="bibr" rid="R316">316</xref>]. This is due to the activation of MEK1/2 and Rho by S1PRs [<xref ref-type="bibr" rid="R316">316</xref>]. This signal transduction also involves protein kinase D2 (PKD2) [<xref ref-type="bibr" rid="R317">317</xref>]. The activation of S1PRs activates PKD2. As a consequence, GBM cells express the proteins involved in migration and invasion, in particular proteins associated with plasminogen, integrin α-2, integrin α-4, and MMP1 [<xref ref-type="bibr" rid="R317">317</xref>].</p>
<p>S1P-dependent GBM cell migration and invasion is influenced by other signaling pathways; in particular EGFR-Src-PKCδ activates SphK1 [<xref ref-type="bibr" rid="R315">315</xref>]. As a consequence, PAI-1 is expressed in U-373 MG and A172 cells [<xref ref-type="bibr" rid="R315">315</xref>]. S1P-dependent expression of PAI-1 and uPAR may also be enhanced by IL-1 [<xref ref-type="bibr" rid="R316">316</xref>].</p>
<p>In some models, S1PR<sub>1</sub> and S1PR<sub>2</sub> activation inhibits migration but increases invasiveness by increasing the adhesion of U-87 MG, U-118 MG, U-251 MG and U-373 MG cells [<xref ref-type="bibr" rid="R293">293</xref>, <xref ref-type="bibr" rid="R303">303</xref>, <xref ref-type="bibr" rid="R318">318</xref>]. This process depends on the induction of cysteine-rich angiogenic inducer 61/CCN family member 1 (Cyr61/CCN1) expression [<xref ref-type="bibr" rid="R293">293</xref>, <xref ref-type="bibr" rid="R303">303</xref>].</p>
<p>Another very important route in the migration and transfiguration of GBM cells by S1P is Ca<sup>2+</sup> mobilization [<xref ref-type="bibr" rid="R295">295</xref>, <xref ref-type="bibr" rid="R296">296</xref>, <xref ref-type="bibr" rid="R306">306</xref>]. Activation of S1PRs results in signal transductions involving MAPK, RhoA/ROK, and phospholipase C [<xref ref-type="bibr" rid="R296">296</xref>]. This signaling also involves membrane-type-1 MMP and the glucose-6-phosphate transporter; the silencing of their expression impairs the effect of S1P on Ca<sup>2+</sup> mobilization [<xref ref-type="bibr" rid="R296">296</xref>].</p>
<p>The migration of GBM cells via Ca<sup>2+</sup> mobilization may partly depend on cytoplasmic S1P, i.e. independently of S1PRs [<xref ref-type="bibr" rid="R295">295</xref>]. In particular, S1P activates transient receptor potential C1 (TRPC1), which causes Ca<sup>2+</sup> mobilization in the cytoplasm [<xref ref-type="bibr" rid="R295">295</xref>]. In U-252 MG cells, this mechanism is induced by PDGFR activation, in particular the synthesis of S1P.</p>
</sec>
<sec id="s6_7">
<title>Tumor immune evasion: effect on macrophages</title>
<p>In GBM, TAM play an important role in immune modulation and tumor development [<xref ref-type="bibr" rid="R75">75</xref>]. The amount of TAM increases with the grade of the glioma [<xref ref-type="bibr" rid="R319">319</xref>]. Thus, they constitute a significant percentage of cells in the GBM tumor [<xref ref-type="bibr" rid="R176">176</xref>, <xref ref-type="bibr" rid="R320">320</xref>, <xref ref-type="bibr" rid="R321">321</xref>].</p>
<p>There are currently no studies showing the effects of S1P from glioma or GBM on TAM. Nevertheless, on the basis of work on melanoma [<xref ref-type="bibr" rid="R322">322</xref>], breast cancer [<xref ref-type="bibr" rid="R323">323</xref>] and S1P biochemistry research in GBM, it can be deduced that this hormone significantly influences macrophage behavior in brain tumors particularly angiogenesis [<xref ref-type="bibr" rid="R292">292</xref>–<xref ref-type="bibr" rid="R294">294</xref>].</p>
<p>No sudden angiogenesis occurs during a growth in tumor volume. Angiogenesis is only induced by hypoxia and signaling pathways activated by tumor microenvironment [<xref ref-type="bibr" rid="R324">324</xref>]. Cell apoptosis occurs very often in tumor microenvironment. Apoptotic bodies contain S1P produced by SphK2, which affects macrophages [<xref ref-type="bibr" rid="R325">325</xref>–<xref ref-type="bibr" rid="R329">329</xref>]. However, SphK1 may also be activated during apoptosis, especially during the action of antitumor drugs [<xref ref-type="bibr" rid="R283">283</xref>]. S1P in apoptotic bodies causes large changes in macrophages; it activates S1PR<sub>1</sub>, which results in an increase in HIF-1α expression even in normoxia [<xref ref-type="bibr" rid="R328">328</xref>]. As S1P alone does not increase the expression of HIF-1α, in order to induce a given effect the apoptotic bodies also activate other non-S1P signaling pathways. With regard to the effect of S1P on HIF-1α expression, the second factor is TGF-β. An increase in HIF-1α expression activates mechanisms leading to angiogenesis in the tumor.</p>
<p>SphK activity is not important in the differentiation of progenitor cells into monocytes [<xref ref-type="bibr" rid="R330">330</xref>]. In contrast, S1P is important in the egress of monocytes from the spleen and bone marrow, as demonstrated by the use of FTY720. This process is dependent on S1PRs, with the exception of S1PR<sub>3</sub> [<xref ref-type="bibr" rid="R331">331</xref>]. In monocytes already circulating in the blood, particularly in immunosuppressive mouse monocytes (CD45<sup>+</sup>CD11b<sup>+</sup>Gr1<sup>−</sup>), activation of receptors S1PR<sub>2</sub> and S1PR<sub>3</sub> by S1P activates PI3K and induces migration of these cells [<xref ref-type="bibr" rid="R332">332</xref>–<xref ref-type="bibr" rid="R334">334</xref>]. Activation of S1PR<sub>1</sub> and S1PR<sub>5</sub> does not result in the migration of monocytes [<xref ref-type="bibr" rid="R334">334</xref>, <xref ref-type="bibr" rid="R335">335</xref>].</p>
<p>Targeted monocyte migration induced by S1P is partly dependent on thrombin. S1P induces increased expression of protease-activated receptor-4 (PAR-4), a thrombin receptor [<xref ref-type="bibr" rid="R336">336</xref>], which directs the migration of monocytes to the site of elevated thrombin activity. This receptor also increases expression of COX-2. Monocyte migration mediated by S1P and thrombin can exist within the GBM tumor because this cancer has elevated thrombin activity and increased activity of SphK1 and S1P levels [<xref ref-type="bibr" rid="R337">337</xref>].</p>
<p>Activating S1PR<sub>1</sub> and S1PR<sub>3</sub> on macrophages, S1P acts as a chemoattractant for these cells [<xref ref-type="bibr" rid="R283">283</xref>, <xref ref-type="bibr" rid="R332">332</xref>, <xref ref-type="bibr" rid="R338">338</xref>–<xref ref-type="bibr" rid="R340">340</xref>]. Activation of S1PRs in macrophages results in ADP secretion and the synthesis of extracellular ATP via adenylate kinase activity. In consequence, the P2X<sub>7</sub> receptor is activated on macrophages [<xref ref-type="bibr" rid="R341">341</xref>]. This results in changes in actin polymerization, which facilitates migration. In contrast, S1PR<sub>2</sub> activation reduces macrophage migration [<xref ref-type="bibr" rid="R338">338</xref>, <xref ref-type="bibr" rid="R342">342</xref>], which is associated with increased cAMP levels and decreased PKB phosphorylation.</p>
<p>In addition to the effect on chemotaxis, S1P results in increased expression of intercellular adhesion molecule I (ICAM-1), which increases monocyte adhesion to these cells. This effect has been demonstrated on HUVEC, where ICAM-1 expression was dependent on S1PR<sub>1</sub> [<xref ref-type="bibr" rid="R343">343</xref>]. S1P has also been shown to increase expression of E-selectin in HUVEC [<xref ref-type="bibr" rid="R344">344</xref>]. This effect depended on S1PR<sub>1</sub> which activated PI3K-PKB and ERK1/2 MAPK pathways. It induced an increase in SphK activity with intracellular S1P playing the role of a second messenger [<xref ref-type="bibr" rid="R344">344</xref>]. Intracellular S1P activates NF-κB, which increases the expression of genes dependent on this transcription factor, including an increased expression of E-selectin [<xref ref-type="bibr" rid="R345">345</xref>–<xref ref-type="bibr" rid="R347">347</xref>].</p>
<p>S1P has also been shown to increase ICAM-1 expression on human pulmonary alveolar epithelial cells in a process mediated by S1PR<sub>1</sub> and S1PR<sub>3</sub> [<xref ref-type="bibr" rid="R348">348</xref>]. In these cells, ICAM-1 expression depended on the activation of ERK1/2 MAPK, p38 MAPK and JNK MAPK, and on c-Src kinase, EGFR, PDGFR and PKB [<xref ref-type="bibr" rid="R348">348</xref>]. However, S1P seems to disrupt the adhesion of monocytes to the walls of blood vessels [<xref ref-type="bibr" rid="R349">349</xref>]. It causes rearrangement on HUVEC integrins α<sub>5</sub>β<sub>1</sub> and α<sub>V</sub>β<sub>3</sub> cells, which impairs monocyte adhesion to these cells [<xref ref-type="bibr" rid="R350">350</xref>]. In addition to the effect on adhesion proteins, S1P increases the expression of chemokines that attract monocytes and macrophages. Via S1PR<sub>1</sub> and S1PR<sub>3</sub>, S1P causes an increase in the expression of CCL2/MCP-1 in HUVEC [<xref ref-type="bibr" rid="R343">343</xref>]. An increase in the expression of other chemokines may also be involved in the S1P-induced migration of monocytes. CYM-5442, an S1PR<sub>1</sub> agonist, reduces the expression of CCL2/MCP-1 and CCL7/MCP-3 in HUVEC [<xref ref-type="bibr" rid="R351">351</xref>].</p>
<p>Macrophages phagocytose the apoptotic bodies, which enables the removal of cells that are subject to apoptosis. S1P from apoptotic bodies activates S1PR<sub>1</sub> on macrophages and inhibits their apoptosis [<xref ref-type="bibr" rid="R326">326</xref>]. This effect is dependent on the level of intracellular Ca<sup>2+</sup> and the activation of ERK1/2 and PI3K. It increases the expression of Bcl-2 and Bcl-x<sub>L</sub> and causes the phosphorylation of Bcl-2-associated death promoter (BAD) in these cells. High density lipoproteins (HDL), which contain S1P, also inhibit macrophage apoptosis [<xref ref-type="bibr" rid="R352">352</xref>]. In particular, S1PR<sub>1</sub>, S1PR<sub>2</sub> and S1PR<sub>3</sub> are activated, which results in the activation of the STAT3-JAK2 pathway and therefore an increase in survivin expression.</p>
<p>Nevertheless, the phagocytosis itself also partly depends on S1P. S1PR<sub>2</sub> reduces the intensity of <italic>Escherichia coli</italic> phagocytosis by increasing the RhoA-GTP level. This causes a contraction of the macrophages [<xref ref-type="bibr" rid="R353">353</xref>]. S1PR<sub>2</sub> reduces the amount of Rac1-GTP, which inhibits actin polymerization and therefore disrupts phagocytosis in macrophages [<xref ref-type="bibr" rid="R353">353</xref>]. However, S1PR<sub>2</sub> stimulates antibody-dependent phagocytosis [<xref ref-type="bibr" rid="R354">354</xref>].</p>
<p>S1P reduces the pro-inflammatory immune response in macrophages. Via S1PR<sub>1</sub>, but not S1PR<sub>2</sub>, S1P reduces the expression of inflammatory cytokines from LPS-activated macrophages. In particular, it reduces the expression of IL-12, TNF-α and CCL2/MCP-1 and increases the expression of arginase I. Which enzyme reduces nitric oxide (NO) production in macrophages. S1P also reduces the activation of NF-κB in LPS-treated macrophages, which reduces the expression of iNOS [<xref ref-type="bibr" rid="R355">355</xref>].</p>
<p>Activation of macrophages by proinflammatory agents, such as LPS or TNF-α, results in increased production and secretion of proinflammatory cytokines. Nevertheless, SphKs do not participate in the signal transduction induced by LPS or TNF-α as demonstrated <italic>in vivo</italic> and <italic>in vitro</italic> using gene knockouts of these enzymes in murine monocytes and macrophages [<xref ref-type="bibr" rid="R330">330</xref>]. Similar results have been obtained on RAW 264.7 macrophages [<xref ref-type="bibr" rid="R356">356</xref>]. SphK1 does not affect the LPS-induced prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) production. On the other hand, increased SphK1 activity is required in RAW 264.7 to increase PGE<sub>2</sub> production in response to TNF-α [<xref ref-type="bibr" rid="R356">356</xref>], which is related to S1P involvement as a second messenger in TNF-α–induced activation of NF-κB [<xref ref-type="bibr" rid="R345">345</xref>–<xref ref-type="bibr" rid="R347">347</xref>]. Then, after chemotaxis, this hormone silences excessive immune response in macrophages [<xref ref-type="bibr" rid="R285">285</xref>]. However, this property of S1P also plays an important role in cancer immune evasion [<xref ref-type="bibr" rid="R322">322</xref>, <xref ref-type="bibr" rid="R323">323</xref>, <xref ref-type="bibr" rid="R357">357</xref>]. S1P polarizes to M2 macrophages [<xref ref-type="bibr" rid="R322">322</xref>, <xref ref-type="bibr" rid="R323">323</xref>, <xref ref-type="bibr" rid="R326">326</xref>, <xref ref-type="bibr" rid="R329">329</xref>], with a significant role of increased HO-1 expression in this process. HO-1 expression is due to the activation of two pathways by S1PR<sub>1</sub>: a p38 MAPK-dependent pathway and another which activates STAT1 and increases VEGF expression [<xref ref-type="bibr" rid="R329">329</xref>]. Then, an increase in HO-1 activity causes an increase in expression of antiapoptotic proteins in macrophages, in particular Bcl-x<sub>L</sub> and Bcl-2 [<xref ref-type="bibr" rid="R329">329</xref>]. HO-1 also increases the expression of adenosine A<sub>2A</sub> receptor in macrophages, one of the immunosuppressive mechanisms in immune cells [<xref ref-type="bibr" rid="R329">329</xref>].</p>
<p>S1P significantly changes the secretory profile of macrophages. In apoptotic bodies S1P increases the expression of COX-2 protein, in part by stabilizing COX-2 mRNA [<xref ref-type="bibr" rid="R356">356</xref>, <xref ref-type="bibr" rid="R327">327</xref>, <xref ref-type="bibr" rid="R358">358</xref>]. In addition to the effect on this enzyme, S1P also increases the activity of microsomal prostaglandin E synthase-1 (mPGES1) and decreases the activity of prostaglandin D synthase (PGDS) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH). In the tumor microenvironment, this increases the production of PGE<sub>2</sub>, a compound which participates in many mechanisms of GBM development [<xref ref-type="bibr" rid="R359">359</xref>, <xref ref-type="bibr" rid="R360">360</xref>]. S1P increases the expression of lipocalin 2 (LCN2) in macrophages, resulting in lymphangiogenesis in the breast tumor model [<xref ref-type="bibr" rid="R361">361</xref>].</p>
<p>S1P also influences NO production in macrophages. The activation of S1PR<sub>2</sub> on macrophages by the apoptotic bodies [<xref ref-type="bibr" rid="R362">362</xref>] induces the activation of extracellular signal-regulated kinase 5 (ERK5) and subsequent activation of the cAMP responsive element binding protein (CREB). This, in turn, increases the expression of arginase II, an enzyme that metabolizes L-arginine, an amino acid that serves as a substrate for nitric oxide synthase. This results in a reduction in iNOS activity and NO production. ERK5 also increases expression of CD206 and VEGF. Independently of ERK5, activation of S1PR<sub>2</sub> results in an increase in IL-10 expression [<xref ref-type="bibr" rid="R362">362</xref>].</p>
<p>As a result of exposure to S1P, indoleamine 2,3-dioxygenase (IDO), IL-8/CXCL8, IL-10 and CD206 expression increases, NO levels decrease, TNF-α and IL-12 expression decreases, i.e. polarization to M2 macrophages occurs [<xref ref-type="bibr" rid="R284">284</xref>, <xref ref-type="bibr" rid="R322">322</xref>, <xref ref-type="bibr" rid="R323">323</xref>, <xref ref-type="bibr" rid="R326">326</xref>, <xref ref-type="bibr" rid="R329">329</xref>].</p>
<p>In resident peritoneal macrophages, S1P reduces the production of poinflammatory cytokines via S1PR<sub>2</sub>, as has been demonstrated on a model with an abnormal activity of this receptor. Knockout of Gα<sub>12/13</sub>, a significant protein in the transduction of signals from S1PR<sub>2</sub> increased the expression of iNOS and COX-2, and the expression of pro-inflammatory cytokines such as IL-6, TNF-α and IFN-γ, and chemokines CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES and CXCL10/IP-10 [<xref ref-type="bibr" rid="R363">363</xref>]. This shows an immunosuppressive effect of S1P on these cells. However, in mouse bone marrow-derived macrophages, knockout of Gα<sub>12/13</sub> caused an increase in the expression of iNOS and IL-6 but not COX-2 nor the cytokines IL-1β, IL-10 and TNF-α [<xref ref-type="bibr" rid="R363">363</xref>]. At physiological concentrations, S1P alone did not result in an increased production of TNF-α, IL-6, IL-10, IL-12, or CCL2/MCP-1 in bone marrow-derived macrophages or in these cells differentiated to M1 or M2 macrophages [<xref ref-type="bibr" rid="R364">364</xref>]. S1P also did not affect phagocytic capacity or iNOS expression in that model.</p>
</sec>
<sec id="s6_8">
<title>FTY720 as an immunosuppressive drug</title>
<p>Knowledge of the effect of S1P on individual immune cells, including cells in the tumor niche, is incomplete. So far, some studies have been based on the influence of FTY720, a compound with complex effects on S1PR. Therefore, here we will discuss the mechanisms of FTY720 action to better understand the effect of S1P on various immune system cells.</p>
<p>2-amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride (FTY720/fingolimod) is an S1P analogue which exhibits immunosuppressive activity. FTY720 is phosphorylated by both SphK isoforms [<xref ref-type="bibr" rid="R365">365</xref>, <xref ref-type="bibr" rid="R366">366</xref>], but phosphorylation by SphK2 has better reaction parameters than SphK1. Therefore, in the human body FTY720 is phosphorylated mainly by SphK2 [<xref ref-type="bibr" rid="R367">367</xref>–<xref ref-type="bibr" rid="R371">371</xref>]. A reverse reaction, i.e. the dephosphorylation of FTY720-P, is carried out by lipid phosphatase 3 (LPP3) and to a lesser extent by SPP1 in cells [<xref ref-type="bibr" rid="R372">372</xref>]. Due to the uneven distribution of both SphK isoforms across human organs, FTY720 is mostly phosphorylated in the spleen, brain and lung [<xref ref-type="bibr" rid="R365">365</xref>, <xref ref-type="bibr" rid="R373">373</xref>]. To a lesser degree, phosphorylation occurs in blood and lymph nodes, and is very low in other organs.</p>
<p>FTY720-P is an agonist of S1PR<sub>1</sub>, S1PR<sub>3</sub>, S1PR<sub>4</sub> and S1PR<sub>5</sub> [<xref ref-type="bibr" rid="R373">373</xref>]. However, studies on S1PR<sub>2</sub> show that FTY720-P at a concentration of 40nM can activate some signaling pathways through this receptor [<xref ref-type="bibr" rid="R374">374</xref>, <xref ref-type="bibr" rid="R375">375</xref>]. Binding affinities of FTY720-P for receptors S1PR<sub>1</sub>, S1PR<sub>3</sub> and S1PR<sub>5</sub> are about 10nM, while100nM for S1PR<sub>4</sub> [<xref ref-type="bibr" rid="R373">373</xref>]. At higher concentrations also non-phosphorylated form of FTY720 can activate S1PR<sub>1</sub> (binding affinities of 300±51nM), and S1PR<sub>5</sub> (binding affinities 2623 ± 317nM) [<xref ref-type="bibr" rid="R376">376</xref>]. In this way, it activates these receptors and acts similarly to S1P. Nanomolar concentrations of FTY720 cause permanent internalization, downregulation and finally degradation of S1PR<sub>1</sub> and S1PR<sub>5</sub>, and to a lesser extent S1PR<sub>2</sub> [<xref ref-type="bibr" rid="R377">377</xref>]. FTY720-P also shows similar properties against S1PR<sub>1</sub> [<xref ref-type="bibr" rid="R378">378</xref>–<xref ref-type="bibr" rid="R380">380</xref>]. As a result, FTY720 and FTY720-P disrupt the signal transmission from these receptors. Eventually, FTY720 is inactivated in the liver via ω-hydroxylation catalyzed by CYP4F2 and to a lesser extent by CYP4F3B [<xref ref-type="bibr" rid="R381">381</xref>].</p>
<p>Due to its properties, FTY720 has been investigated as an immunosuppressive agent in organ and tissue transplants [<xref ref-type="bibr" rid="R382">382</xref>–<xref ref-type="bibr" rid="R386">386</xref>]. In particular, FTY720 accumulates in lymph nodes and inhibits the egress of lymphocytes [<xref ref-type="bibr" rid="R387">387</xref>]. This reduces the number of these cells in the blood and thereby reduces the immune response [<xref ref-type="bibr" rid="R388">388</xref>]. FTY720 is a potential anti-inflammatory drug in ischemia-reperfusion injury [<xref ref-type="bibr" rid="R389">389</xref>, <xref ref-type="bibr" rid="R390">390</xref>]. FTY720 can also penetrate the blood-brain barrier [<xref ref-type="bibr" rid="R391">391</xref>], reducing inflammation in the brain [<xref ref-type="bibr" rid="R392">392</xref>]. Therefore, it can be used as a drug against relapsing-remitting multiple sclerosis, and has already been approved by the FDA for universal use [<xref ref-type="bibr" rid="R393">393</xref>–<xref ref-type="bibr" rid="R395">395</xref>].</p>
</sec>
<sec id="s6_9">
<title>Sphingosine-1-phosphate and microglial cells</title>
<p>S1P is a hormone involved in the activation of the microglia by pro-inflammatory factors. An activation of these cells by a pro-inflammatory factor such as LPS results in an increase in the expression and activity of SphK1 and thus an increase in the production of S1P [<xref ref-type="bibr" rid="R396">396</xref>]. The effect of LPS on IL-1β and TNF-α production in BV2 microglial cells is cancelled by SphK1 gene knockout, or the use of an inhibitor of this enzyme [<xref ref-type="bibr" rid="R397">397</xref>, <xref ref-type="bibr" rid="R398">398</xref>]. Without pro-inflammatory factor LPS, S1P alone only slightly increases TNF-α and IL-1β production [<xref ref-type="bibr" rid="R396">396</xref>].</p>
<p>SphK1 gene knockout, or the use of an inhibitor of this enzyme, only partially suppress the effect of LPS on iNOS expression [<xref ref-type="bibr" rid="R396">396</xref>]. This shows that SphK1 activity only partially participates in the LPS-induced expression of this enzyme. In contrast, SphK1 gene knockout significantly lowers iNOS expression. Blocking of S1PR<sub>1</sub> activity does not completely suppress the effect of LPS on the expression of proinflammatory cytokines in microglial cells. Probably, other S1PRs are involved in this mechanism, or, in part, this effect depends on the S1P intracellular pool. However, further research is necessary in this area.</p>
<p>Based on current knowledge, it can be concluded that S1P plays the role of a second messenger within the microglial cell. TNF-α and cerebral ischemia reperfusion and oxygen-glucose deprivation reperfusion result in increased SphK1 activity. As a result, intracellular S1P levels increase, which in turn increases the activity of TNF receptor-associated factor 2 (TRAF2) [<xref ref-type="bibr" rid="R345">345</xref>, <xref ref-type="bibr" rid="R346">346</xref>, <xref ref-type="bibr" rid="R347">347</xref>]. The subsequent activation of E3 ubiquitin ligase eventually results in the activation of NF-κB, followed by the expression of genes dependent on this transcription factor. An example of the effect of this signal transmission pathway is the production of IL-17 which acts neurotoxically [<xref ref-type="bibr" rid="R347">347</xref>, <xref ref-type="bibr" rid="R399">399</xref>].</p>
<p>The importance of SphK1, S1P and S1PR<sub>1</sub> for inflammatory reactions in the brain allows for the development of a therapeutic approach that could protect this organ from damage. An example of such a therapeutic approach is the use of FTY720, which has been shown to inhibit LPS-induced microglia activation <italic>in vitro</italic> [<xref ref-type="bibr" rid="R397">397</xref>, <xref ref-type="bibr" rid="R400">400</xref>, <xref ref-type="bibr" rid="R401">401</xref>] and <italic>in vivo</italic> in mice with ischemic lesion [<xref ref-type="bibr" rid="R402">402</xref>]. FTY720 acts partly via the disruption of S1PR<sub>1</sub>, as demonstrated by the use of W146, an antagonist of this receptor [<xref ref-type="bibr" rid="R400">400</xref>]. Due to the effect on S1PRs, FTY720 interferes with signal transmission from p38 MAPK without affecting JNK1/2 MAPK [<xref ref-type="bibr" rid="R401">401</xref>].</p>
<p>In addition to the effects on inflammatory cytokines in inflammations, FTY720 increases expression of brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF), which both have a neuroprotective effect [<xref ref-type="bibr" rid="R400">400</xref>]. In contrast, FTY720 does not alter the production of IL-6, IL-10, IL-12p40 and TNF-α in microglial cells activated by CD40L or toll-like receptor 3 (TLR3) ligand [<xref ref-type="bibr" rid="R403">403</xref>]. This shows that the effect of S1PRs and so the action of FTY720 can occur only in some immune responses.</p>
</sec>
<sec id="s6_10">
<title>Sphingosine-1-phosphate and myeloid-derived suppressor cells</title>
<p>Myeloid-derived suppressor cells (MDSC) are a very important element in GBM mechanisms. These cells are present in significant numbers in the GBM tumor. It is estimated that they represent 40%±20% of all CD11b<sup>+</sup> cells in this tumor [<xref ref-type="bibr" rid="R176">176</xref>]. GBM patients also have an elevated number of these cells in the blood. MDSC are mainly involved in cancer immune evasion but also in angiogenesis and cancer cell migration [<xref ref-type="bibr" rid="R404">404</xref>, <xref ref-type="bibr" rid="R405">405</xref>].</p>
<p>In the functioning of MDSC, an important role is played by S1P, as evidenced by experiments involving FTY720. This drug caused an <italic>in vivo</italic> increase in MDSC activity in the spleen of murine sclerodermatous chronic graft-versus-host disease [<xref ref-type="bibr" rid="R406">406</xref>] and in the spleen and liver of the immune-mediated hepatic injury model [<xref ref-type="bibr" rid="R407">407</xref>] and in tumors [<xref ref-type="bibr" rid="R408">408</xref>]. Due to these properties, FTY720 silences the immune response, protecting the organs from damage, but also participating in tumor processes.</p>
<p>MDSC accumulation is dependent on increased expression of CXCL1/GROα and CXCL2/GROβ as well as increased expression on the MDSC receptor for these chemokines: CXCR2 [<xref ref-type="bibr" rid="R407">407</xref>]. In the tumor, activation of the S1PR<sub>3</sub>-ERK1/2 MAPK pathway on MDSC by FTY720 results in increased expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), resulting in MDSC accumulation in the tumor niche and autocrine stimulation of immunosuppressive functions of these cells [<xref ref-type="bibr" rid="R408">408</xref>–<xref ref-type="bibr" rid="R410">410</xref>]. These results show that S1PR<sub>3</sub> activation by carcinogenic S1P can stimulate MDSC immunosuppressive activity in the tumor niche.</p>
<p>Prolonged exposure to FTY720 also causes a disturbance in the transmission of signals from S1PR<sub>1</sub> that independently of PI3K-PKB reduces the activity of mTOR, thus increasing the expression of iNOS in the MDSC [<xref ref-type="bibr" rid="R407">407</xref>]. An increase in the concentration of NO causes the differentiation and stimulation of T<sub>reg</sub> function, which is as an important mechanism of the immunosuppressive effect of FTY720 on these cells. However, such an action can help facilitate the development of cancer [<xref ref-type="bibr" rid="R411">411</xref>, <xref ref-type="bibr" rid="R412">412</xref>].</p>
<p>The balance of the effect of S1P on S1PR<sub>1</sub> and S1PR<sub>3</sub> in the activity of MDSC in tumor niche requires further studies.</p>
</sec>
<sec id="s6_11">
<title>Sphingosine-1-phosphate and regulatory T cells</title>
<p>S1P also influences the function of T<sub>reg</sub> cells. In naïve CD4<sup>+</sup> T cells S1PR<sub>1</sub> causes activation of mTOR [<xref ref-type="bibr" rid="R413">413</xref>]. The activation of this pathway causes Smad3 malfunction. Thus, S1P and FTY720 disrupt <italic>in vitro</italic> and <italic>in vivo</italic> cell differentiation to T<sub>reg</sub> but stimulate differentiation into cytotoxic T<sub>H</sub>1. This mechanism is an element of a negative feedback mechanism that inhibits overly extensive TGF-β action, as the latter causes an increase in SphK1 expression. S1P then disrupts the action of TGF-β [<xref ref-type="bibr" rid="R413">413</xref>]. However, FTY720 in other experimental conditions causes permanent down-regulation and degradation of S1PR<sub>1</sub> which interferes with signal transduction through the receptor [<xref ref-type="bibr" rid="R377">377</xref>–<xref ref-type="bibr" rid="R380">380</xref>]. This enhances the immunosuppressive effect.</p>
<p><italic>In vivo</italic> experiments show that FTY720 causes differentiation and an increase in T<sub>reg</sub> numbers in the spleen [<xref ref-type="bibr" rid="R414">414</xref>], but FTY720 does not affect the proliferation of these cells [<xref ref-type="bibr" rid="R414">414</xref>, <xref ref-type="bibr" rid="R415">415</xref>]. Wolf et al. have shown that FTY720 does disrupt T<sub>reg</sub> proliferation by inhibiting IL-2-dependent STAT5 phosphorylation [<xref ref-type="bibr" rid="R416">416</xref>]. In inflammatory reactions, FTY720 causes <italic>in vivo</italic> retention of T<sub>reg</sub> in lymph nodes near the inflammatory sites, but not from the spleen [<xref ref-type="bibr" rid="R417">417</xref>]. An increase in T<sub>reg</sub> numbers results in an immune response near the lymph nodes [<xref ref-type="bibr" rid="R418">418</xref>].</p>
<p>S1P participates in the silencing of the immune response in the tumor microenvironment. S1P causes the S1PR<sub>1</sub>-mediated activation of STAT3, and thereby accumulation of T<sub>reg</sub> in the tumor niche, as evidenced in an <italic>in vivo</italic> model of the B16 melanoma cell line, MB49 bladder carcinoma line, and in patients with breast cancer [<xref ref-type="bibr" rid="R419">419</xref>, <xref ref-type="bibr" rid="R420">420</xref>]. So far no study has analyzed the effect of S1P on T<sub>reg</sub> in the tumor niche. Research on FTY720 show that this drug supports the functions of these cells. The active form of FTY720-P induces an increased expression of TGF-β1 and FoxP3 marker in T<sub>reg</sub> cells [<xref ref-type="bibr" rid="R415">415</xref>, <xref ref-type="bibr" rid="R421">421</xref>]. On the other hand it does not cause a significant increase in IL-10 production in these cells. In addition, FTY720 expresses the Foxp3 marker on Foxp3<sup>−</sup>CD4<sup>+</sup>T cells <italic>in vivo</italic> [<xref ref-type="bibr" rid="R417">417</xref>]. This indicates that S1P has an opposite, anti-cancer effect by disturbing the functions of T<sub>reg</sub>.</p>
</sec>
<sec id="s6_12">
<title>Sphingosine-1-phosphate and neutrophils</title>
<p>The effect of S1P on neutrophils in the tumor microenvironment is poorly understood. Also, the effect of S1P on neutrophil functions is still debatable. <italic>In vivo</italic> and <italic>in vitro</italic> murine models showed that the knockout of SphK1 or SphK2 had no effect on the migration and respiratory burst of neutrophils [<xref ref-type="bibr" rid="R422">422</xref>]. However, other experiments show the importance of the SphK1-S1P pathway in the physiology of these cells. The activation of S1PR<sub>1</sub> results in the <italic>in vivo</italic> infiltration of neutrophils during inflammatory reactions [<xref ref-type="bibr" rid="R423">423</xref>]. Different inflammatory reactions depend on different mechanisms. During an allergic response, neutrophil infiltration is dependent on SphK1 activity but not on S1PR<sub>1</sub>, S1PR<sub>2</sub> and S1PR<sub>3</sub> activity [<xref ref-type="bibr" rid="R424">424</xref>].</p>
<p>The direct effect of S1P on neutrophils consists of a moderate inhibition of neutrophil migration via HUVEC and inhibits chemotaxis stimulated by IL-8/CXCL8 or formyl-methionyl-leucyl-phenylalanine (fMLP) [<xref ref-type="bibr" rid="R425">425</xref>]. Indirectly, S1P acts on neutrophil migration by causing increased expression of IL-8/CXCL8, a chemokine acting on neutrophils. The effect of S1P on IL-8/CXCL8 production has been demonstrated in normal epithelial virus-transformed BEAS-2B cell line [<xref ref-type="bibr" rid="R426">426</xref>–<xref ref-type="bibr" rid="R428">428</xref>], A549 lung carcinoma line [<xref ref-type="bibr" rid="R429">429</xref>] and human airway smooth muscle [<xref ref-type="bibr" rid="R430">430</xref>]. This mechanism is involved in airway inflammation. In BEAS-2B cells the effect of S1P on the expression of IL-8/CXCL8 depends on the activation S1PR<sub>2</sub> [<xref ref-type="bibr" rid="R428">428</xref>]. This enables the activation of NF-κB and an increase in IL-8/CXCL8 expression. Importantly, this effect is independent of EGFR. In BEAS-2B cells S1P can also activate ERK1/2 MAPK, depending on phospholipase D (PLD) in these cells [<xref ref-type="bibr" rid="R426">426</xref>, <xref ref-type="bibr" rid="R427">427</xref>]. ERK1/2 MAPK and PLD activation may also involve an increase in intracellular Ca<sup>2+</sup> concentration, as demonstrated in experiments on A549 cells [<xref ref-type="bibr" rid="R429">429</xref>].</p>
<p>Activation of ERK1/2 MAPK results in an increase in IL-8/CXCL8 expression. The mechanism of S1P effect on IL-8/CXCL8 expression is cell dependent. In HUVEC S1P increases expression of IL-8/CXCL8 by activating S1PR<sub>1</sub> and S1PR<sub>3</sub> [<xref ref-type="bibr" rid="R343">343</xref>]. In human airway smooth muscle isolated from patients, the effect of S1P on the expression of IL-8/CXCL8 was dependent on p38 and ERK1/2 MAPK, but independent of NF-κB [<xref ref-type="bibr" rid="R430">430</xref>]. p38 and ERK1/2 MAPK activate mitogen and stress activated kinase 1 (MSK1) which results in an increase in IL-8/CXCL8 expression.</p>
<p>In addition to the effects on chemokines, S1P increases the expression of ICAM-1 on cells such as A549 [<xref ref-type="bibr" rid="R429">429</xref>] and HUVECs [<xref ref-type="bibr" rid="R343">343</xref>]. This helps in the diapedesis of neutrophils. S1P also increases IL-8/CXCL8 expression in ovarian cancer cells such as HEY, OCC1 and SKOV3 [<xref ref-type="bibr" rid="R431">431</xref>]. The effect of S1P on cells in the GBM niche requires further studies. S1P is mainly synthesized by GSC [<xref ref-type="bibr" rid="R305">305</xref>]. If S1P exerts a chemotactic effect on neutrophils via IL-8/CXCL8 then this may explain the presence of these cells near the GSC [<xref ref-type="bibr" rid="R185">185</xref>]. However, the association of S1P with the recruitment and distribution of neutrophils in GBM has yet to be investigated.</p>
<p>Neutrophils are short-lived cells that undergo rapid apoptosis [<xref ref-type="bibr" rid="R432">432</xref>]. Activation of these cells by pro-inflammatory factors blocks the apoptosis, with an important role played by SphK1: an LPS-induced increase in the expression and activity of SphK1 inhibits the intensity of neutrophil apoptosis via activation of PI3K [<xref ref-type="bibr" rid="R433">433</xref>] and p38 MAPK [<xref ref-type="bibr" rid="R434">434</xref>, <xref ref-type="bibr" rid="R435">435</xref>]. A similar mechanism occurs in the activity of GM-CSF [<xref ref-type="bibr" rid="R433">433</xref>].</p>
<p>Extracellular S1P and SphK1 activity in cells increases the respiratory burst in activated neutrophils. In particular, studies on neutrophil activation by fMLP [<xref ref-type="bibr" rid="R433">433</xref>, <xref ref-type="bibr" rid="R436">436</xref>, <xref ref-type="bibr" rid="R437">437</xref>] and activation of the receptor for immunoglobulin Fcγ [<xref ref-type="bibr" rid="R438">438</xref>] show an increase in the production of S1P in immune responses, which augments the respiratory burst in activated neutrophils. S1P affects the activity of NADPH oxidase in two ways. It activates the PI3K-PKB pathway [<xref ref-type="bibr" rid="R433">433</xref>, <xref ref-type="bibr" rid="R437">437</xref>] and independently of PI3K it increases intracellular Ca<sup>2+</sup> concentration [<xref ref-type="bibr" rid="R433">433</xref>, <xref ref-type="bibr" rid="R434">434</xref>]. The increase in intracellular Ca<sup>2+</sup> concentration results in activation of p38 MAPK and consequently S100A8/A9 translocation and thereby an increase in NADPH oxidase activity [<xref ref-type="bibr" rid="R434">434</xref>]. However, this impact still requires further research because Zemann et al. had earlier shown that a knockout of the SphK1 gene did not affect the intensity of the respiratory burst induced by fMLP [<xref ref-type="bibr" rid="R422">422</xref>].</p>
<p>Enzymes involved in S1P production may also inhibit the respiratory burst. In particular, LPS causes increased expression of SphK1 in neutrophils [<xref ref-type="bibr" rid="R439">439</xref>]. This protein, regardless of its enzymatic activity, stabilizes JNK MAPK and thus distorts the signal transmission through this kinase. Consequently, it reduces NADPH oxidase activation.</p>
<p>Neutrophils accumulate in GBM tumors, which results in a deterioration in prognosis for patients [<xref ref-type="bibr" rid="R186">186</xref>, <xref ref-type="bibr" rid="R187">187</xref>]. In the tumor niche, neutrophils secrete many substances involved in angiogenesis, migration and invasion of tumor cells and in tumor immune evasion [<xref ref-type="bibr" rid="R127">127</xref>, <xref ref-type="bibr" rid="R440">440</xref>]. Nevertheless, the significance of these cells in the context of cancer processes is poorly understood. The impact of S1P on tumor neutrophils is even less understood. However, <italic>in vitro</italic> studies show that S1P activity on neutrophil is similar to the behavior (migration and apoptosis inhibition) of these cells in the tumor niche. Significantly, the respiratory burst in neutrophils associated with cancers is at a low level [<xref ref-type="bibr" rid="R127">127</xref>]. S1P does increase the respiratory burst, but in the tumor microenvironment there are no substances that stimulate it.</p>
</sec>
</sec>
<sec id="s7">
<title>MULTI-DRUG THERAPY AGAINST SECRETORY FACTORS</title>
<sec id="s7_1">
<title>Therapeutic strategies for the treatment of glioblastoma multiforme</title>
<p>Treatment limitations such as high average age onset, tumor localization, and still inadequate knowledge of GBM pathophysiology, are cited as factors contributing to the short median survival [<xref ref-type="bibr" rid="R441">441</xref>]. Currently, standard therapeutic procedures in GBM include surgical resection of tumors followed by radiotherapy and chemotherapy. Surveys so far confirm that tumor resection should be performed to the maximum extent possible [<xref ref-type="bibr" rid="R442">442</xref>]. The next step in GBM treatment is radiotherapy, i.e. external beam radiation therapy [<xref ref-type="bibr" rid="R443">443</xref>] or stereotactic radiosurgery (gamma knife) [<xref ref-type="bibr" rid="R444">444</xref>]. Radiotherapy is combined with chemotherapy, in particular fotemustine or cyclically administered TMZ [<xref ref-type="bibr" rid="R445">445</xref>, <xref ref-type="bibr" rid="R446">446</xref>]. Both these compounds are alkylating agents and thus, by damaging DNA, they inhibit cell proliferation. Nevertheless, the currently used therapeutic approach to GBM treatment is very ineffective, with very low 5-year survival [<xref ref-type="bibr" rid="R4">4</xref>]. Therefore, new therapeutic methods are being sought.</p>
</sec>
<sec id="s7_2">
<title>Novel therapies</title>
<p>Novel therapies are being developed to support the classic GBM treatment. Many of these therapies are still at clinical level [<xref ref-type="bibr" rid="R447">447</xref>]. The novel therapies include, among others, calorie restricted ketogenic diet [<xref ref-type="bibr" rid="R448">448</xref>–<xref ref-type="bibr" rid="R451">451</xref>], immunotherapy [<xref ref-type="bibr" rid="R452">452</xref>–<xref ref-type="bibr" rid="R455">455</xref>] and the use of oncolytic viruses [<xref ref-type="bibr" rid="R456">456</xref>–<xref ref-type="bibr" rid="R458">458</xref>]. New chemotherapeutics are also being developed to generate personalized therapy [<xref ref-type="bibr" rid="R459">459</xref>–<xref ref-type="bibr" rid="R460">460</xref>].</p>
</sec>
<sec id="s7_3">
<title>Calorie restricted ketogenic diet</title>
<p>Changes in the metabolism of carbohydrates and fats are one of the ‘hallmarks of cancer’ [<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref>]. First demonstrated by Otto Warburg, after whom it was named the Warburg effect [<xref ref-type="bibr" rid="R461">461</xref>, <xref ref-type="bibr" rid="R462">462</xref>], the phenomenon is based on the intense anaerobic glycolysis that produces lactic acid and acidification in the tumor microenvironment. Lactic acid and low pH in the tumor are one of the most important elements of the tumor microenvironment which cause cancer immune evasion [<xref ref-type="bibr" rid="R463">463</xref>]. To some extent, the Warburg effect also makes tumor cells dependent on carbohydrates as a major source of energy, as cancer cells are not able to use ketone bodies as a source of energy. Therefore the implementation of the ketogenic diet, i.e. carbohydrate-restricted diet, causes the ‘starvation’ of cancer cells, including GBM [<xref ref-type="bibr" rid="R449">449</xref>, <xref ref-type="bibr" rid="R464">464</xref>]. Normal cells, including nerve cells, are able to metabolize ketone bodies. Due to the metabolic difference between GBM and non-cancer cells, a combination of a calorie restricted ketogenic diet with a standard therapeutic approach is proposed [<xref ref-type="bibr" rid="R448">448</xref>–<xref ref-type="bibr" rid="R451">451</xref>].</p>
</sec>
<sec id="s7_4">
<title>Immunotherapy</title>
<p>Certain hopes are also linked to two therapeutic approaches, which may act on non-cancer cells or directly on tumor cells. The first approach targets cells associated with the tumor, particularly T<sub>reg</sub>, macrophages and microglia, which have a significant effect on tumor immune evasion [<xref ref-type="bibr" rid="R59">59</xref>, <xref ref-type="bibr" rid="R465">465</xref>]. The second approach aims at stimulating the cells of the immune system to destroy cancer cells [<xref ref-type="bibr" rid="R452">452</xref>–<xref ref-type="bibr" rid="R455">455</xref>]. The combination of these two strategies is also advocated because of tumor immune evasion processes that compromise the effects of immunotherapy [<xref ref-type="bibr" rid="R238">238</xref>, <xref ref-type="bibr" rid="R454">454</xref>, <xref ref-type="bibr" rid="R466">466</xref>]. Therefore, the use of antitumor immunostimulant drugs, especially the use of pro-inflammatory cytokines, should increase the therapeutic effects of immunotherapy. This therapeutic approach, as well as immunotherapy itself, specifically destroy tumor cells. As a result, it has fewer side effects compared to non-specific drugs destroying dividing cells [<xref ref-type="bibr" rid="R467">467</xref>–<xref ref-type="bibr" rid="R470">470</xref>].</p>
</sec>
<sec id="s7_5">
<title>Multi-drug therapy as a strategy against glioblastoma multiforme: personalized therapy</title>
<p>The ongoing research on GBM continues to reveal specific mechanisms in the development of GBM, which helps develop therapies targeted at a specific enzyme, tissue hormone, or other specific tumorigenic agent in a particular patient. This is known as personalized therapy [<xref ref-type="bibr" rid="R459">459</xref>, <xref ref-type="bibr" rid="R460">460</xref>].</p>
<p>Nevertheless, GBM is a tumor with a very high intratumoral heterogeneity. GBM cells in each patient exhibit a different sensitivity to a given drug. It is estimated that 1/4 of all GBM cells in a given patient are resistant to TMZ and 1/10 are very susceptible to this drug [<xref ref-type="bibr" rid="R22">22</xref>]. Therefore, the use of a single drug in GBM results in unsatisfactory therapeutic outcomes. An example of this is TMZ, which, when given to patients undergoing radiotherapy and neurosurgical intervention, results in an increase in the 5-year survival from 1.9% to 9.8% [<xref ref-type="bibr" rid="R4">4</xref>]. One also should not forget about the serious side effect of antineoplastic drugs. The use of many drugs and therapeutic approaches at the same time will result in compounding side effects [<xref ref-type="bibr" rid="R471">471</xref>].</p>
</sec>
<sec id="s7_6">
<title>Multi-drug therapy as a strategy against intratumoral heterogeneity</title>
<p>The extension of the personalized therapy may be a multi-drug therapy, with particular emphasis on the secretory factors in a tumor. Using only one drug often causes GBM recurrence, because a significant percentage of tumor cells are resistant to the drug [<xref ref-type="bibr" rid="R22">22</xref>]. It is much less likely to find a tumor cell resistant to two drugs at the same time, and even less so to five drugs. If TMZ is used in addition to radiotherapy, it can increase the 5-year survival rate 5 times. The use of an additional drug can further increase this rate [<xref ref-type="bibr" rid="R308">308</xref>, <xref ref-type="bibr" rid="R472">472</xref>–<xref ref-type="bibr" rid="R476">476</xref>]. It is best to include a drug that attacks a GBM specific target that does not have a significant function in healthy cells. As a result, the side effects of this drug will be smaller. One example of this is the use of drugs against CMV infection [<xref ref-type="bibr" rid="R475">475</xref>, <xref ref-type="bibr" rid="R477">477</xref>, <xref ref-type="bibr" rid="R478">478</xref>].</p>
<p>When choosing drugs for a multidrug therapy, how they interwork should be considered. One should be chosen from the ‘hallmarks of cancer’ and then match all drugs to the selected target. At the same time, GBM contains many mechanisms that trigger the stimulation of proliferation, apoptosis inhibition or tumor immune evasion. The use of four drugs inhibiting proliferation and one specifically impairing tumor immune evasion results in the response of tumor cells similar to when only anti-proliferative drugs are used. Tumor immune evasion mechanisms vary in the tumor microenvironment. Blocking of one signaling particle leads to the drug's action only in a small part of the tumor (i.e. due to intratumoral heterogeneity), or a lack of therapeutic effects associated with the complementary action of other immune evasion mechanisms.</p>
<p>NT, S1P, GDF-15 and CMV infection have almost identical properties and functions. Within GBM, their concentrations are increased, and the expression of their receptors and enzyme activity responsible for their production also increase. All these factors have implications for all significant ‘hallmarks of cancer’ such as stimulated proliferation, inhibited apoptosis, tumorigenic effect on GSC, angiogenesis, migration, invasion, and tumor immune evasion. In addition, the increase in the concentrations of these factors is not local, but gradually occurs throughout the tumor. This offsets certain problems associated with intratumoral heterogeneity. One may even assume that in the tumor microenvironment there is a pool of all the secretory factors that complement and cooperate with one another. Therefore, multi-drug therapy may be used to interfere with various secretory factors. As a result, tumorigenic and antitumoral imbalance in the tumor microenvironment may be impaired, consequently leading to the destruction of all tumor cells [<xref ref-type="bibr" rid="R479">479</xref>].</p>
</sec>
<sec id="s7_7">
<title>Antineoplastic agents fighting cytomegalovirus infection</title>
<p>Based on knowledge used to develop the currently used therapies, cytostatics are used to treat cancer [<xref ref-type="bibr" rid="R480">480</xref>]. These drugs or X-rays destroy only dividing cells. Due to the fact that GSC are rarely-dividing cells with drug resistance enzymes, this therapeutic approach has only the short-term effect of decreasing tumor mass [<xref ref-type="bibr" rid="R481">481</xref>]. During such therapy, GSC are not destroyed, which results in the recurrence of cancer. Evaluated on the basis of available literature, the role of CMV in tumoral mechanisms in GBM brings some therapeutic hopes. In particular, tropism of CMV for CD133<sup>+</sup> GSC and the significance of this virus in GSC functions make these cells significant in CMV/GBM therapy [<xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R50">50</xref>].</p>
<p>The growth of a tumor associated with chronic CMV infection takes years. During this process Darwinian-like selection of cells occurs, in terms of tumor processes, resulting in the formation of advanced cancer [<xref ref-type="bibr" rid="R12">12</xref>]. In these, tumor processes are fully dependent on the pro-tumor properties of CMV. This leads to the susceptibility of such tumors to antiviral drugs used against CMV [<xref ref-type="bibr" rid="R473">473</xref>, <xref ref-type="bibr" rid="R475">475</xref>]. Currently, the proposed approach is to combine radiotherapy and TMZ with the use of antiviral drugs or immunotherapy against CMV.</p>
<p>Cidofovir and valganciclovir are being tested as antiviral drugs in CMV infection, while other new drugs are also being developed. Cidofovir is an analog of cytosine. It inhibits DNA polymerase activity not only in CMV but also in other viruses [<xref ref-type="bibr" rid="R482">482</xref>]. This counteracts CMV replication. However, the activity of cidofovir is very non-specific [<xref ref-type="bibr" rid="R473">473</xref>]. This drug is also a substrate for non-viral DNA polymerases in dividing cells. As a result, cidofovir causes <italic>in vitro</italic> DNA double-stranded breaks and apoptosis of U-87 MG and SF7796 cells, independently of CMV infection [<xref ref-type="bibr" rid="R473">473</xref>]. Also, this drug <italic>in vivo</italic> enhances the survival of athymic mice intracranially inoculated with U-87 MG and SF7796 cells [<xref ref-type="bibr" rid="R473">473</xref>].</p>
<p>Another anti-CMV drug tested against GBM is valganciclovir. This drug is specifically phosphorylated by the UL97 kinase viral protein [<xref ref-type="bibr" rid="R482">482</xref>]. This reaction is necessary to convert this prodrug into active ganciclovir. Because valganciclovir penetrates the blood-brain barrier, it can be used in GBM therapy [<xref ref-type="bibr" rid="R483">483</xref>, <xref ref-type="bibr" rid="R484">484</xref>]. Combined with standard therapy in clinical trials, valganciclovir brings a significant increase in mean survival rate. The effects of valganciclovir can occur after only 6 months of therapy with this prodrug. At this point the 4 year postoperative survival and median overall survival increase from 5.9% and 13.1 months to 27.3% and 24.1 months, respectively [<xref ref-type="bibr" rid="R475">475</xref>]. Continuation of valganciclovir therapy can significantly increase median overall survival to 56.4 months [<xref ref-type="bibr" rid="R474">474</xref>]. Also the combination of valganciclovir with bevacizumab, radiotherapy and TMZ increases the 6-month progression-free survival and average survival [<xref ref-type="bibr" rid="R485">485</xref>].</p>
<p>In addition to the use of antiviral drugs, researchers also recommend the use of immunotherapy against CMV in GBM treatment, especially the use of autologous dendritic cells [<xref ref-type="bibr" rid="R466">466</xref>] or autologous cytotoxic T cells [<xref ref-type="bibr" rid="R478">478</xref>, <xref ref-type="bibr" rid="R486">486</xref>–<xref ref-type="bibr" rid="R488">488</xref>] vaccinated with specific CMV antigens. Autologous dendritic cells are sensitized to the pp65 viral protein and then are introduced into the body of the patient. The combination of this therapeutic approach with neurosurgery, radiotherapy and TMZ increases overall survival from 19.2 months to 41.1 months and long-term progression-free survival from 8.0 months to 25.3 months [<xref ref-type="bibr" rid="R466">466</xref>]. In addition to dendritic cells, CMV/GBM immunotherapy uses autologous cytotoxic T cells that are sensitized to CMV antigens by autologous dendritic cells [<xref ref-type="bibr" rid="R488">488</xref>–<xref ref-type="bibr" rid="R490">490</xref>] or autologous peripheral blood mononuclear cells [<xref ref-type="bibr" rid="R478">478</xref>, <xref ref-type="bibr" rid="R486">486</xref>, <xref ref-type="bibr" rid="R487">487</xref>]. The use of autologous cytotoxic T cells in GBM therapy increases the mean overall survival from 4.3 months to 79.8 months [<xref ref-type="bibr" rid="R478">478</xref>].</p>
</sec>
<sec id="s7_8">
<title>Antitumor agents directed against neurotensin and neurotensin receptor</title>
<p>Many anti-cancer drugs directed against NT and NTSR<sub>1</sub> (Table <xref ref-type="table" rid="T2">2</xref>) are currently being tested. In the research of new GBM therapies, the most significant in this group of compounds is a NTSR<sub>1</sub> antagonist: SR48692 [<xref ref-type="bibr" rid="R202">202</xref>, <xref ref-type="bibr" rid="R491">491</xref>–<xref ref-type="bibr" rid="R493">493</xref>]. This compound exhibits antitumor properties <italic>in vitro</italic> by inhibiting proliferation and cell migration of U-87 MG GBM cells and GL261 gliomas [<xref ref-type="bibr" rid="R202">202</xref>]. Also SR48692 has therapeutic properties <italic>in vivo</italic> in C57BL/6 mice intracranially inoculated with GL261 cells [<xref ref-type="bibr" rid="R202">202</xref>].</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<title>Experimental anti-cancer drugs and pharmaceutical agents against NT and NTSR<sub>1</sub></title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Drug</th>
<th align="center" colspan="1" rowspan="1" valign="top">Mechanism of action</th>
<th align="center" colspan="1" rowspan="1" valign="top">Research model</th>
<th align="center" colspan="1" rowspan="1" valign="top">Bibliography</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SR48692</td>
<td align="center" colspan="1" rowspan="1" valign="top">NTSR<sub>1</sub> antagonist</td>
<td align="center" colspan="1" rowspan="1" valign="top">A375 melanoma cell line <italic>in vitro</italic><break></break><bold>GL261 murine glioma cell line <italic>in vitro</italic> and <italic>in vivo</italic></bold><break></break>NCI-H209 small cell lung cancer cells <italic>in vitro</italic> and <italic>in vivo</italic><break></break>PANC-1 pancreatic cell line <italic>in vitro</italic><break></break><bold>U-87 MG glioblastoma cell line <italic>in vitro</italic></bold></td>
<td align="center" colspan="1" rowspan="1" valign="top">202, 491-493</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neurotensin analogs</td>
<td align="center" colspan="1" rowspan="1" valign="top">NTR<sub>1</sub>-targeted drug</td>
<td align="center" colspan="1" rowspan="1" valign="top">HT-29 colorectal adenocarcinoma cell line <italic>in vitro</italic> and <italic>in vivo</italic><break></break>NCI-H446 small cell lung cancer cells <italic>in vitro</italic> and <italic>in vivo</italic><break></break>WiDr colorectal adenocarcinoma cell line <italic>in vitro</italic> and <italic>in vivo</italic><break></break>Ductal pancreatic adenocarcinoma clinical trial</td>
<td align="center" colspan="1" rowspan="1" valign="top">494-499</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DOTA- and DTPA- chelated neurotensin analogs</td>
<td align="center" colspan="1" rowspan="1" valign="top">NTR<sub>1</sub>-targeted drug</td>
<td align="center" colspan="1" rowspan="1" valign="top">HT-29 colorectal adenocarcinoma cell line <italic>in vitro</italic> and <italic>in vivo</italic></td>
<td align="center" colspan="1" rowspan="1" valign="top">500-502</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neurotensin Branched Peptides</td>
<td align="center" colspan="1" rowspan="1" valign="top">NTR<sub>1</sub>-targeted drug</td>
<td align="center" colspan="1" rowspan="1" valign="top">HT-29 human adenocarcinoma cell line <italic>in vitro</italic> and <italic>in vivo</italic><break></break>HT-1376 bladder cancer cell line <italic>in vitro</italic> and <italic>in vivo</italic></td>
<td align="center" colspan="1" rowspan="1" valign="top">503, 504</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neurotensin polyplex</td>
<td align="center" colspan="1" rowspan="1" valign="top">Gene transfection</td>
<td align="center" colspan="1" rowspan="1" valign="top">N1E-115 neuroblastoma cell line <italic>in vitro</italic> and <italic>in vivo</italic></td>
<td align="center" colspan="1" rowspan="1" valign="top">505-507</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Compounds that destroy tumor cells which overexpress NTSRs are also being tested on models of other tumors. These are NT derivatives labelled with radioactive isotopes or cytostatic drugs such as methotrexate or gemcitabine. An example of NT derivatives is a modified fragment of this hormone that does not undergo rapid proteolytic degradation [<xref ref-type="bibr" rid="R494">494</xref>–<xref ref-type="bibr" rid="R499">499</xref>]. Such an NT analog may be further chelated by diethylenetriamine pentaacetic acid (DTPA) or 1,4,7,10-tetraazacyldodecane-1,4,7,10-tetraacetic acid (DOTA) to enhance stability [<xref ref-type="bibr" rid="R500">500</xref>–<xref ref-type="bibr" rid="R502">502</xref>]. Another possibility are oligobranched peptides containing a NT fragment in their sequence which is recognized by NTSR<sub>1</sub> [<xref ref-type="bibr" rid="R503">503</xref>, <xref ref-type="bibr" rid="R504">504</xref>]. By labeling such NT derivatives with radioactive isotopes or cytostatic drugs, such drugs specifically destroy tumor cells that overexpress NTSR<sub>1</sub>. In addition to this therapeutic approach, a gene therapy is being tested in which a NT polyplex is used, i.e. a vector composed of NT, poly-L-lysine, and a plasmid encoding an antitumor protein such as thymidine kinase [<xref ref-type="bibr" rid="R505">505</xref>–<xref ref-type="bibr" rid="R507">507</xref>]. Nevertheless, these NT derivatives, used in the treatment of other cancers, do not cross the blood-brain barrier and so cannot be used in GBM therapy. Hence the search for the new methods of weakening the blood-brain barrier or carrying drugs through this barrier [<xref ref-type="bibr" rid="R508">508</xref>–<xref ref-type="bibr" rid="R511">511</xref>].</p>
</sec>
<sec id="s7_9">
<title>Drugs directed against growth differentiation factor-15</title>
<p>The GDF-15 receptor is currently unknown. Therefore, the most important route in anticancer therapy directed against this secretory factor are antibodies neutralizing GDF-15 [<xref ref-type="bibr" rid="R512">512</xref>]. Nevertheless, the blood-brain barrier prevents the use of these antibodies in GBM therapy [<xref ref-type="bibr" rid="R509">509</xref>–<xref ref-type="bibr" rid="R511">511</xref>].</p>
</sec>
<sec id="s7_10">
<title>Drugs targeted at the sphingosine-1-phosphate pathway</title>
<p>In anti-cancer therapy directed against S1P, much attention is given to the inhibitors of SphKs [<xref ref-type="bibr" rid="R513">513</xref>–<xref ref-type="bibr" rid="R516">516</xref>]. In particular, the best known is the specific inhibitor SphK1: 2R,3S,4E)-N-methyl-5-(4’-pentylphenyl)-2-aminopent-4-ene-1,3-diol (SK1-I) both SphK: 2-(p-hydroxyanilino)-4-p-chlorophenyl)thiazole (SKI-II) [<xref ref-type="bibr" rid="R517">517</xref>, <xref ref-type="bibr" rid="R518">518</xref>]. Their efficacy against GBM has also been confirmed <italic>in vitro</italic> on various cell lines such as A-172, LN-18, LN-229, U-87 MG, U-251 MG and T98G [<xref ref-type="bibr" rid="R301">301</xref>, <xref ref-type="bibr" rid="R302">302</xref>, <xref ref-type="bibr" rid="R308">308</xref>, <xref ref-type="bibr" rid="R472">472</xref>]. Also on the <italic>in vivo</italic> model, SphKs inhibitors have shown antitumor properties against GBM. SK1-I reduces tumor mass, inhibits angiogenesis and causes apoptosis of tumor cells, and increases the survival of nude mice intracranially inoculated with LN-229 cells [<xref ref-type="bibr" rid="R301">301</xref>]. In addition, SKI-II destroys tumor cells <italic>in vivo</italic> in nude mice inoculated subcutaneously with U-87 MG cells [<xref ref-type="bibr" rid="R302">302</xref>]. In GBM therapy with SphK inhibitors, it is also proposed to combine these drugs with the currently applied therapy, in particular with TMZ, to increase the therapeutic effect [<xref ref-type="bibr" rid="R308">308</xref>, <xref ref-type="bibr" rid="R472">472</xref>].</p>
<p><italic>In vitro</italic> and <italic>in vivo</italic> studies indicate that FTY720/fingolimod micromolar concentration has antitumor properties [<xref ref-type="bibr" rid="R519">519</xref>, <xref ref-type="bibr" rid="R520">520</xref>]. FTY720 <italic>in vitro</italic> inhibits proliferation and migration, and causes apoptosis of GBM cell lines such as U-87 MG, U-251 MG, T98G and GSC isolated from GBM tumors [<xref ref-type="bibr" rid="R521">521</xref>–<xref ref-type="bibr" rid="R525">525</xref>]. This <italic>in vivo</italic> compound reduces tumor mass, causes apoptosis and necrosis of tumor cells, and increases survival of nude mice intracranially inoculated with GSC from GBM tumors [<xref ref-type="bibr" rid="R522">522</xref>]. Also, FTY720 produces the same effects in nude mice subcutaneously inoculated with U-87 MG and U-251 MG cells [<xref ref-type="bibr" rid="R524">524</xref>]. FTY720 penetrates the blood-brain barrier and can therefore be used in GBM therapy [<xref ref-type="bibr" rid="R391">391</xref>, <xref ref-type="bibr" rid="R522">522</xref>, <xref ref-type="bibr" rid="R524">524</xref>]. Activation of S1PRs causes GBM cell proliferation. Nevertheless, tumor cells are characterized by frequent mutations in the p53 protein [<xref ref-type="bibr" rid="R526">526</xref>]. This results in a lack of stimulation of cell proliferation by S1PRs activation [<xref ref-type="bibr" rid="R304">304</xref>] and thereby enhances the antitumor activity of FTY720 that is dependent and independent of these receptors [<xref ref-type="bibr" rid="R520">520</xref>]. At nanomolar concentrations, FTY720 causes down-regulation and degradation of S1PRs [<xref ref-type="bibr" rid="R377">377</xref>]. Its antineoplastic properties can only be observed at micromolar concentrations, which indicates the the mechanisms of the antineoplastic action of FTY720 is independent of S1RPs</p>
<p>FTY720 also inhibits angiogenesis and cancels the action of VEGF by reducing vascular permeability and reduced sprouting of HUVEC at concentrations below 1 nM, by acting on CXCR4 and S1PR [<xref ref-type="bibr" rid="R367">367</xref>, <xref ref-type="bibr" rid="R527">527</xref>]. CXCR4 receptors are receptors whose activation may be involved in angiogenesis. This receptor may be regulated by S1PRs [<xref ref-type="bibr" rid="R528">528</xref>–<xref ref-type="bibr" rid="R530">530</xref>]. Nevertheless, the effect of FTY720 on CXCR4 in angiogenesis inhibition should be further explored. Also in an <italic>in vivo</italic> model, FTY720 inhibited tumor growth and angiogenesis in mice inoculated with PLC/PRF/5 and Huh7 human hepatocellular carcinoma lines at a dose of 10mg/kg per day [<xref ref-type="bibr" rid="R531">531</xref>], B16/BL6 murine melanoma at 3mg/kg daily [<xref ref-type="bibr" rid="R378">378</xref>], and Lewis lung carcinoma LLC1 line at a dose of 10 mg/kg daily [<xref ref-type="bibr" rid="R527">527</xref>].</p>
<p>However, the GBM tumor does not consist only of tumor cells but also of tumor-associated cells, in particular immune cells. Immune reactions also play a very important role in tackling cancer. The use of immunosuppressive drugs such as FTY720 results in the impairment of the immune system and consequently may facilitate the development of GBM as well as other tumors [<xref ref-type="bibr" rid="R411">411</xref>, <xref ref-type="bibr" rid="R412">412</xref>].</p>
<p>In addition to SphK inhibitors, researchers postulate the use of S1PR antagonists in the treatment of tumors [<xref ref-type="bibr" rid="R532">532</xref>, <xref ref-type="bibr" rid="R533">533</xref>]. It is also advocated to use S1P-neutralizing antibodies acting on many types of cancer [<xref ref-type="bibr" rid="R534">534</xref>–<xref ref-type="bibr" rid="R537">537</xref>]. However, this therapeutic approach has not been studied in terms of glioma and GBM, because the blood-brain barrier significantly impedes the transmission of antibodies to the microenvironment of these tumors. On the other hand, some hope may lie in the search for new methods of transmitting various substances through the barrier [<xref ref-type="bibr" rid="R509">509</xref>–<xref ref-type="bibr" rid="R511">511</xref>].</p>
</sec>
<sec id="s7_11">
<title>Anti-cancer drugs directed against other secretory factors</title>
<p>Nonsteroidal anti-inflammatory drugs (NSAIDs), in particular selective COX-2 inhibitors and nonselective cyclooxygenase inhibitors, have been reported to reduce the production of PGE<sub>2</sub> [<xref ref-type="bibr" rid="R359">359</xref>, <xref ref-type="bibr" rid="R360">360</xref>, <xref ref-type="bibr" rid="R538">538</xref>–<xref ref-type="bibr" rid="R540">540</xref>], or CD39 and CD73 inhibitors reducing adenosine production [<xref ref-type="bibr" rid="R541">541</xref>–<xref ref-type="bibr" rid="R544">544</xref>]. All of the therapeutic agents that have been mentioned so far can be used in combination with drugs that interfere with the action of tissue hormones with a greater importance for GBM, for example, tyrosine kinase inhibitors or anti-EGFR or anti-EGFRvIII antibodies [<xref ref-type="bibr" rid="R545">545</xref>–<xref ref-type="bibr" rid="R547">547</xref>].</p>
<sec id="s7_11_1">
<title>Problem I: blood-brain barrier</title>
<p>The blood-brain barrier protects the central nervous system against various toxic and biological chemicals. It is impervious to antibodies and a significant number of drugs [<xref ref-type="bibr" rid="R509">509</xref>–<xref ref-type="bibr" rid="R511">511</xref>]. This greatly hampers the treatment of diseases in this organ. Although within GBM the barrier is suppressed, some GBM parts are still protected by it [<xref ref-type="bibr" rid="R509">509</xref>–<xref ref-type="bibr" rid="R511">511</xref>]. Therefore, NT labelled with radioactive isotopes or cytostatic drugs, as well as specific anti-S1P or anti-GDF-15 antibodies or some of the aforementioned anti-cancer drugs, are ineffective in GBM therapy [<xref ref-type="bibr" rid="R507">507</xref>]. This is why researchers are looking for new therapeutic substances that are able to penetrate this barrier. Another field is the search for drugs that would weaken the action of the blood-brain barrier, or for compounds that would carry conjugated substances through this barrier. One example is angiopep-2, which carries NT through this barrier [<xref ref-type="bibr" rid="R508">508</xref>]. Advancement of knowledge in solving this problem is necessary in the development of new therapeutic methods in GBM.</p>
</sec>
<sec id="s7_11_2">
<title>Problem II: compounding side effects</title>
<p>The use of multidrug therapies that target physiological factors presents a high risk of side effects compounding [<xref ref-type="bibr" rid="R471">471</xref>]. Therefore, lower concentrations of all drugs should be used so that only fewer of the enzymes are inactivated. Lower antibody concentrations should also neutralize some of the hormones. As a result of the development of tumoral processes, there are many more aforementioned enzymes, tissue hormones or receptors in the tumor niche or a cancer cell then in non-cancer tissue [<xref ref-type="bibr" rid="R202">202</xref>, <xref ref-type="bibr" rid="R262">262</xref>, <xref ref-type="bibr" rid="R263">263</xref>, <xref ref-type="bibr" rid="R288">288</xref>, <xref ref-type="bibr" rid="R289">289</xref>, <xref ref-type="bibr" rid="R292">292</xref>–<xref ref-type="bibr" rid="R294">294</xref>]. If these molecules are chosen as the target of therapy, it is more likely that the drug acts at lower concentrations in the tumor cell than in a healthy cell [<xref ref-type="bibr" rid="R493">493</xref>]. In this case, the effect of such a therapy on cancer cells would be more toxic than for healthy cells. By reducing the concentration of secretory factors such as NT, S1P, GDF-15, from very high to physiological or even lower levels, it may have a destructive effect on the viability of the tumor cell. In contrast, in the healthy cell a slight decrease in the aforementioned hormones is going to have a much smaller adverse effect. The tumor microenvironment selects tumor cells in a certain direction [<xref ref-type="bibr" rid="R479">479</xref>]. As a result, tumor cells are dependent on this environment, in particular on secretory factors, which are very often elevated during cancer development and act on all ‘hallmarks of cancer’.</p>
</sec>
<sec id="s7_11_3">
<title>Problem III: therapy duration</title>
<p>GBM is a cancer that recurs despite surgical intervention, radiotherapy and chemotherapy. This is associated with the dissemination of cancer cells across many areas of the brain. After the excision of the main tumor, tumor cells are distributed throughout the entire brain. Over time, they become activated and a new relapse site emerges. Therefore, the effects of some experimental therapies are only visible after more than 6 months of taking the drug [<xref ref-type="bibr" rid="R474">474</xref>, <xref ref-type="bibr" rid="R475">475</xref>].</p>
<p>A therapeutic approach based on the interference with the tumor microenvironment disturbs the development of cancer and the formation of a relapse site. Nevertheless, to achieve some therapeutic success, it is required to destroy all cancer cells which create relapse sites. Therefore, therapy must last until this goal is completed.</p>
</sec>
</sec>
</sec>
<sec id="s8">
<title>CONCLUSION - INTRATUMORAL HETEROGENEITY AS A TARGET OF RESEARCH</title>
<p>To better understand the effects of multidrug therapies, it is important to focus on the changes that occur in tumor processes, and in particular those that lead to intratumoral heterogeneity. Many changes in cancer cells are interrelated, and so GBM tumor cell subtypes exhibit specialization and play different functions [<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R21">21</xref>]. The discovery of patterns of changes in tumor cells will help divide them according to their susceptibility to particular drugs [<xref ref-type="bibr" rid="R548">548</xref>]. This will also allow an understanding of the interrelationships between the individual cells in the tumor and, consequently an ability to interfere with the communication between the cells [<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R21">21</xref>]. In this way, it will be possible to develop adequate multidrug therapies with 100% effectiveness and minimal side effects.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="con">
<p>
<bold>Author contributions</bold>
</p>
<p>Jan Korbecki - literature search and review, writing the manuscript, final acceptance of the manuscript.</p>
<p>Izabela Gutowska - participated in writing the manuscript.</p>
<p>Ireneusz Kojder - participated in writing the manuscript.</p>
<p>Dariusz Jeżewski - final acceptance of the manuscript.</p>
<p>Marta Goschorska - participated in writing the manuscript.</p>
<p>Agnieszka Łukomska - participated in writing the manuscript.</p>
<p>Anna Lubkowska - final acceptance of the manuscript.</p>
<p>Dariusz Chlubek - final acceptance of the manuscript.</p>
<p>Irena Baranowska-Bosiacka - manuscript concept, literature search and review, writing the manuscript, final acceptance of the manuscript.</p>
</fn>
<fn fn-type="COI-statement">
<p>
<bold>CONFLICTS OF INTEREST</bold>
</p>
<p>The authors declare no conflicts of interest.</p>
</fn>
<fn fn-type="supported-by">
<p>
<bold>FUNDING</bold>
</p>
<p>This study was supported by the statutory budget of the Department of Biochemistry and Medical Chemistry, Pomeranian Medical University.</p>
</fn>
</fn-group>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>ATF5</term>
<def>
<p>Activating transcription factor 5</p>
</def>
</def-item>
<def-item>
<term>CCL</term>
<def>
<p>CC motif chemokine ligand</p>
</def>
</def-item>
<def-item>
<term>CDK</term>
<def>
<p>Cyclin-dependent kinase</p>
</def>
</def-item>
<def-item>
<term>CMV</term>
<def>
<p>Cytomegalovirus</p>
</def>
</def-item>
<def-item>
<term>CTGF</term>
<def>
<p>Connective tissue growth factor</p>
</def>
</def-item>
<def-item>
<term>CX3CL</term>
<def>
<p>C-X3-C motif chemokine ligand</p>
</def>
</def-item>
<def-item>
<term>CXCL</term>
<def>
<p>C-X-C motif chemokine ligand</p>
</def>
</def-item>
<def-item>
<term>EGF</term>
<def>
<p>Epidermal growth factor</p>
</def>
</def-item>
<def-item>
<term>EGFR</term>
<def>
<p>Epidermal growth factor receptor</p>
</def>
</def-item>
<def-item>
<term>ERK1/2</term>
<def>
<p>Extracellular signal-regulated kinase 1 and 2</p>
</def>
</def-item>
<def-item>
<term>FAK</term>
<def>
<p>Focal adhesion kinase</p>
</def>
</def-item>
<def-item>
<term>GBM</term>
<def>
<p>Glioblastoma multiforme</p>
</def>
</def-item>
<def-item>
<term>GDF-15</term>
<def>
<p>Growth differentiation factor-15</p>
</def>
</def-item>
<def-item>
<term>GSC</term>
<def>
<p>Glioblastoma stem cells</p>
</def>
</def-item>
<def-item>
<term>HIF</term>
<def>
<p>Hypoxia inducible factor</p>
</def>
</def-item>
<def-item>
<term>HLA</term>
<def>
<p>Human leukocyte antigen</p>
</def>
</def-item>
<def-item>
<term>HO-1</term>
<def>
<p>Heme oxygenase 1</p>
</def>
</def-item>
<def-item>
<term>HUVEC</term>
<def>
<p>Human umbilical vein endothelial cells</p>
</def>
</def-item>
<def-item>
<term>IDO</term>
<def>
<p>Indoleamine 2,3-dioxygenase</p>
</def>
</def-item>
<def-item>
<term>IE86</term>
<def>
<p>Immediate early 86</p>
</def>
</def-item>
<def-item>
<term>IGF-1R</term>
<def>
<p>Insulin-like growth factor 1 receptor</p>
</def>
</def-item>
<def-item>
<term>IL</term>
<def>
<p>Interleukin</p>
</def>
</def-item>
<def-item>
<term>LPS</term>
<def>
<p>Lipopolysaccharide</p>
</def>
</def-item>
<def-item>
<term>MAPK</term>
<def>
<p>Mitogen-activated protein kinase</p>
</def>
</def-item>
<def-item>
<term>MCP-1</term>
<def>
<p>Monocyte chemoattractant protein 1</p>
</def>
</def-item>
<def-item>
<term>MHC</term>
<def>
<p>Major histocompatibility complex</p>
</def>
</def-item>
<def-item>
<term>MIP</term>
<def>
<p>Macrophage inflammatory protein</p>
</def>
</def-item>
<def-item>
<term>MMP</term>
<def>
<p>Matrix metalloproteinase</p>
</def>
</def-item>
<def-item>
<term>NT</term>
<def>
<p>Neurotensin</p>
</def>
</def-item>
<def-item>
<term>NTSR<sub>1-4</sub></term>
<def>
<p>NT receptor subtype 1-4</p>
</def>
</def-item>
<def-item>
<term>PAI-1</term>
<def>
<p>Plasminogen activator inhibitor-1</p>
</def>
</def-item>
<def-item>
<term>PDGF</term>
<def>
<p>Platelet-derived growth factor</p>
</def>
</def-item>
<def-item>
<term>PI3K</term>
<def>
<p>Phosphatidylinositol-4,5-bisphosphate 3-kinase</p>
</def>
</def-item>
<def-item>
<term>PKB</term>
<def>
<p>Protein kinase B</p>
</def>
</def-item>
<def-item>
<term>PKC</term>
<def>
<p>Protein kinase C</p>
</def>
</def-item>
<def-item>
<term>PLC-β</term>
<def>
<p>Phospholipase C-β</p>
</def>
</def-item>
<def-item>
<term>PPARγ</term>
<def>
<p>Peroxisome proliferator-activated receptor γ</p>
</def>
</def-item>
<def-item>
<term>RANTES</term>
<def>
<p>Regulated on activation,normal T-cell expressed and secreted</p>
</def>
</def-item>
<def-item>
<term>S1P</term>
<def>
<p>Sphingosine-1-phosphate</p>
</def>
</def-item>
<def-item>
<term>S1PR<sub>1-5</sub></term>
<def>
<p>S1P receptor 1-5</p>
</def>
</def-item>
<def-item>
<term>sNTSR<sub>3</sub></term>
<def>
<p>Soluble NT receptor subtype 3</p>
</def>
</def-item>
<def-item>
<term>SphK</term>
<def>
<p>Sphingosine kinase</p>
</def>
</def-item>
<def-item>
<term>SPL</term>
<def>
<p>S1P lyase</p>
</def>
</def-item>
<def-item>
<term>SPP</term>
<def>
<p>S1P-catalyzed phosphohydrolase</p>
</def>
</def-item>
<def-item>
<term>STAT</term>
<def>
<p>Signal transducer and activator of transcription</p>
</def>
</def-item>
<def-item>
<term>TAM</term>
<def>
<p>Tumor-associated macrophages</p>
</def>
</def-item>
<def-item>
<term>TGF-β</term>
<def>
<p>Transforming growth factor β</p>
</def>
</def-item>
<def-item>
<term>TMZ</term>
<def>
<p>Temozolomide</p>
</def>
</def-item>
<def-item>
<term>TNF-α</term>
<def>
<p>Tumor necrosis factor α</p>
</def>
</def-item>
<def-item>
<term>UPA</term>
<def>
<p>Urokinase-type plasminogen activator</p>
</def>
</def-item>
<def-item>
<term>uPAR</term>
<def>
<p>Receptor for urokinase-type plasminogen activator</p>
</def>
</def-item>
<def-item>
<term>VEGF</term>
<def>
<p>Vascular endothelial growth factor</p>
</def>
</def-item>
<def-item>
<term>vIL-10</term>
<def>
<p>Viral interleukin-10.</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartzbaum</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Aldape</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Wrensch</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Epidemiology and molecular pathology of glioma</article-title>
<source/>Nat Clin Pract Neurol
          <year>2006</year>
<volume>2</volume>
<fpage>494</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="pmid">16932614</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ostrom</surname>
<given-names>QT</given-names>
</name>
<name>
<surname>Gittleman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rouse</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dowling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wolinsky</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kruchko</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Barnholtz-Sloan</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011</article-title>
<source/>Neuro Oncol
          <year>2014</year>
<volume>16</volume>
<fpage>iv1</fpage>
<lpage>iv63</lpage>
<pub-id pub-id-type="pmid">25304271</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Recent therapeutic advances and insights of recurrent glioblastoma multiforme</article-title>
<source/>Front Biosci (Landmark Ed)
          <year>2013</year>
<volume>18</volume>
<fpage>676</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="pmid">23276952</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stupp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hegi</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>van den Bent</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Taphoorn</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Janzer</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Ludwin</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Allgeier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Belanger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hau</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brandes</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Gijtenbeek</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial</article-title>
<source/>Lancet Oncol
          <year>2009</year>
<volume>10</volume>
<fpage>459</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="pmid">19269895</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Tirosh</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Trombetta</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Shalek</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wakimoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cahill</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Nahed</surname>
<given-names>BV</given-names>
</name>
<name>
<surname>Curry</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Martuza</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Rozenblatt-Rosen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Suvà</surname>
<given-names>ML</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma</article-title>
<source/>Science
          <year>2014</year>
<volume>344</volume>
<fpage>1396</fpage>
<lpage>1401</lpage>
<pub-id pub-id-type="pmid">24925914</pub-id>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Khong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Parkinson</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Dwight</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ikin</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Vafaee</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Howell</surname>
<given-names>VM</given-names>
</name>
</person-group>
<article-title>Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma</article-title>
<source/>Sci Rep
          <year>2016</year>
<volume>6</volume>
<fpage>22477</fpage>
<pub-id pub-id-type="pmid">26940435</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eschbacher</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Gaw</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ranjbar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Plasencia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dueck</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Nakaji</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Karis</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Quarles</surname>
<given-names>CC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radiogenomics to characterize regional genetic heterogeneity in glioblastoma</article-title>
<source/>Neuro Oncol
          <year>2017</year>
<volume>19</volume>
<fpage>128</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="pmid">27502248</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Aquino</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Nogueira</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>da Fonseca</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>de Souza Silva</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Carvalho Mda</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Domont</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Zanchin</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Fischer Jde</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme</article-title>
<source/>Front Oncol
          <year>2016</year>
<volume>6</volume>
<fpage>183</fpage>
<pub-id pub-id-type="pmid">27597932</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulus</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Peiffer</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Intratumoral histologic heterogeneity of gliomas. A quantitative study</article-title>
<source/>Cancer
          <year>1989</year>
<volume>64</volume>
<fpage>442</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="pmid">2736491</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sottoriva</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Spiteri</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Piccirillo</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Touloumis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>VP</given-names>
</name>
<name>
<surname>Marioni</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tavaré</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2013</year>
<volume>110</volume>
<fpage>4009</fpage>
<lpage>4014</lpage>
<pub-id pub-id-type="pmid">23412337</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colwell</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Larion</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Seldomridge</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Sizdahkhani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells</article-title>
<source/>Neuro Oncol
          <year>2017</year>
<volume>19</volume>
<fpage>887</fpage>
<lpage>896</lpage>
<pub-id pub-id-type="pmid">28339582</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cahill</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kinzler</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Vogelstein</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lengauer</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Genetic instability and darwinian selection in tumours</article-title>
<source/>Trends Cell Biol
          <year>1999</year>
<volume>9</volume>
<fpage>M57</fpage>
<lpage>M60</lpage>
<pub-id pub-id-type="pmid">10611684</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanahan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Hallmarks of cancer: the next generation</article-title>
<source/>Cell
          <year>2011</year>
<volume>144</volume>
<fpage>646</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="pmid">21376230</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanahan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>The hallmarks of cancer</article-title>
<source/>Cell
          <year>2000</year>
<volume>100</volume>
<fpage>57</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">10647931</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liebelt</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Shingu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Glioma stem cells: signaling, microenvironment, and therapy</article-title>
<source/>Stem Cells Int
          <year>2016</year>
<volume>2016</volume>
<fpage>7849890</fpage>
<pub-id pub-id-type="pmid">26880988</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ströbele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nonnenmacher</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Siegelin</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stroh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hasslacher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Enzenmüller</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Strauss</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Karpel-Massler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Westhoff</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Debatin</surname>
<given-names>KM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A paired comparison between glioblastoma “stem cells” and differentiated cells</article-title>
<source/>Int J Cancer
          <year>2016</year>
<volume>138</volume>
<fpage>1709</fpage>
<lpage>1718</lpage>
<pub-id pub-id-type="pmid">26519239</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denicolaï</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tabouret</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Colin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Metellus</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nanni</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Boucard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tchoghandjian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meyronet</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baeza-Kallee</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chinot</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Figarella-Branger</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Molecular heterogeneity of glioblastomas: does location matter?</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>902</fpage>
<lpage>913</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.6433">https://doi.org/10.18632/oncotarget.6433</ext-link>
</comment>
<pub-id pub-id-type="pmid">26637806</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szerlip</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Pedraza</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chakravarty</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Azim</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ozawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Huse</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Jhanwar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leversha</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Mikkelsen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Brennan</surname>
<given-names>CW</given-names>
</name>
</person-group>
<article-title>Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2012</year>
<volume>109</volume>
<fpage>3041</fpage>
<lpage>3046</lpage>
<pub-id pub-id-type="pmid">22323597</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugimori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Boman</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Awaji</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kozano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ogata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurimoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Discovery of power-law growth in the self-renewal of heterogeneous glioma stem cell populations</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0135760</fpage>
<pub-id pub-id-type="pmid">26284929</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonavia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Inda</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Cavenee</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Furnari</surname>
<given-names>FB</given-names>
</name>
</person-group>
<article-title>Heterogeneity maintenance in glioblastoma: a social network</article-title>
<source/>Cancer Res
          <year>2011</year>
<volume>71</volume>
<fpage>4055</fpage>
<lpage>4060</lpage>
<pub-id pub-id-type="pmid">21628493</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doucette</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Aldape</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dziurzynski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heimberger</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas</article-title>
<source/>Cancer Immunol Res
          <year>2013</year>
<volume>1</volume>
<fpage>112</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="pmid">24409449</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reimand</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Head</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Kushida</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bayani</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pressey</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lionel</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>ID</given-names>
</name>
<name>
<surname>Cusimano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Squire</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>SW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2015</year>
<volume>112</volume>
<fpage>851</fpage>
<lpage>856</lpage>
<pub-id pub-id-type="pmid">25561528</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landolfo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gariglio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gribaudo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lembo</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The human cytomegalovirus</article-title>
<source/>Pharmacol Ther
          <year>2003</year>
<volume>98</volume>
<fpage>269</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="pmid">12782241</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobbs</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Harkins</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Samanta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Bharara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>King</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Nabors</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Cobbs</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Britt</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus infection and expression in human malignant glioma</article-title>
<source/>Cancer Res
          <year>2002</year>
<volume>62</volume>
<fpage>3347</fpage>
<lpage>3350</lpage>
<pub-id pub-id-type="pmid">12067971</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Schmittling</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Learn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McLendon</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma</article-title>
<source/>Neuro Oncol
          <year>2008</year>
<volume>10</volume>
<fpage>10</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">17951512</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheurer</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Bondy</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Aldape</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>T</given-names>
</name>
<name>
<surname>El-Zein</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Detection of human cytomegalovirus in different histological types of gliomas</article-title>
<source/>Acta Neuropathol
          <year>2008</year>
<volume>116</volume>
<fpage>79</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">18351367</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhattacharjee</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Renzette</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kowalik</surname>
<given-names>TF</given-names>
</name>
</person-group>
<article-title>Genetic analysis of cytomegalovirus in malignant gliomas</article-title>
<source/>J Virol
          <year>2012</year>
<volume>86</volume>
<fpage>6815</fpage>
<lpage>6824</lpage>
<pub-id pub-id-type="pmid">22496213</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stragliotto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Orrego</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peredo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Taher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Willems</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Söderberg-Naucler</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival; -a case-control study</article-title>
<source/>Herpesviridae
          <year>2012</year>
<volume>3</volume>
<fpage>3</fpage>
<pub-id pub-id-type="pmid">22424569</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Orrego</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peredo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dzabic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wolmer-Solberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Strååt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stragliotto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival</article-title>
<source/>J Clin Virol
          <year>2013</year>
<volume>57</volume>
<fpage>36</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">23391370</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>dos Santos</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Stangherlin</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Figueiredo</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Corrêa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>High prevalence of HCMV and viral load in tumor tissues and peripheral blood of glioblastoma multiforme patients</article-title>
<source/>J Med Virol
          <year>2014</year>
<volume>86</volume>
<fpage>1953</fpage>
<lpage>1961</lpage>
<pub-id pub-id-type="pmid">24173908</pub-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Association between human cytomegalovirus infection and histone acetylation level in various histological types of glioma</article-title>
<source/>Oncol Lett
          <year>2015</year>
<volume>10</volume>
<fpage>2812</fpage>
<lpage>2820</lpage>
<pub-id pub-id-type="pmid">26722247</pub-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shamran</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Kadhim</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Kareem</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taub</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Nagarkatti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nagarkatti</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>UP</given-names>
</name>
</person-group>
<article-title>Detection of human cytomegalovirus in different histopathological types of glioma in Iraqi patients</article-title>
<source/>Biomed Res Int
          <year>2015</year>
<volume>2015</volume>
<fpage>642652</fpage>
<pub-id pub-id-type="pmid">25710012</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fonseca</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Kawamura</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carvalho Mda</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The prevalence of human cytomegalovirus DNA in gliomas of Brazilian patients</article-title>
<source/>Mem Inst Oswaldo Cruz
          <year>2012</year>
<volume>107</volume>
<fpage>953</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="pmid">23147156</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucas</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bruggeman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dunham</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Specht</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The detection of CMV pp65 and IE1 in glioblastoma multiforme</article-title>
<source/>J Neurooncol
          <year>2011</year>
<volume>103</volume>
<fpage>231</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="pmid">20820869</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Karimi Arzenani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shirkoohi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rokouei</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alipour Eskandani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nikravesh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Expression of insulin-like growth factor binding protein-2 (IGFBP-2) gene in negative and positive human cytomegalovirus glioblastoma multiforme tissues</article-title>
<source/>Med Oncol
          <year>2014</year>
<volume>31</volume>
<fpage>812</fpage>
<pub-id pub-id-type="pmid">24352760</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumgarten</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Michaelis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rothweiler</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Starzetz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rabenau</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jennewein</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Braczynski</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seifert</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Steinbach</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Allwinn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mittelbronn</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics</article-title>
<source/>Neuro Oncol
          <year>2014</year>
<volume>16</volume>
<fpage>1469</fpage>
<lpage>1477</lpage>
<pub-id pub-id-type="pmid">25155358</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cimino</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sehn</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>JS</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Duncavage</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>Detection of viral pathogens in high grade gliomas from unmapped next-generation sequencing data</article-title>
<source/>Exp Mol Pathol
          <year>2014</year>
<volume>96</volume>
<fpage>310</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="pmid">24704430</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamashita</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Isomura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takemura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Motomura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tsujiuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Natsume</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Toyokuni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tsurumi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Lack of presence of the human cytomegalovirus in human glioblastoma</article-title>
<source/>Mod Pathol
          <year>2014</year>
<volume>27</volume>
<fpage>922</fpage>
<lpage>929</lpage>
<pub-id pub-id-type="pmid">24336154</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strong</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>E</given-names>
<suffix>4th</suffix>
</name>
<name>
<surname>Lin</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Baddoo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Ware</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Flemington</surname>
<given-names>EK</given-names>
</name>
</person-group>
<article-title>A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus - tumor association</article-title>
<source/>Acta Neuropathol Commun
          <year>2016</year>
<volume>4</volume>
<fpage>71</fpage>
<pub-id pub-id-type="pmid">27402152</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Ory</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ramírez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>García Comas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>León</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sagües</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Is there a change in cytomegalovirus seroepidemiology in Spain?</article-title>
<source/>Eur J Epidemiol
          <year>2004</year>
<volume>19</volume>
<fpage>85</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">15012028</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staras</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Dollard</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Radford</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Flanders</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Pass</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Seroprevalence of cytomegalovirus infection in the United States, 1988-1994</article-title>
<source/>Clin Infect Dis
          <year>2006</year>
<volume>43</volume>
<fpage>1143</fpage>
<lpage>1151</lpage>
<pub-id pub-id-type="pmid">17029132</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Seroprevalence and risk factors of human cytomegalovirus infection in the eastern Chinese population</article-title>
<source/>Arch Virol
          <year>2009</year>
<volume>154</volume>
<fpage>561</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="pmid">19263193</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lübeck</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Doerr</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Rabenau</surname>
<given-names>HF</given-names>
</name>
</person-group>
<article-title>Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed?</article-title>
<source/>Med Microbiol Immunol
          <year>2010</year>
<volume>199</volume>
<fpage>53</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">19949960</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bates</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brantsaeter</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus (CMV) in Africa: a neglected but important pathogen</article-title>
<source/>J Virus Erad
          <year>2016</year>
<volume>2</volume>
<fpage>136</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="pmid">27482452</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobbs</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Denham</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kraus</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity</article-title>
<source/>Cancer Res
          <year>2008</year>
<volume>68</volume>
<fpage>724</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="pmid">18245472</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dziurzynski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hatiboglu</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cahill</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Prabhu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sawaya</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Heimberger</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype</article-title>
<source/>Clin Cancer Res
          <year>2011</year>
<volume>17</volume>
<fpage>4642</fpage>
<lpage>4649</lpage>
<pub-id pub-id-type="pmid">21490182</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avdic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>McSharry</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Clancy</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Steain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Abendroth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Slobedman</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to repress host immune responses</article-title>
<source/>J Virol
          <year>2013</year>
<volume>87</volume>
<fpage>10273</fpage>
<lpage>10282</lpage>
<pub-id pub-id-type="pmid">23864618</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matlaf</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Harkins</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Bezrookove</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cobbs</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Cytomegalovirus pp71 protein is expressed in human glioblastoma and promotes pro-angiogenic signaling by activation of stem cell factor</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e68176</fpage>
<pub-id pub-id-type="pmid">23861869</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiallos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Judkins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Matlaf</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Prichard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dittmer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cobbs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus gene expression in long-term infected glioma stem cells</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e116178</fpage>
<pub-id pub-id-type="pmid">25549333</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Matlaf</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Akhavan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bezrookove</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Decker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ghanny</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hadaczek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bengtsson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohlfest</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Luciani-Torres</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Harkins</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cytomegalovirus immediate-early proteins promote stemness properties in glioblastoma</article-title>
<source/>Cancer Res
          <year>2015</year>
<volume>75</volume>
<fpage>3065</fpage>
<lpage>3076</lpage>
<pub-id pub-id-type="pmid">26239477</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Wit</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Mujić-Delić</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Senten</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Fraile-Ramos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Siderius</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus encoded chemokine receptor US28 activates the HIF-1α/PKM2 axis in glioblastoma cells</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>67966</fpage>
<lpage>67985</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.11817">https://doi.org/10.18632/oncotarget.11817</ext-link>
</comment>
<pub-id pub-id-type="pmid">27602585</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuijpers</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Baars</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Dantin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van den Burg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Lier</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Roosnek</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Human NK cells can control CMV infection in the absence of T cells</article-title>
<source/>Blood
          <year>2008</year>
<volume>112</volume>
<fpage>914</fpage>
<lpage>915</lpage>
<pub-id pub-id-type="pmid">18650467</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sinzger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Frascaroli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Reichel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bayer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schirmbeck</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus-induced NKG2C(hi) CD57(hi) natural killer cells are effectors dependent on humoral antiviral immunity</article-title>
<source/>J Virol
          <year>2013</year>
<volume>87</volume>
<fpage>7717</fpage>
<lpage>7725</lpage>
<pub-id pub-id-type="pmid">23637420</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieira Braga</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Hertoghs</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>van Lier</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>van Gisbergen</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Molecular characterization of HCMV-specific immune responses: parallels between CD8(+) T cells, CD4(+) T cells, and NK cells</article-title>
<source/>Eur J Immunol
          <year>2015</year>
<volume>45</volume>
<fpage>2433</fpage>
<lpage>2445</lpage>
<pub-id pub-id-type="pmid">26228786</pub-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sinzger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reichel</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Just</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Natural killer cells can inhibit the transmission of human cytomegalovirus in cell culture by using mechanisms from innate and adaptive immune responses</article-title>
<source/>J Virol
          <year>2015</year>
<volume>89</volume>
<fpage>2906</fpage>
<lpage>2917</lpage>
<pub-id pub-id-type="pmid">25540381</pub-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lischka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Antiviral strategies to combat cytomegalovirus infections in transplant recipients</article-title>
<source/>Curr Opin Pharmacol
          <year>2008</year>
<volume>8</volume>
<fpage>541</fpage>
<lpage>548</lpage>
<pub-id pub-id-type="pmid">18662804</pub-id>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fisher</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation</article-title>
<source/>Transpl Infect Dis
          <year>2009</year>
<volume>11</volume>
<fpage>195</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="pmid">19228345</pub-id>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perng</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites</article-title>
<source/>Front Oncol
          <year>2015</year>
<volume>5</volume>
<fpage>153</fpage>
<pub-id pub-id-type="pmid">26217588</pub-id>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>See</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Waziri</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression</article-title>
<source/>J Neurooncol
          <year>2015</year>
<volume>123</volume>
<fpage>405</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="pmid">26123363</pub-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Magri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Muntasell</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heredia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baía</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Angulo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>López-Botet</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization</article-title>
<source/>J Leukoc Biol
          <year>2011</year>
<volume>90</volume>
<fpage>717</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="pmid">21742939</pub-id>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinclair</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sissons</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Latency and reactivation of human cytomegalovirus</article-title>
<source/>J Gen Virol
          <year>2006</year>
<volume>87</volume>
<fpage>1763</fpage>
<lpage>1779</lpage>
<pub-id pub-id-type="pmid">16760381</pub-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hargett</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shenk</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>Experimental human cytomegalovirus latency in CD14+ monocytes</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2010</year>
<volume>107</volume>
<fpage>20039</fpage>
<lpage>20044</lpage>
<pub-id pub-id-type="pmid">21041645</pub-id>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noriega</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Haye</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Kraus</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Kowalsky</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Tortorella</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus modulates monocyte-mediated innate immune responses during short-term experimental latency <italic>in vitro</italic></article-title>
<source/>J Virol
          <year>2014</year>
<volume>88</volume>
<fpage>9391</fpage>
<lpage>9405</lpage>
<pub-id pub-id-type="pmid">24920803</pub-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodrum</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus latency: approaching the gordian knot</article-title>
<source/>Annu Rev Virol
          <year>2016</year>
<volume>3</volume>
<fpage>333</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="pmid">27501258</pub-id>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhn</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Beall</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Kolattukudy</surname>
<given-names>PE</given-names>
</name>
</person-group>
<article-title>The cytomegalovirus US28 protein binds multiple CC chemokines with high affinity</article-title>
<source/>Biochem Biophys Res Commun
          <year>1995</year>
<volume>211</volume>
<fpage>325</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">7540006</pub-id>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beisser</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Laurent</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Virelizier</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Michelson</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus chemokine receptor gene US28 is transcribed in latently infected THP-1 monocytes</article-title>
<source/>J Virol
          <year>2001</year>
<volume>75</volume>
<fpage>5949</fpage>
<lpage>5957</lpage>
<pub-id pub-id-type="pmid">11390596</pub-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vomaske</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Melnychuk</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>L</given-names>
</name>
<name>
<surname>DeFilippis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Früh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schlaepfer</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Streblow</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Differential ligand binding to a human cytomegalovirus chemokine receptor determines cell type-specific motility</article-title>
<source/>PLoS Pathog
          <year>2009</year>
<volume>5</volume>
<fpage>e1000304</fpage>
<pub-id pub-id-type="pmid">19229316</pub-id>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hjortø</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kiilerich-Pedersen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Selmeczi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kledal</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>NB</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus chemokine receptor US28 induces migration of cells on a CX3CL1-presenting surface</article-title>
<source/>J Gen Virol
          <year>2013</year>
<volume>94</volume>
<fpage>1111</fpage>
<lpage>1120</lpage>
<pub-id pub-id-type="pmid">23303826</pub-id>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchesi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Locatelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Solinas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Erreni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Allavena</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mantovani</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer</article-title>
<source/>J Neuroimmunol
          <year>2010</year>
<volume>224</volume>
<fpage>39</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">20630606</pub-id>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zujovic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Benavides</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vigé</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Taupin</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation</article-title>
<source/>Glia
          <year>2000</year>
<volume>29</volume>
<fpage>305</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="pmid">10652441</pub-id>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizuno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawanokuchi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Numata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Production and neuroprotective functions of fractalkine in the central nervous system</article-title>
<source/>Brain Res
          <year>2003</year>
<volume>979</volume>
<fpage>65</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">12850572</pub-id>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erreni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Solinas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brescia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Osti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zunino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Destro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roncalli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mantovani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Draghi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Levi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Baena</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1</article-title>
<source/>Eur J Cancer
          <year>2010</year>
<volume>46</volume>
<fpage>3383</fpage>
<lpage>3392</lpage>
<pub-id pub-id-type="pmid">20728344</pub-id>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hattermann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sebens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Helm</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Mentlein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mehdorn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Held-Feindt</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Chemokine expression profile of freshly isolated human glioblastoma-associated macrophages/microglia</article-title>
<source/>Oncol Rep
          <year>2014</year>
<volume>32</volume>
<fpage>270</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">24859792</pub-id>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Held-Feindt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hattermann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Müerköster</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Wedderkopp</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Knerlich-Lukoschus</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ungefroren</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mehdorn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Mentlein</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs)</article-title>
<source/>Exp Cell Res
          <year>2010</year>
<volume>316</volume>
<fpage>1553</fpage>
<lpage>1566</lpage>
<pub-id pub-id-type="pmid">20184883</pub-id>
</element-citation>
</ref>
<ref id="R75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komohara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kuratsu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Takeya</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas</article-title>
<source/>J Pathol
          <year>2008</year>
<volume>216</volume>
<fpage>15</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">18553315</pub-id>
</element-citation>
</ref>
<ref id="R76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Pfaffle</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Kreklywich</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Othieno</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Streblow</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model</article-title>
<source/>Cell Host Microbe
          <year>2010</year>
<volume>8</volume>
<fpage>284</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="pmid">20833379</pub-id>
</element-citation>
</ref>
<ref id="R77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Herold-Mende</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Riede</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Fusenig</surname>
<given-names>NE</given-names>
</name>
</person-group>
<article-title>Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression</article-title>
<source/>Am J Pathol
          <year>1999</year>
<volume>155</volume>
<fpage>1557</fpage>
<lpage>1567</lpage>
<pub-id pub-id-type="pmid">10550313</pub-id>
</element-citation>
</ref>
<ref id="R78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huong</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Raab-Traub</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus</article-title>
<source/>Nature
          <year>2003</year>
<volume>424</volume>
<fpage>456</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="pmid">12879076</pub-id>
</element-citation>
</ref>
<ref id="R79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Akhavan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cobbs</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection</article-title>
<source/>Nature
          <year>2008</year>
<volume>455</volume>
<fpage>391</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="pmid">18701889</pub-id>
</element-citation>
</ref>
<ref id="R80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nazarenko</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hede</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hedrén</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lindström</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Nistér</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>PDGF and PDGF receptors in glioma</article-title>
<source/>Ups J Med Sci
          <year>2012</year>
<volume>117</volume>
<fpage>99</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="pmid">22509804</pub-id>
</element-citation>
</ref>
<ref id="R81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liffers</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lamszus</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schulte</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>EGFR amplification and glioblastoma stem-like cells</article-title>
<source/>Stem Cells Int
          <year>2015</year>
<volume>2015</volume>
<fpage>427518</fpage>
<pub-id pub-id-type="pmid">26136784</pub-id>
</element-citation>
</ref>
<ref id="R82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCormick</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Control of apoptosis by human cytomegalovirus</article-title>
<source/>Curr Top Microbiol Immunol
          <year>2008</year>
<volume>325</volume>
<fpage>281</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="pmid">18637512</pub-id>
</element-citation>
</ref>
<ref id="R83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus inhibits apoptosis by regulating the activating transcription factor 5 signaling pathway in human malignant glioma cells</article-title>
<source/>Oncol Lett
          <year>2014</year>
<volume>8</volume>
<fpage>1051</fpage>
<lpage>1057</lpage>
<pub-id pub-id-type="pmid">25120656</pub-id>
</element-citation>
</ref>
<ref id="R84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strååt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wolmer-Solberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kyo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Björkholm</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sjöberg</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of telomerase by human cytomegalovirus</article-title>
<source/>J Natl Cancer Inst
          <year>2009</year>
<volume>101</volume>
<fpage>488</fpage>
<lpage>497</lpage>
<pub-id pub-id-type="pmid">19318640</pub-id>
</element-citation>
</ref>
<ref id="R85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalejta</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Shenk</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2003</year>
<volume>100</volume>
<fpage>3263</fpage>
<lpage>3268</lpage>
<pub-id pub-id-type="pmid">12626766</pub-id>
</element-citation>
</ref>
<ref id="R86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalejta</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Bechtel</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Shenk</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors</article-title>
<source/>Mol Cell Biol
          <year>2003</year>
<volume>23</volume>
<fpage>1885</fpage>
<lpage>1895</lpage>
<pub-id pub-id-type="pmid">12612064</pub-id>
</element-citation>
</ref>
<ref id="R87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Downregulation of GFAP, TSP-1, and p53 in human glioblastoma cell line, U373MG, by IE1 protein from human cytomegalovirus</article-title>
<source/>Glia
          <year>2005</year>
<volume>51</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">15779089</pub-id>
</element-citation>
</ref>
<ref id="R88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The S phase of the cell cycle and its perturbation by human cytomegalovirus</article-title>
<source/>Rev Med Virol
          <year>2007</year>
<volume>17</volume>
<fpage>423</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="pmid">17676653</pub-id>
</element-citation>
</ref>
<ref id="R89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spector</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus riding the cell cycle</article-title>
<source/>Med Microbiol Immunol
          <year>2015</year>
<volume>204</volume>
<fpage>409</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="pmid">25776080</pub-id>
</element-citation>
</ref>
<ref id="R90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Huong</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling</article-title>
<source/>J Virol
          <year>2001</year>
<volume>75</volume>
<fpage>6022</fpage>
<lpage>6032</lpage>
<pub-id pub-id-type="pmid">11390604</pub-id>
</element-citation>
</ref>
<ref id="R91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobbs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matlaf</surname>
<given-names>L</given-names>
</name>
<name>
<surname>McAllister</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yount</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rahlin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Harkins</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bezrookove</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and invasiveness via PDGFR-alpha activation</article-title>
<source/>Oncotarget
          <year>2014</year>
<volume>5</volume>
<fpage>1091</fpage>
<lpage>1100</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.1787">https://doi.org/10.18632/oncotarget.1787</ext-link>
</comment>
<pub-id pub-id-type="pmid">24658280</pub-id>
</element-citation>
</ref>
<ref id="R92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slinger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Maussang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Siderius</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fraile-Ramos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lira</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis</article-title>
<source/>Sci Signal
          <year>2010</year>
<volume>3</volume>
<fpage>ra58</fpage>
<pub-id pub-id-type="pmid">20682912</pub-id>
</element-citation>
</ref>
<ref id="R93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maussang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Langemeijer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fitzsimons</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Stigter-van Walsum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dijkman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Borg</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Slinger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tensen</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>van Dongen</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Leurs</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2</article-title>
<source/>Cancer Res
          <year>2009</year>
<volume>69</volume>
<fpage>2861</fpage>
<lpage>2869</lpage>
<pub-id pub-id-type="pmid">19318580</pub-id>
</element-citation>
</ref>
<ref id="R94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Matlaf</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bezrookove</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Harkins</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Soteropoulos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cobbs</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype</article-title>
<source/>Cancer Res
          <year>2011</year>
<volume>71</volume>
<fpage>6643</fpage>
<lpage>6653</lpage>
<pub-id pub-id-type="pmid">21900396</pub-id>
</element-citation>
</ref>
<ref id="R95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>An</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus infection contributes to glioma disease progression via upregulating endocan expression</article-title>
<source/>Transl Res
          <year>2016</year>
<volume>177</volume>
<fpage>113</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="pmid">27474433</pub-id>
</element-citation>
</ref>
<ref id="R96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobbs</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Denham</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Britt</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Pieper</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kraus</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness</article-title>
<source/>J Neurooncol
          <year>2007</year>
<volume>85</volume>
<fpage>271</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="pmid">17589804</pub-id>
</element-citation>
</ref>
<ref id="R97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Zagorski</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Brenneman</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Avery</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>O’Connor CM. US28 is a potent activator of phospholipase C during HCMV infection of clinically relevant target cells</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e50524</fpage>
<pub-id pub-id-type="pmid">23209769</pub-id>
</element-citation>
</ref>
<ref id="R98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Assinger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yaiw</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Göttesdorfer</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Leib-Mösch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus (HCMV) induces human endogenous retrovirus (HERV) transcription</article-title>
<source/>Retrovirology
          <year>2013</year>
<volume>10</volume>
<fpage>132</fpage>
<pub-id pub-id-type="pmid">24219971</pub-id>
</element-citation>
</ref>
<ref id="R99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacManiman</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Meuser</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Botto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jarvis</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Caposio</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus-encoded pUL7 is a novel CEACAM1-like molecule responsible for promotion of angiogenesis</article-title>
<source/>MBio
          <year>2014</year>
<volume>5</volume>
<fpage>e02035</fpage>
<pub-id pub-id-type="pmid">25352622</pub-id>
</element-citation>
</ref>
<ref id="R100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trgovcich</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cebulla</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sedmak</surname>
<given-names>DD</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus protein pp71 disrupts major histocompatibility complex class I cell surface expression</article-title>
<source/>J Virol
          <year>2006</year>
<volume>80</volume>
<fpage>951</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="pmid">16378997</pub-id>
</element-citation>
</ref>
<ref id="R101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Wills</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus immunity and immune evasion</article-title>
<source/>Virus Res
          <year>2011</year>
<volume>157</volume>
<fpage>151</fpage>
<lpage>160</lpage>
<pub-id pub-id-type="pmid">21056604</pub-id>
</element-citation>
</ref>
<ref id="R102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noriega</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Redmann</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tortorella</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Diverse immune evasion strategies by human cytomegalovirus</article-title>
<source/>Immunol Res
          <year>2012</year>
<volume>54</volume>
<fpage>140</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="pmid">22454101</pub-id>
</element-citation>
</ref>
<ref id="R103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barel</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Ressing</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pizzato</surname>
<given-names>N</given-names>
</name>
<name>
<surname>van Leeuwen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Le Bouteiller</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lenfant</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wiertz</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation</article-title>
<source/>J Immunol
          <year>2003</year>
<volume>171</volume>
<fpage>6757</fpage>
<lpage>6765</lpage>
<pub-id pub-id-type="pmid">14662880</pub-id>
</element-citation>
</ref>
<ref id="R104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rölle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Olweus</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures</article-title>
<source/>APMIS
          <year>2009</year>
<volume>117</volume>
<fpage>413</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="pmid">19400865</pub-id>
</element-citation>
</ref>
<ref id="R105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pangault</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Le Friec</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guilloux</surname>
<given-names>V</given-names>
</name>
<name>
<surname>André</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fauchet</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection</article-title>
<source/>J Immunol
          <year>2000</year>
<volume>164</volume>
<fpage>6426</fpage>
<lpage>6434</lpage>
<pub-id pub-id-type="pmid">10843698</pub-id>
</element-citation>
</ref>
<ref id="R106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pizzato</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Garmy-Susini</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Le Bouteiller</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lenfant</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Down-regulation of HLA-G1 cell surface expression in human cytomegalovirus infected cells</article-title>
<source/>Am J Reprod Immunol
          <year>2003</year>
<volume>50</volume>
<fpage>328</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="pmid">14672336</pub-id>
</element-citation>
</ref>
<ref id="R107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Modulators of the balance between M1 and M2 macrophages during pregnancy</article-title>
<source/>Front Immunol
          <year>2017</year>
<volume>8</volume>
<fpage>120</fpage>
<pub-id pub-id-type="pmid">28232836</pub-id>
</element-citation>
</ref>
<ref id="R108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchesi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Villabona</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Seliger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lundqvist</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kiessling</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Masucci</surname>
<given-names>GV</given-names>
</name>
</person-group>
<article-title>HLA-dependent tumour development: a role for tumour associate macrophages?</article-title>
<source/>J Transl Med
          <year>2013</year>
<volume>11</volume>
<fpage>247</fpage>
<pub-id pub-id-type="pmid">24093459</pub-id>
</element-citation>
</ref>
<ref id="R109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenfant</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pizzato</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Davrinche</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Le Bouteiller</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Horuzsko</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice</article-title>
<source/>J Gen Virol
          <year>2003</year>
<volume>84</volume>
<fpage>307</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="pmid">12560562</pub-id>
</element-citation>
</ref>
<ref id="R110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>So</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Vijayan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>WS</given-names>
</name>
</person-group>
<article-title>Soluble human leukocyte antigen G5 polarizes differentiation of macrophages toward a decidual macrophage-like phenotype</article-title>
<source/>Hum Reprod
          <year>2015</year>
<volume>30</volume>
<fpage>2263</fpage>
<lpage>2274</lpage>
<pub-id pub-id-type="pmid">26307092</pub-id>
</element-citation>
</ref>
<ref id="R111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Overbeek</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Vasaikar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patro</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Kostopoulou</surname>
<given-names>ON</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shafi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ananthaseshan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tsipras</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Davoudi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mohammad</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human cytomegalovirus may promote tumour progression by upregulating arginase-2</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>30</volume>
<fpage>47221</fpage>
<lpage>47231</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.9722">https://doi.org/10.18632/oncotarget.9722</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cinatl</surname>
<given-names>J</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Blaheta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bittoova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scholz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Margraf</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>JU</given-names>
</name>
<name>
<surname>Cinatl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doerr</surname>
<given-names>HW</given-names>
</name>
</person-group>
<article-title>Decreased neutrophil adhesion to human cytomegalovirus-infected retinal pigment epithelial cells is mediated by virus-induced up-regulation of Fas ligand independent of neutrophil apoptosis</article-title>
<source/>J Immunol
          <year>2000</year>
<volume>165</volume>
<fpage>4405</fpage>
<lpage>4413</lpage>
<pub-id pub-id-type="pmid">11035078</pub-id>
</element-citation>
</ref>
<ref id="R113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Identification of novel viral interleukin-10 isoforms of human cytomegalovirus AD169</article-title>
<source/>Virus Res
          <year>2008</year>
<volume>131</volume>
<fpage>213</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="pmid">17976852</pub-id>
</element-citation>
</ref>
<ref id="R114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slobedman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Avdic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Abendroth</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Virus-encoded homologs of cellular interleukin-10 and their control of host immune function</article-title>
<source/>J Virol
          <year>2009</year>
<volume>83</volume>
<fpage>9618</fpage>
<lpage>9629</lpage>
<pub-id pub-id-type="pmid">19640997</pub-id>
</element-citation>
</ref>
<ref id="R115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aiba-Masago</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>RY</given-names>
</name>
<name>
<surname>Shinmura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kosugi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tsutsui</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Murine cytomegalovirus immediate-early promoter directs astrocyte-specific expression in transgenic mice</article-title>
<source/>Am J Pathol
          <year>1999</year>
<volume>154</volume>
<fpage>735</fpage>
<lpage>743</lpage>
<pub-id pub-id-type="pmid">10079251</pub-id>
</element-citation>
</ref>
<ref id="R116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawasaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kosugi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tsutsui</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The amount of immature glial cells in organotypic brain slices determines the susceptibility to murine cytomegalovirus infection</article-title>
<source/>Lab Invest
          <year>2002</year>
<volume>82</volume>
<fpage>1347</fpage>
<lpage>1358</lpage>
<pub-id pub-id-type="pmid">12379769</pub-id>
</element-citation>
</ref>
<ref id="R117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsutsui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kosugi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kawasaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kaneta</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Roles of neural stem progenitor cells in cytomegalovirus infection of the brain in mouse models</article-title>
<source/>Pathol Int
          <year>2008</year>
<volume>58</volume>
<fpage>257</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="pmid">18429823</pub-id>
</element-citation>
</ref>
<ref id="R118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Den Pol</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Mocarski</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Saederup</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Cytomegalovirus cell tropism, replication, and gene transfer in brain</article-title>
<source/>J Neurosci
          <year>1999</year>
<volume>19</volume>
<fpage>10948</fpage>
<lpage>10965</lpage>
<pub-id pub-id-type="pmid">10594076</pub-id>
</element-citation>
</ref>
<ref id="R119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheeran</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yager</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Gekker</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Cytomegalovirus induces cytokine and chemokine production differentially in microglia and astrocytes: antiviral implications</article-title>
<source/>J Neurovirol
          <year>2001</year>
<volume>7</volume>
<fpage>135</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">11517386</pub-id>
</element-citation>
</ref>
<ref id="R120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheeran</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gekker</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Decreased cytomegalovirus expression following proinflammatory cytokine treatment of primary human astrocytes</article-title>
<source/>J Immunol
          <year>2000</year>
<volume>164</volume>
<fpage>926</fpage>
<lpage>933</lpage>
<pub-id pub-id-type="pmid">10623841</pub-id>
</element-citation>
</ref>
<ref id="R121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stacey</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>N TA</given-names>
</name>
<name>
<surname>Clare</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dolton</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stack</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Klenerman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gallimore</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Snelgrove</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lawley</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Dougan</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV</article-title>
<source/>Cell Host Microbe
          <year>2014</year>
<volume>15</volume>
<fpage>471</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">24721575</pub-id>
</element-citation>
</ref>
<ref id="R122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheeran</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>CXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10</article-title>
<source/>J Virol
          <year>2003</year>
<volume>77</volume>
<fpage>4502</fpage>
<lpage>4515</lpage>
<pub-id pub-id-type="pmid">12663757</pub-id>
</element-citation>
</ref>
<ref id="R123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheeran</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Gekker</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yager</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>CD4(+) lymphocyte-mediated suppression of cytomegalovirus expression in human astrocytes</article-title>
<source/>Clin Diagn Lab Immunol
          <year>2000</year>
<volume>7</volume>
<fpage>710</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="pmid">10882679</pub-id>
</element-citation>
</ref>
<ref id="R124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mutnal</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Memory T cells persisting in the brain following MCMV infection induce long-term microglial activation via interferon-γ</article-title>
<source/>J Neurovirol
          <year>2011</year>
<volume>17</volume>
<fpage>424</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="pmid">21800103</pub-id>
</element-citation>
</ref>
<ref id="R125">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecointe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dugas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Leclerc</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hery</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Delfraissy</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Tardieu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus infection reduces surface CCR5 expression in human microglial cells, astrocytes and monocyte-derived macrophages</article-title>
<source/>Microbes Infect
          <year>2002</year>
<volume>4</volume>
<fpage>1401</fpage>
<lpage>1408</lpage>
<pub-id pub-id-type="pmid">12475630</pub-id>
</element-citation>
</ref>
<ref id="R126">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Straschewski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patrone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gallina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Frascaroli</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration</article-title>
<source/>J Virol
          <year>2011</year>
<volume>85</volume>
<fpage>5150</fpage>
<lpage>5158</lpage>
<pub-id pub-id-type="pmid">21367908</pub-id>
</element-citation>
</ref>
<ref id="R127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fridlender</surname>
<given-names>ZG</given-names>
</name>
<name>
<surname>Albelda</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Tumor-associated neutrophils: friend or foe?</article-title>
<source/>Carcinogenesis
          <year>2012</year>
<volume>33</volume>
<fpage>949</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="pmid">22425643</pub-id>
</element-citation>
</ref>
<ref id="R128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chanmee</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ontong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Itano</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Tumor-associated macrophages as major players in the tumor microenvironment</article-title>
<source/>Cancers (Basel)
          <year>2014</year>
<volume>6</volume>
<fpage>1670</fpage>
<lpage>1690</lpage>
<pub-id pub-id-type="pmid">25125485</pub-id>
</element-citation>
</ref>
<ref id="R129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Miska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wainwright</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Dey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rivetta</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kanojia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pituch</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pytel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells</article-title>
<source/>Cancer Res
          <year>2016</year>
<volume>76</volume>
<fpage>5671</fpage>
<lpage>5682</lpage>
<pub-id pub-id-type="pmid">27530322</pub-id>
</element-citation>
</ref>
<ref id="R130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avdic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McSharry</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Steain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Poole</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abendroth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Slobedman</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus-encoded human interleukin-10 (IL-10) homolog amplifies its immunomodulatory potential by upregulating human IL-10 in monocytes</article-title>
<source/>J Virol
          <year>2016</year>
<volume>90</volume>
<fpage>3819</fpage>
<lpage>3827</lpage>
<pub-id pub-id-type="pmid">26792743</pub-id>
</element-citation>
</ref>
<ref id="R131">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kossmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Morganti-Kossmann</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Orenstein</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Britt</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Wahl</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>PD</given-names>
</name>
</person-group>
<article-title>Cytomegalovirus production by infected astrocytes correlates with transforming growth factor-beta release</article-title>
<source/>J Infect Dis
          <year>2003</year>
<volume>187</volume>
<fpage>534</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">12599069</pub-id>
</element-citation>
</ref>
<ref id="R132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>XX</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>HCMV induces dysregulation of glutamate uptake and transporter expression in human fetal astrocytes</article-title>
<source/>Neurochem Res
          <year>2014</year>
<volume>39</volume>
<fpage>2407</fpage>
<lpage>2418</lpage>
<pub-id pub-id-type="pmid">25293581</pub-id>
</element-citation>
</ref>
<ref id="R133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maus</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Glutamate and α-ketoglutarate: key players in glioma metabolism</article-title>
<source/>Amino Acids
          <year>2017</year>
<volume>49</volume>
<fpage>21</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">27752843</pub-id>
</element-citation>
</ref>
<ref id="R134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Platten</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kretz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Naumann</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Aulwurm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Egashira</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Isenmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weller</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas</article-title>
<source/>Ann Neurol
          <year>2003</year>
<volume>54</volume>
<fpage>388</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="pmid">12953273</pub-id>
</element-citation>
</ref>
<ref id="R135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pham</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5</article-title>
<source/>J Neuroimmunol
          <year>2012</year>
<volume>246</volume>
<fpage>10</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">22425022</pub-id>
</element-citation>
</ref>
<ref id="R136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben-Baruch</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The multifaceted roles of chemokines in malignancy</article-title>
<source/>Cancer Metastasis Rev
          <year>2006</year>
<volume>25</volume>
<fpage>357</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="pmid">17016763</pub-id>
</element-citation>
</ref>
<ref id="R137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaidi</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Merlino</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The two faces of interferon-γ in cancer</article-title>
<source/>Clin Cancer Res
          <year>2011</year>
<volume>17</volume>
<fpage>6118</fpage>
<lpage>6124</lpage>
<pub-id pub-id-type="pmid">21705455</pub-id>
</element-citation>
</ref>
<ref id="R138">
<label>138</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Schachtele</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Mutnal</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Chronic reactive gliosis following regulatory T cell depletion during acute MCMV encephalitis</article-title>
<source/>Glia
          <year>2015</year>
</element-citation>
</ref>
<ref id="R139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mutnal</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Cheeran</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Excess neutrophil infiltration during cytomegalovirus brain infection of interleukin-10-deficient mice</article-title>
<source/>J Neuroimmunol
          <year>2010</year>
<volume>227</volume>
<fpage>101</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="pmid">20655600</pub-id>
</element-citation>
</ref>
<ref id="R140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Craigen</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>MacCormac</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Westwick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Akbar</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Grundy</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration</article-title>
<source/>Immunology
          <year>1997</year>
<volume>92</volume>
<fpage>138</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="pmid">9370936</pub-id>
</element-citation>
</ref>
<ref id="R141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sparer</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Gosling</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schall</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Mocarski</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Expression of human CXCR2 in murine neutrophils as a model for assessing cytomegalovirus chemokine vCXCL-1 function <italic>in vivo</italic></article-title>
<source/>J Interferon Cytokine Res
          <year>2004</year>
<volume>24</volume>
<fpage>611</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="pmid">15626158</pub-id>
</element-citation>
</ref>
<ref id="R142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller-Kittrell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Penfold</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Richmond</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sparer</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>Functional characterization of chimpanzee cytomegalovirus chemokine, vCXCL-1(CCMV)</article-title>
<source/>Virology
          <year>2007</year>
<volume>364</volume>
<fpage>454</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="pmid">17433398</pub-id>
</element-citation>
</ref>
<ref id="R143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lüttichau</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<fpage>9137</fpage>
<lpage>9146</lpage>
<pub-id pub-id-type="pmid">20044480</pub-id>
</element-citation>
</ref>
<ref id="R144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dogra</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Masi</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Pitt</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>de Kruijf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Sparer</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>Novel human cytomegalovirus viral chemokines, vCXCL-1s, display functional selectivity for neutrophil signaling and function</article-title>
<source/>J Immunol
          <year>2015</year>
<volume>195</volume>
<fpage>227</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="pmid">25987741</pub-id>
</element-citation>
</ref>
<ref id="R145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy</article-title>
<source/>J Neurooncol
          <year>2011</year>
<volume>104</volume>
<fpage>83</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">21116835</pub-id>
</element-citation>
</ref>
<ref id="R146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krasnikova</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Arefieva</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Pylaeva</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Sidorova</surname>
<given-names>MV</given-names>
</name>
</person-group>
<article-title>Ingramon, a peptide inhibitor of MCP-1 chemokine, reduces migration of blood monocytes stimulated by glioma-conditioned medium</article-title>
<source/>Bull Exp Biol Med
          <year>2016</year>
<volume>160</volume>
<fpage>480</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="pmid">26906197</pub-id>
</element-citation>
</ref>
<ref id="R147">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schachtele</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Mutnal</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Lokensgard</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1</article-title>
<source/>Glia
          <year>2014</year>
<volume>62</volume>
<fpage>1582</fpage>
<lpage>1594</lpage>
<pub-id pub-id-type="pmid">24890099</pub-id>
</element-citation>
</ref>
<ref id="R148">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bivins-Smith</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Yurochko</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage</article-title>
<source/>J Immunol
          <year>2008</year>
<volume>181</volume>
<fpage>698</fpage>
<lpage>711</lpage>
<pub-id pub-id-type="pmid">18566437</pub-id>
</element-citation>
</ref>
<ref id="R149">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bayer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Varani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Straschewski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bachem</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Söderberg-Naucler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Frascaroli</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus infection of M1 and M2 macrophages triggers inflammation and autologous T-cell proliferation</article-title>
<source/>J Virol
          <year>2013</year>
<volume>87</volume>
<fpage>67</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">23055571</pub-id>
</element-citation>
</ref>
<ref id="R150">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Naing</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rawlinson</surname>
<given-names>WD</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus directly modulates expression of chemokine CCL2 (MCP-1) during viral replication</article-title>
<source/>J Gen Virol
          <year>2013</year>
<volume>94</volume>
<fpage>24495</fpage>
<lpage>24503</lpage>
</element-citation>
</ref>
<ref id="R151">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naing</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Webel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schmeiser</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marschall</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rawlinson</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Stimulatory effects of human cytomegalovirus tegument protein pp71 lead to increased expression of CCL2 (monocyte chemotactic protein-1) during infection</article-title>
<source/>J Gen Virol
          <year>2015</year>
<volume>96</volume>
<fpage>1855</fpage>
<lpage>1862</lpage>
<pub-id pub-id-type="pmid">25711967</pub-id>
</element-citation>
</ref>
<ref id="R152">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saederup</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Dairaghi</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Schall</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Mocarski</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1999</year>
<volume>96</volume>
<fpage>10881</fpage>
<lpage>10886</lpage>
<pub-id pub-id-type="pmid">10485920</pub-id>
</element-citation>
</ref>
<ref id="R153">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wagner</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Brizic</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Prager</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Trsan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Arapovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lemmermann</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Podlech</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reddehase</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lemnitzer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bosse</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Gimpfl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marcinowski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The viral chemokine MCK-2 of murine cytomegalovirus promotes infection as part of a gH/gL/MCK-2 complex</article-title>
<source/>PLoS Pathog
          <year>2013</year>
<volume>9</volume>
<fpage>e1003493</fpage>
<pub-id pub-id-type="pmid">23935483</pub-id>
</element-citation>
</ref>
<ref id="R154">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spencer</surname>
<given-names>JV</given-names>
</name>
</person-group>
<article-title>The cytomegalovirus homolog of interleukin-10 requires phosphatidylinositol 3-kinase activity for inhibition of cytokine synthesis in monocytes</article-title>
<source/>J Virol
          <year>2007</year>
<volume>81</volume>
<fpage>2083</fpage>
<lpage>2086</lpage>
<pub-id pub-id-type="pmid">17121792</pub-id>
</element-citation>
</ref>
<ref id="R155">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway</article-title>
<source/>Viruses
          <year>2012</year>
<volume>4</volume>
<fpage>1335</fpage>
<lpage>1353</lpage>
<pub-id pub-id-type="pmid">23012630</pub-id>
</element-citation>
</ref>
<ref id="R156">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Odeberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Reduced expression of HLA class II molecules and Iinterleukin-10- and transforming growth factor beta1-independent suppression of T-cell proliferation in human cytomegalovirus-infected macrophage cultures</article-title>
<source/>J Virol
          <year>2001</year>
<volume>75</volume>
<fpage>5174</fpage>
<lpage>5181</lpage>
<pub-id pub-id-type="pmid">11333898</pub-id>
</element-citation>
</ref>
<ref id="R157">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nijaguna</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Urbach</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shwetha</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Sravani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Chandramouli</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Arivazhagan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Santosh</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Somasundaram</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Glioblastoma-derived macrophage colony-stimulating factor (MCSF) induces microglial release of insulin-like growth factor-binding protein 1 (IGFBP1) to promote angiogenesis</article-title>
<source/>J Biol Chem
          <year>2015</year>
<volume>290</volume>
<fpage>23401</fpage>
<lpage>23415</lpage>
<pub-id pub-id-type="pmid">26245897</pub-id>
</element-citation>
</ref>
<ref id="R158">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas</article-title>
<source/>Mol Biol Rep
          <year>2011</year>
<volume>38</volume>
<fpage>3585</fpage>
<lpage>3591</lpage>
<pub-id pub-id-type="pmid">21088899</pub-id>
</element-citation>
</ref>
<ref id="R159">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevenson</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Collins-McMillen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Cieply</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Bentz</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Yurochko</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>HCMV reprogramming of infected monocyte survival and differentiation: a Goldilocks phenomenon</article-title>
<source/>Viruses
          <year>2014</year>
<volume>6</volume>
<fpage>782</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="pmid">24531335</pub-id>
</element-citation>
</ref>
<ref id="R160">
<label>160</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins-McMillen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Nogalski</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Stevenson</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Caskey</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Cieply</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Yurochko</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus promotes survival of infected monocytes via a distinct temporal regulation of cellular Bcl-2 family proteins</article-title>
<source/>J Virol
          <year>2015</year>
<volume>90</volume>
<fpage>2356</fpage>
<lpage>2371</lpage>
<pub-id pub-id-type="pmid">26676786</pub-id>
</element-citation>
</ref>
<ref id="R161">
<label>161</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cojohari</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Peppenelli</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus induces an atypical activation of Akt to stimulate the survival of short-lived monocytes</article-title>
<source/>J Virol
          <year>2016</year>
<volume>90</volume>
<fpage>6443</fpage>
<lpage>6452</lpage>
<pub-id pub-id-type="pmid">27147739</pub-id>
</element-citation>
</ref>
<ref id="R162">
<label>162</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchmeier</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>NR</given-names>
</name>
</person-group>
<article-title>Suppression of monocyte functions by human cytomegalovirus</article-title>
<source/>Immunology
          <year>1989</year>
<volume>66</volume>
<fpage>278</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="pmid">2538390</pub-id>
</element-citation>
</ref>
<ref id="R163">
<label>163</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bivins-Smith</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Yurochko</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>NF-kappaB and phosphatidylinositol 3-kinase activity mediates the HCMV-induced atypical M1/M2 polarization of monocytes</article-title>
<source/>Virus Res
          <year>2009</year>
<volume>144</volume>
<fpage>329</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="pmid">19427341</pub-id>
</element-citation>
</ref>
<ref id="R164">
<label>164</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frascaroli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Varani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moepps</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sinzger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Landini</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus subverts the functions of monocytes, impairing chemokine-mediated migration and leukocyte recruitment</article-title>
<source/>J Virol
          <year>2006</year>
<volume>80</volume>
<fpage>7578</fpage>
<lpage>7589</lpage>
<pub-id pub-id-type="pmid">16840337</pub-id>
</element-citation>
</ref>
<ref id="R165">
<label>165</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poglitsch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weichhart</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hecking</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Werzowa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Katholnig</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Antlanger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krmpotic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jonjic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hörl</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Zlabinger</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Puchhammer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Säemann</surname>
<given-names>MD</given-names>
</name>
</person-group>
<article-title>CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages</article-title>
<source/>Am J Transplant
          <year>2012</year>
<volume>12</volume>
<fpage>1458</fpage>
<lpage>1468</lpage>
<pub-id pub-id-type="pmid">22390651</pub-id>
</element-citation>
</ref>
<ref id="R166">
<label>166</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCormick</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Roback</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Livingston-Rosanoff</surname>
<given-names>D</given-names>
</name>
<name>
<surname>St Clair</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The human cytomegalovirus UL36 gene controls caspase-dependent and -independent cell death programs activated by infection of monocytes differentiating to macrophages</article-title>
<source/>J Virol
          <year>2010</year>
<volume>84</volume>
<fpage>5108</fpage>
<lpage>5123</lpage>
<pub-id pub-id-type="pmid">20219915</pub-id>
</element-citation>
</ref>
<ref id="R167">
<label>167</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Muckova</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lzicarova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vybihal</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Svoboda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fadrus</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Smrcka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Slaby</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Lakomy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vanhara</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krenova</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Michalek</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity?</article-title>
<source/>J Neuroimmunol
          <year>2010</year>
<volume>220</volume>
<fpage>131</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">20167379</pub-id>
</element-citation>
</ref>
<ref id="R168">
<label>168</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hengel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Reusch</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Geginat</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Holtappels</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ruppert</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hellebrand</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Koszinowski</surname>
<given-names>UH</given-names>
</name>
</person-group>
<article-title>Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus</article-title>
<source/>J Virol
          <year>2000</year>
<volume>74</volume>
<fpage>7861</fpage>
<lpage>7868</lpage>
<pub-id pub-id-type="pmid">10933693</pub-id>
</element-citation>
</ref>
<ref id="R169">
<label>169</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strieter</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Burdick</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Mestas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gomperts</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Keane</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Belperio</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Cancer CXC chemokine networks and tumour angiogenesis</article-title>
<source/>Eur J Cancer
          <year>2006</year>
<volume>42</volume>
<fpage>768</fpage>
<lpage>778</lpage>
<pub-id pub-id-type="pmid">16510280</pub-id>
</element-citation>
</ref>
<ref id="R170">
<label>170</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schober</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zernecke</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Chemokines in vascular remodeling</article-title>
<source/>Thromb Haemost
          <year>2007</year>
<volume>97</volume>
<fpage>730</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="pmid">17479183</pub-id>
</element-citation>
</ref>
<ref id="R171">
<label>171</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keeley</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Mehrad</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Strieter</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Chemokines as mediators of neovascularization</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2008</year>
<volume>28</volume>
<fpage>1928</fpage>
<lpage>1936</lpage>
<pub-id pub-id-type="pmid">18757292</pub-id>
</element-citation>
</ref>
<ref id="R172">
<label>172</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frascaroli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Varani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blankenhorn</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pretsch</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bacher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bucala</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Landini</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor</article-title>
<source/>J Immunol
          <year>2009</year>
<volume>182</volume>
<fpage>477</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="pmid">19109179</pub-id>
</element-citation>
</ref>
<ref id="R173">
<label>173</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umemura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Saio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suwa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kitoh</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nonaka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Balazs</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adany</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takami</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics</article-title>
<source/>J Leukoc Biol
          <year>2008</year>
<volume>83</volume>
<fpage>1136</fpage>
<lpage>1144</lpage>
<pub-id pub-id-type="pmid">18285406</pub-id>
</element-citation>
</ref>
<ref id="R174">
<label>174</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szulzewsky</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pelz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Synowitz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Markovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Langmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Holtman</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Eggen</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Boddeke</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Hambardzumyan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Kettenmann</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0116644</fpage>
<pub-id pub-id-type="pmid">25658639</pub-id>
</element-citation>
</ref>
<ref id="R175">
<label>175</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szulzewsky</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>S</given-names>
</name>
<name>
<surname>de Witte</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ulas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Markovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schultze</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Synowitz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Kettenmann</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Human glioblastoma-associated microglia/monocytes express a distinct RNA profile compared to human control and murine samples</article-title>
<source/>Glia
          <year>2016</year>
<volume>64</volume>
<fpage>1416</fpage>
<lpage>1436</lpage>
<pub-id pub-id-type="pmid">27312099</pub-id>
</element-citation>
</ref>
<ref id="R176">
<label>176</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Gabrusiewicz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Healy</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Maiti</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Elakkad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liebelt</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Yaghi</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Ezhilarasan</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype</article-title>
<source/>JCI Insight
          <year>2016</year>
</element-citation>
</ref>
<ref id="R177">
<label>177</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Towler</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ebrahimi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Davison</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Dargan</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus transcriptome activity differs during replication in human fibroblast, epithelial and astrocyte cell lines</article-title>
<source/>J Gen Virol
          <year>2012</year>
<volume>93</volume>
<fpage>1046</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="pmid">22258857</pub-id>
</element-citation>
</ref>
<ref id="R178">
<label>178</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>CD4+Foxp3- type 1 regulatory T cells in glioblastoma multiforme suppress T cell responses through multiple pathways and are regulated by tumor-associated macrophages</article-title>
<source/>Int J Biochem Cell Biol
          <year>2016</year>
<volume>81</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">27644153</pub-id>
</element-citation>
</ref>
<ref id="R179">
<label>179</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tovar-Salazar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Patterson-Bartlett</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jesser</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Regulatory function of cytomegalovirus-specific CD4+CD27-CD28- T cells</article-title>
<source/>Virology
          <year>2010</year>
<volume>398</volume>
<fpage>158</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="pmid">20034645</pub-id>
</element-citation>
</ref>
<ref id="R180">
<label>180</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Brestrich</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wlodarski</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schmueck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roemhild</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Babel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kurtz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maciejewski</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Reinke</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cytomegalovirus-specific regulatory and effector T cells share TCR clonality--possible relation to repetitive CMV infections</article-title>
<source/>Am J Transplant
          <year>2012</year>
<volume>12</volume>
<fpage>669</fpage>
<lpage>681</lpage>
<pub-id pub-id-type="pmid">22081907</pub-id>
</element-citation>
</ref>
<ref id="R181">
<label>181</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terrazzini</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bajwa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cheek</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Seddiki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>A novel cytomegalovirus-induced regulatory-type T-cell subset increases in size during older life and links virus-specific immunity to vascular pathology</article-title>
<source/>J Infect Dis
          <year>2014</year>
<volume>209</volume>
<fpage>1382</fpage>
<lpage>1392</lpage>
<pub-id pub-id-type="pmid">24203779</pub-id>
</element-citation>
</ref>
<ref id="R182">
<label>182</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clement</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stacey</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Abdul-Karim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gimeno Brias</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Costa Bento</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scurr</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ghazal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Carlesso</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Clare</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Godkin</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence</article-title>
<source/>PLoS Pathog
          <year>2016</year>
<volume>12</volume>
<fpage>e1006050</fpage>
<pub-id pub-id-type="pmid">27926930</pub-id>
</element-citation>
</ref>
<ref id="R183">
<label>183</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gredmark</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tilburgs</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Human cytomegalovirus inhibits cytokine-induced macrophage differentiation</article-title>
<source/>J Virol
          <year>2004</year>
<volume>78</volume>
<fpage>10378</fpage>
<lpage>10389</lpage>
<pub-id pub-id-type="pmid">15367604</pub-id>
</element-citation>
</ref>
<ref id="R184">
<label>184</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Strate</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Hillebrands</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lycklama à Nijeholt</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Beljaars</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bruggeman</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Van Luyn</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rozing</surname>
<given-names>J</given-names>
</name>
<name>
<surname>The</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Meijer</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Molema</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Harmsen</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Dissemination of rat cytomegalovirus through infected granulocytes and monocytes <italic>in vitro</italic> and <italic>in vivo</italic></article-title>
<source/>J Virol
          <year>2003</year>
<volume>77</volume>
<fpage>11274</fpage>
<lpage>11278</lpage>
<pub-id pub-id-type="pmid">14512575</pub-id>
</element-citation>
</ref>
<ref id="R185">
<label>185</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Ham</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>CD133 regulates IL-1β signaling and neutrophil recruitment in glioblastoma</article-title>
<source/>Mol Cells
          <year>2017</year>
<volume>40</volume>
<fpage>515</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="pmid">28736425</pub-id>
</element-citation>
</ref>
<ref id="R186">
<label>186</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cederarv</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wolmer-Solberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tammik</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stragliotto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Peredo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fornara</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Dzabic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Taher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Skarman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients</article-title>
<source/>Oncoimmunology
          <year>2015</year>
<volume>5</volume>
<fpage>e1075693</fpage>
<pub-id pub-id-type="pmid">27057448</pub-id>
</element-citation>
</ref>
<ref id="R187">
<label>187</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Prognostic role of neutrophil lymphocyte ratio in patients with glioma</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>59217</fpage>
<lpage>59224</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.19484">https://doi.org/10.18632/oncotarget.19484</ext-link>
</comment>
<pub-id pub-id-type="pmid">28938630</pub-id>
</element-citation>
</ref>
<ref id="R188">
<label>188</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackson</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Garcia-Verdugo</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Gil-Perotin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Quinones-Hinojosa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>VandenBerg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Alvarez-Buylla</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling</article-title>
<source/>Neuron
          <year>2006</year>
<volume>51</volume>
<fpage>187</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="pmid">16846854</pub-id>
</element-citation>
</ref>
<ref id="R189">
<label>189</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Price</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Chiocca</surname>
<given-names>EA</given-names>
</name>
</person-group>
<article-title>Modeling cytomegalovirus infection in mouse tumor models</article-title>
<source/>Front Oncol
          <year>2015</year>
<volume>5</volume>
<fpage>61</fpage>
<pub-id pub-id-type="pmid">25853089</pub-id>
</element-citation>
</ref>
<ref id="R190">
<label>190</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleczkowska</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lipkowski</surname>
<given-names>AW</given-names>
</name>
</person-group>
<article-title>Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation--a review</article-title>
<source/>Eur J Pharmacol
          <year>2013</year>
<volume>716</volume>
<fpage>54</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">23500196</pub-id>
</element-citation>
</ref>
<ref id="R191">
<label>191</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hermey</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The Vps10p-domain receptor family</article-title>
<source/>Cell Mol Life Sci
          <year>2009</year>
<volume>66</volume>
<fpage>2677</fpage>
<lpage>2689</lpage>
<pub-id pub-id-type="pmid">19434368</pub-id>
</element-citation>
</ref>
<ref id="R192">
<label>192</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Devader</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Béraud-Dufour</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mazella</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Focal adhesion kinase dependent activation of the PI3 kinase pathway by the functional soluble form of neurotensin receptor-3 in HT29 cells</article-title>
<source/>Int J Biochem Cell Biol
          <year>2013</year>
<volume>45</volume>
<fpage>952</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="pmid">23395631</pub-id>
</element-citation>
</ref>
<ref id="R193">
<label>193</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Devader</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lacas-Gervais</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Béraud-Dufour</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mazella</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Impairement of HT29 cancer cells cohesion by the soluble form of neurotensin receptor-3</article-title>
<source/>Genes Cancer
          <year>2014</year>
<volume>5</volume>
<fpage>240</fpage>
<lpage>249</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/genesandcancer.22">https://doi.org/10.18632/genesandcancer.22</ext-link>
</comment>
<pub-id pub-id-type="pmid">25221642</pub-id>
</element-citation>
</ref>
<ref id="R194">
<label>194</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evers</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Neurotensin and growth of normal and neoplastic tissues</article-title>
<source/>Peptides
          <year>2006</year>
<volume>27</volume>
<fpage>2424</fpage>
<lpage>2433</lpage>
<pub-id pub-id-type="pmid">16904238</pub-id>
</element-citation>
</ref>
<ref id="R195">
<label>195</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalafatakis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Triantafyllou</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Contribution of neurotensin in the immune and neuroendocrine modulation of normal and abnormal enteric function</article-title>
<source/>Regul Pept
          <year>2011</year>
<volume>170</volume>
<fpage>7</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">21549161</pub-id>
</element-citation>
</ref>
<ref id="R196">
<label>196</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uhl</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Distribution of neurotensin and its receptor in the central nervous system</article-title>
<source/>Ann N Y Acad Sci
          <year>1982</year>
<volume>400</volume>
<fpage>132</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="pmid">6301323</pub-id>
</element-citation>
</ref>
<ref id="R197">
<label>197</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>St-Gelais</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jomphe</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Trudeau</surname>
<given-names>LE</given-names>
</name>
</person-group>
<article-title>The role of neurotensin in central nervous system pathophysiology: what is the evidence?</article-title>
<source/>J Psychiatry Neurosci
          <year>2006</year>
<volume>31</volume>
<fpage>229</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="pmid">16862241</pub-id>
</element-citation>
</ref>
<ref id="R198">
<label>198</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boules</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fredrickson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Richelson</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Diverse roles of neurotensin agonists in the central nervous system</article-title>
<source/>Front Endocrinol (Lausanne)
          <year>2013</year>
<volume>4</volume>
<fpage>36</fpage>
<pub-id pub-id-type="pmid">23526754</pub-id>
</element-citation>
</ref>
<ref id="R199">
<label>199</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferraro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tomasini</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Siniscalchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fuxe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tanganelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Antonelli</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Neurotensin increases endogenous glutamate release in rat cortical slices</article-title>
<source/>Life Sci
          <year>2000</year>
<volume>66</volume>
<fpage>927</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="pmid">10714893</pub-id>
</element-citation>
</ref>
<ref id="R200">
<label>200</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antonelli</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fuxe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tomasini</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Mazzoni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Agnati</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Tanganelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ferraro</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment</article-title>
<source/>Prog Neurobiol
          <year>2007</year>
<volume>83</volume>
<fpage>92</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">17673354</pub-id>
</element-citation>
</ref>
<ref id="R201">
<label>201</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferraro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Beggiato</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tomasini</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Fuxe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tanganelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Antonelli</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Neurotensin regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor functional activity: an <italic>in vivo</italic> microdialysis study</article-title>
<source/>J Neurosci Res
          <year>2011</year>
<volume>89</volume>
<fpage>1618</fpage>
<lpage>1626</lpage>
<pub-id pub-id-type="pmid">21656844</pub-id>
</element-citation>
</ref>
<ref id="R202">
<label>202</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ouyang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients</article-title>
<source/>Mol Cancer
          <year>2015</year>
<volume>14</volume>
<fpage>21</fpage>
<pub-id pub-id-type="pmid">25644759</pub-id>
</element-citation>
</ref>
<ref id="R203">
<label>203</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Neurotensin signaling regulates stem-like traits of glioblastoma stem cells through activation of IL-8/CXCR1/STAT3 pathway</article-title>
<source/>Cell Signal
          <year>2014</year>
<volume>26</volume>
<fpage>2896</fpage>
<lpage>2902</lpage>
<pub-id pub-id-type="pmid">25200966</pub-id>
</element-citation>
</ref>
<ref id="R204">
<label>204</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ouyang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p</article-title>
<source/>Neuro Oncol
          <year>2016</year>
<volume>18</volume>
<fpage>216</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="pmid">26180082</pub-id>
</element-citation>
</ref>
<ref id="R205">
<label>205</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayala-Sarmiento</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Martinez-Fong</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Segovia</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The internalization of neurotensin by the low-affinity neurotensin receptors (NTSR2 and vNTSR2) activates ERK 1/2 in glioma cells and allows neurotensin-polyplex transfection of tGAS1</article-title>
<source/>Cell Mol Neurobiol
          <year>2015</year>
<volume>35</volume>
<fpage>785</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="pmid">25772140</pub-id>
</element-citation>
</ref>
<ref id="R206">
<label>206</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servotte</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Camby</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Debeir</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Deroanne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Lapière</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kiss</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nusgens</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Decaestecker</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The <italic>in vitro</italic> influences of neurotensin on the motility characteristics of human U373 glioblastoma cells</article-title>
<source/>Neuropathol Appl Neurobiol
          <year>2006</year>
<volume>32</volume>
<fpage>575</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="pmid">17083472</pub-id>
</element-citation>
</ref>
<ref id="R207">
<label>207</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Tveteraas</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Aasrum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ødegård</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dawood</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dajani</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Christoffersen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sandnes</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells</article-title>
<source/>BMC Cancer
          <year>2011</year>
<volume>11</volume>
<fpage>421</fpage>
<pub-id pub-id-type="pmid">21961726</pub-id>
</element-citation>
</ref>
<ref id="R208">
<label>208</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>YP</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>IO</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>K</given-names>
</name>
<name>
<surname>To</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>KW</given-names>
</name>
</person-group>
<article-title>CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling</article-title>
<source/>Hepatology
          <year>2012</year>
<volume>55</volume>
<fpage>807</fpage>
<lpage>820</lpage>
<pub-id pub-id-type="pmid">21994122</pub-id>
</element-citation>
</ref>
<ref id="R209">
<label>209</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dupouy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Doan</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Mourra</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>De Wever</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Llorca</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Cayre</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kouchkar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gompel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Forgez</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice</article-title>
<source/>Oncotarget
          <year>2014</year>
<volume>5</volume>
<fpage>8235</fpage>
<lpage>8251</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.1632">https://doi.org/10.18632/oncotarget.1632</ext-link>
</comment>
<pub-id pub-id-type="pmid">25249538</pub-id>
</element-citation>
</ref>
<ref id="R210">
<label>210</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Younes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dupouy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lupo</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Mourra</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fléjou</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Trédaniel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Régnard</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Damotte</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Alifano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Forgez</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib</article-title>
<source/>Oncotarget
          <year>2014</year>
<volume>5</volume>
<fpage>8252</fpage>
<lpage>8269</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.1633">https://doi.org/10.18632/oncotarget.1633</ext-link>
</comment>
<pub-id pub-id-type="pmid">25249545</pub-id>
</element-citation>
</ref>
<ref id="R211">
<label>211</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moody</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Mantey</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>RT</given-names>
</name>
</person-group>
<article-title>SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner</article-title>
<source/>Life Sci
          <year>2014</year>
<volume>100</volume>
<fpage>25</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">24496038</pub-id>
</element-citation>
</ref>
<ref id="R212">
<label>212</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akter</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>OS</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer</article-title>
<source/>Tumour Biol
          <year>2015</year>
<volume>36</volume>
<fpage>6053</fpage>
<lpage>6062</lpage>
<pub-id pub-id-type="pmid">25724188</pub-id>
</element-citation>
</ref>
<ref id="R213">
<label>213</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amorino</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Deeble</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway</article-title>
<source/>Oncogene
          <year>2007</year>
<volume>26</volume>
<fpage>745</fpage>
<lpage>756</lpage>
<pub-id pub-id-type="pmid">16862179</pub-id>
</element-citation>
</ref>
<ref id="R214">
<label>214</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakirtzi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hatziapostolou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karagiannides</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Polytarchou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jaeger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iliopoulos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pothoulakis</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors</article-title>
<source/>Gastroenterology
          <year>2011</year>
<volume>141</volume>
<fpage>1749</fpage>
<lpage>1761</lpage>
<pub-id pub-id-type="pmid">21806946</pub-id>
</element-citation>
</ref>
<ref id="R215">
<label>215</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bakirtzi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Koon</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Pothoulakis</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<fpage>6092</fpage>
<lpage>6099</lpage>
<pub-id pub-id-type="pmid">21212273</pub-id>
</element-citation>
</ref>
<ref id="R216">
<label>216</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersson</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Malmer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bergenheim</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Brännström</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hedman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Henriksson</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas</article-title>
<source/>Acta Neuropathol
          <year>2004</year>
<volume>108</volume>
<fpage>135</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="pmid">15148612</pub-id>
</element-citation>
</ref>
<ref id="R217">
<label>217</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mineo</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Bordron</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Quintin-Roué</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Maurage</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Buhé</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Loisel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Blond</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Berthou</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model</article-title>
<source/>J Neurooncol
          <year>2006</year>
<volume>76</volume>
<fpage>249</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="pmid">16200345</pub-id>
</element-citation>
</ref>
<ref id="R218">
<label>218</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duhem-Tonnelle</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bièche</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Vacher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Loyens</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maurage</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baroncini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Blond</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Prevot</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sharif</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2010</year>
<volume>69</volume>
<fpage>606</fpage>
<lpage>622</lpage>
<pub-id pub-id-type="pmid">20467331</pub-id>
</element-citation>
</ref>
<ref id="R219">
<label>219</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bian</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Glioma-initiating cells: a predominant role in microglia/macrophages tropism to glioma</article-title>
<source/>J Neuroimmunol
          <year>2011</year>
<volume>232</volume>
<fpage>75</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">21056915</pub-id>
</element-citation>
</ref>
<ref id="R220">
<label>220</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Infanger</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Mohanan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Gursel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boockvar</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Fischbach</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche</article-title>
<source/>Cancer Res
          <year>2013</year>
<volume>73</volume>
<fpage>7079</fpage>
<lpage>7089</lpage>
<pub-id pub-id-type="pmid">24121485</pub-id>
</element-citation>
</ref>
<ref id="R221">
<label>221</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy</article-title>
<source/>Brain Tumor Pathol
          <year>2015</year>
<volume>32</volume>
<fpage>229</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="pmid">26437643</pub-id>
</element-citation>
</ref>
<ref id="R222">
<label>222</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The CXCL8-CXCR1/2 pathways in cancer</article-title>
<source/>Cytokine Growth Factor Rev
          <year>2016</year>
<volume>31</volume>
<fpage>61</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">27578214</pub-id>
</element-citation>
</ref>
<ref id="R223">
<label>223</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Ives</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Evers</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells</article-title>
<source/>Clin Cancer Res
          <year>2006</year>
<volume>12</volume>
<fpage>5346</fpage>
<lpage>5355</lpage>
<pub-id pub-id-type="pmid">17000667</pub-id>
</element-citation>
</ref>
<ref id="R224">
<label>224</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Keates</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Kuhnt-Moore</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moyer</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Pothoulakis</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes</article-title>
<source/>J Biol Chem
          <year>2001</year>
<volume>276</volume>
<fpage>44464</fpage>
<lpage>44471</lpage>
<pub-id pub-id-type="pmid">11574537</pub-id>
</element-citation>
</ref>
<ref id="R225">
<label>225</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Somaï</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gompel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rostène</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Forgez</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Neurotensin counteracts apoptosis in breast cancer cells</article-title>
<source/>Biochem Biophys Res Commun
          <year>2002</year>
<volume>295</volume>
<fpage>482</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="pmid">12150975</pub-id>
</element-citation>
</ref>
<ref id="R226">
<label>226</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najimi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maloteaux</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hermans</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Cytoskeleton-related trafficking of the EAAC1 glutamate transporter after activation of the G(q/11)-coupled neurotensin receptor NTS1</article-title>
<source/>FEBS Lett
          <year>2002</year>
<volume>523</volume>
<fpage>224</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="pmid">12123836</pub-id>
</element-citation>
</ref>
<ref id="R227">
<label>227</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamimae</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Niinuma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamano</surname>
<given-names>HO</given-names>
</name>
<name>
<surname>Nojima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takagi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epigenetic silencing of NTSR1 is associated with lateral and noninvasive growth of colorectal tumors</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>29975</fpage>
<lpage>29990</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.5034">https://doi.org/10.18632/oncotarget.5034</ext-link>
</comment>
<pub-id pub-id-type="pmid">26334593</pub-id>
</element-citation>
</ref>
<ref id="R228">
<label>228</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>70303</fpage>
<lpage>70322</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.11854">https://doi.org/10.18632/oncotarget.11854</ext-link>
</comment>
<pub-id pub-id-type="pmid">27611941</pub-id>
</element-citation>
</ref>
<ref id="R229">
<label>229</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leyton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Garcia-Marin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Moody</surname>
<given-names>TW</given-names>
</name>
</person-group>
<article-title>Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells</article-title>
<source/>Eur J Pharmacol
          <year>2002</year>
<volume>442</volume>
<fpage>179</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="pmid">12065070</pub-id>
</element-citation>
</ref>
<ref id="R230">
<label>230</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olszewski</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells</article-title>
<source/>Mol Oncol
          <year>2009</year>
<volume>3</volume>
<fpage>204</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="pmid">19393580</pub-id>
</element-citation>
</ref>
<ref id="R231">
<label>231</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Busby</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kung</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>CP</given-names>
</name>
</person-group>
<article-title>Angiogenesis is not mediated by prostate cancer neuropeptides</article-title>
<source/>Angiogenesis
          <year>2003</year>
<volume>6</volume>
<fpage>289</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="pmid">15166497</pub-id>
</element-citation>
</ref>
<ref id="R232">
<label>232</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakirtzi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>West</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fiocchi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Iliopoulos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pothoulakis</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The neurotensin-HIF-1α-VEGFα axis orchestrates hypoxia, colonic inflammation, and intestinal angiogenesis</article-title>
<source/>Am J Pathol
          <year>2014</year>
<volume>184</volume>
<fpage>3405</fpage>
<lpage>3414</lpage>
<pub-id pub-id-type="pmid">25307345</pub-id>
</element-citation>
</ref>
<ref id="R233">
<label>233</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tazzyman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Niaz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Murdoch</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth</article-title>
<source/>Semin Cancer Biol
          <year>2013</year>
<volume>23</volume>
<fpage>149</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="pmid">23410638</pub-id>
</element-citation>
</ref>
<ref id="R234">
<label>234</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peck</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Neuropeptides modulating macrophage function</article-title>
<source/>Ann N Y Acad Sci
          <year>1987</year>
<volume>496</volume>
<fpage>264</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="pmid">3037973</pub-id>
</element-citation>
</ref>
<ref id="R235">
<label>235</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Yumkham</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>PG</given-names>
</name>
</person-group>
<article-title>Neurotensin enhances nitric oxide generation via the JAK2-STAT1 pathway in murine macrophage Raw264.7 cells during costimulation with LPS and IFNgamma</article-title>
<source/>Neuropeptides
          <year>2006</year>
<volume>40</volume>
<fpage>221</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">16563502</pub-id>
</element-citation>
</ref>
<ref id="R236">
<label>236</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moura</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Leal</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Tellechea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Neurotensin modulates the migratory and inflammatory response of macrophages under hyperglycemic conditions</article-title>
<source/>Biomed Res Int
          <year>2013</year>
<volume>2013</volume>
<fpage>941764</fpage>
<pub-id pub-id-type="pmid">24000330</pub-id>
</element-citation>
</ref>
<ref id="R237">
<label>237</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemaire</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Neurotensin enhances IL-1 production by activated alveolar macrophages</article-title>
<source/>J Immunol
          <year>1988</year>
<volume>140</volume>
<fpage>2983</fpage>
<lpage>2988</lpage>
<pub-id pub-id-type="pmid">2834448</pub-id>
</element-citation>
</ref>
<ref id="R238">
<label>238</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razavi</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Aujla</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Gholamin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Immune evasion strategies of glioblastoma</article-title>
<source/>Front Surg
          <year>2016</year>
<volume>3</volume>
<fpage>11</fpage>
<pub-id pub-id-type="pmid">26973839</pub-id>
</element-citation>
</ref>
<ref id="R239">
<label>239</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pannell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Szulzewsky</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Matyash</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Kettenmann</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The subpopulation of microglia sensitive to neurotransmitters/neurohormones is modulated by stimulation with LPS, interferon-γ, and IL-4</article-title>
<source/>Glia
          <year>2014</year>
<volume>62</volume>
<fpage>667</fpage>
<lpage>679</lpage>
<pub-id pub-id-type="pmid">24504982</pub-id>
</element-citation>
</ref>
<ref id="R240">
<label>240</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Mazella</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia</article-title>
<source/>J Neurosci
          <year>2003</year>
<volume>23</volume>
<fpage>1198</fpage>
<lpage>1205</lpage>
<pub-id pub-id-type="pmid">12598608</pub-id>
</element-citation>
</ref>
<ref id="R241">
<label>241</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dicou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Mazella</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Neurotensin receptor-3/sortilin mediates neurotensin-induced cytokine/chemokine expression in a murine microglial cell line</article-title>
<source/>J Neurosci Res
          <year>2004</year>
<volume>78</volume>
<fpage>92</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">15372498</pub-id>
</element-citation>
</ref>
<ref id="R242">
<label>242</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Tsilioni</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Leeman</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Theoharides</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2016</year>
</element-citation>
</ref>
<ref id="R243">
<label>243</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bar-Shavit</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Romeo</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Neurotensin modulates human neutrophil locomotion and phagocytic capability</article-title>
<source/>FEBS Lett
          <year>1983</year>
<volume>159</volume>
<fpage>63</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="pmid">6873304</pub-id>
</element-citation>
</ref>
<ref id="R244">
<label>244</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbins</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Gossman</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Rubinstein</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Neurotensin stimulates neutrophil adherence to bronchial epithelial cells <italic>in vitro</italic></article-title>
<source/>Life Sci
          <year>1995</year>
<volume>56</volume>
<fpage>1353</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="pmid">8614258</pub-id>
</element-citation>
</ref>
<ref id="R245">
<label>245</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>da Silva</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Neves</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Moura</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Neurotensin downregulates the pro-inflammatory properties of skin dendritic cells and increases epidermal growth factor expression</article-title>
<source/>Biochim Biophys Acta
          <year>2011</year>
<volume>1813</volume>
<fpage>1863</fpage>
<lpage>1871</lpage>
<pub-id pub-id-type="pmid">21767580</pub-id>
</element-citation>
</ref>
<ref id="R246">
<label>246</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Strelau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Böttner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lingor</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Suter-Crazzolara</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Galter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jaszai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schober</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krieglstein</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Unsicker</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>GDF-15/MIC-1 a novel member of the TGF-beta superfamily</article-title>
<source/>J Neural Transm Suppl
          <year>2000</year>
</element-citation>
</ref>
<ref id="R247">
<label>247</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Eling</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer</article-title>
<source/>Biochem Pharmacol
          <year>2013</year>
<volume>85</volume>
<fpage>597</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="pmid">23220538</pub-id>
</element-citation>
</ref>
<ref id="R248">
<label>248</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Opposing effects of PI3K/Akt and Smad-dependent signaling pathways in NAG-1-induced glioblastoma cell apoptosis</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e96283</fpage>
<pub-id pub-id-type="pmid">24759784</pub-id>
</element-citation>
</ref>
<ref id="R249">
<label>249</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Jager</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Bermúdez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bot</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Koenen</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Bot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kavelaars</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Waard</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Heijnen</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Muriana</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van Berkel</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Kuiper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis</article-title>
<source/>J Exp Med
          <year>2011</year>
<volume>208</volume>
<fpage>217</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">21242297</pub-id>
</element-citation>
</ref>
<ref id="R250">
<label>250</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Artz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Butz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vestweber</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>GDF-15 inhibits integrin activation and mouse neutrophil recruitment through the ALK-5/TGF-βRII heterodimer</article-title>
<source/>Blood
          <year>2016</year>
<volume>128</volume>
<fpage>529</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">27235139</pub-id>
</element-citation>
</ref>
<ref id="R251">
<label>251</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emmerson</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Pickard</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Gonciarz</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Coskun</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hamang</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Sindelar</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Ballman</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Foltz</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Muppidi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alsina-Fernandez</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL</article-title>
<source/>Nat Med
          <year>2017</year>
<volume>23</volume>
<fpage>1215</fpage>
<lpage>1219</lpage>
<pub-id pub-id-type="pmid">28846098</pub-id>
</element-citation>
</ref>
<ref id="R252">
<label>252</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mullican</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Lin-Schmidt</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Chavez</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Furman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>South</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Dinh</surname>
<given-names>TQ</given-names>
</name>
<name>
<surname>Cash-Mason</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Cavanaugh</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates</article-title>
<source/>Nat Med
          <year>2017</year>
<volume>23</volume>
<fpage>1150</fpage>
<lpage>1157</lpage>
<pub-id pub-id-type="pmid">28846097</pub-id>
</element-citation>
</ref>
<ref id="R253">
<label>253</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Padkjær</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hultman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Paulsen</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bugge</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Frantzen</surname>
<given-names>JB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand</article-title>
<source/>Nat Med
          <year>2017</year>
<volume>23</volume>
<fpage>1158</fpage>
<lpage>1166</lpage>
<pub-id pub-id-type="pmid">28846099</pub-id>
</element-citation>
</ref>
<ref id="R254">
<label>254</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Husaini</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Manandhar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lee-Ng</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Harriott</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sainsbury</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Breit</surname>
<given-names>SN</given-names>
</name>
</person-group>
<article-title>Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15</article-title>
<source/>J Cachexia Sarcopenia Muscle
          <year>2012</year>
<volume>3</volume>
<fpage>239</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="pmid">22936174</pub-id>
</element-citation>
</ref>
<ref id="R255">
<label>255</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lerner</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Krieger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Gyuris</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients</article-title>
<source/>J Cachexia Sarcopenia Muscle
          <year>2015</year>
<volume>6</volume>
<fpage>317</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="pmid">26672741</pub-id>
</element-citation>
</ref>
<ref id="R256">
<label>256</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffith</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Hochberg</surname>
<given-names>FH</given-names>
</name>
</person-group>
<article-title>Anorexia and weight loss in glioma patients</article-title>
<source/>Psychosomatics
          <year>1988</year>
<volume>29</volume>
<fpage>335</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="pmid">2841711</pub-id>
</element-citation>
</ref>
<ref id="R257">
<label>257</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadowaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yoshioka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kamitani</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Eling</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines</article-title>
<source/>Int J Cancer
          <year>2012</year>
<volume>130</volume>
<fpage>267</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="pmid">21437897</pub-id>
</element-citation>
</ref>
<ref id="R258">
<label>258</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitson</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lucia</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Growth differentiation factor-15 (GDF-15) suppresses <italic>in vitro</italic> angiogenesis through a novel interaction with connective tissue growth factor (CCN2)</article-title>
<source/>J Cell Biochem
          <year>2013</year>
<volume>114</volume>
<fpage>1424</fpage>
<lpage>1433</lpage>
<pub-id pub-id-type="pmid">23280549</pub-id>
</element-citation>
</ref>
<ref id="R259">
<label>259</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Wild-type p53 attenuates cancer cell motility by inducing growth differentiation factor-15 expression</article-title>
<source/>Endocrinology
          <year>2011</year>
<volume>152</volume>
<fpage>2987</fpage>
<lpage>2995</lpage>
<pub-id pub-id-type="pmid">21586550</pub-id>
</element-citation>
</ref>
<ref id="R260">
<label>260</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshioka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kamitani</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Eling</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A</article-title>
<source/>J Biol Chem
          <year>2008</year>
<volume>283</volume>
<fpage>33129</fpage>
<lpage>33137</lpage>
<pub-id pub-id-type="pmid">18801729</pub-id>
</element-citation>
</ref>
<ref id="R261">
<label>261</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strelau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schmeer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Peterziel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sackmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Herold-Mende</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Weller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Unsicker</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines</article-title>
<source/>Cancer Lett
          <year>2008</year>
<volume>270</volume>
<fpage>30</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">18550273</pub-id>
</element-citation>
</ref>
<ref id="R262">
<label>262</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Codó</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Weller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaulich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schraivogel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Silginer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reifenberger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Meister</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Control of glioma cell migration and invasiveness by GDF-15</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>7732</fpage>
<lpage>7746</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.6816">https://doi.org/10.18632/oncotarget.6816</ext-link>
</comment>
<pub-id pub-id-type="pmid">26741507</pub-id>
</element-citation>
</ref>
<ref id="R263">
<label>263</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shnaper</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Desbaillets</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Murat</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Migliavacca</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schluep</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ostermann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamou</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Stupp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Breit</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>de Tribolet</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hegi</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome</article-title>
<source/>Int J Cancer
          <year>2009</year>
<volume>125</volume>
<fpage>2624</fpage>
<lpage>2630</lpage>
<pub-id pub-id-type="pmid">19521960</pub-id>
</element-citation>
</ref>
<ref id="R264">
<label>264</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urakawa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Utsunomiya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nishio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shigeoka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takase</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kakeji</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Koma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yokozaki</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways</article-title>
<source/>Lab Invest
          <year>2015</year>
<volume>95</volume>
<fpage>491</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="pmid">25730371</pub-id>
</element-citation>
</ref>
<ref id="R265">
<label>265</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Junker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tritschler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mittelbronn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dombrowski</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Breit</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Tabatabai</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wick</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Weller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wischhusen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>GDF-15 contributes to proliferation and immune escape of malignant gliomas</article-title>
<source/>Clin Cancer Res
          <year>2010</year>
<volume>16</volume>
<fpage>3851</fpage>
<lpage>3859</lpage>
<pub-id pub-id-type="pmid">20534737</pub-id>
</element-citation>
</ref>
<ref id="R266">
<label>266</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Min</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Liggett</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Eling</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>NAG-1/GDF15 accumulates in the nucleus and modulates transcriptional regulation of the Smad pathway</article-title>
<source/>Oncogene
          <year>2016</year>
<volume>35</volume>
<fpage>377</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="pmid">25893289</pub-id>
</element-citation>
</ref>
<ref id="R267">
<label>267</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>GT</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Macrophage inhibitory cytokine-1 stimulates proliferation of human umbilical vein endothelial cells by up-regulating cyclins D1 and E through the PI3K/Akt-, ERK-, and JNK-dependent AP-1 and E2F activation signaling pathways</article-title>
<source/>Cell Signal
          <year>2012</year>
<volume>24</volume>
<fpage>1485</fpage>
<lpage>1495</lpage>
<pub-id pub-id-type="pmid">22484283</pub-id>
</element-citation>
</ref>
<ref id="R268">
<label>268</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Growth differentiation factor 15 promotes blood vessel growth by stimulating cell cycle progression in repair of critical-sized calvarial defect</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<fpage>9027</fpage>
<pub-id pub-id-type="pmid">28831101</pub-id>
</element-citation>
</ref>
<ref id="R269">
<label>269</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albertoni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Nozaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Godard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tenan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hamou</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Fairlie</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Breit</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Paralkar</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>de Tribolet</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Van Meir</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Hegi</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1</article-title>
<source/>Oncogene
          <year>2002</year>
<volume>21</volume>
<fpage>4212</fpage>
<lpage>4219</lpage>
<pub-id pub-id-type="pmid">12082608</pub-id>
</element-citation>
</ref>
<ref id="R270">
<label>270</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nowacki</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kojder</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Peritumoral angiogenesis around primary and metastatic brain neoplasms. Morphometric analysis</article-title>
<source/>Folia Neuropathol
          <year>2001</year>
<volume>39</volume>
<fpage>95</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">11680641</pub-id>
</element-citation>
</ref>
<ref id="R271">
<label>271</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>GDF-15 promotes angiogenesis through modulating p53/HIF-1? signaling pathway in hypoxic human umbilical vein endothelial cells</article-title>
<source/>Mol Biol Rep
          <year>2012</year>
<volume>39</volume>
<fpage>4017</fpage>
<lpage>4022</lpage>
<pub-id pub-id-type="pmid">21773947</pub-id>
</element-citation>
</ref>
<ref id="R272">
<label>272</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>GDF15 promotes EMT and metastasis in colorectal cancer</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>860</fpage>
<lpage>872</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.6205">https://doi.org/10.18632/oncotarget.6205</ext-link>
</comment>
<pub-id pub-id-type="pmid">26497212</pub-id>
</element-citation>
</ref>
<ref id="R273">
<label>273</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Growth differentiation factor 15 promotes cell viability, invasion, migration, and angiogenesis in human liver carcinoma cell line HepG2</article-title>
<source/>Clin Res Hepatol Gastroenterol
          <year>2017</year>
<volume>41</volume>
<fpage>408</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="pmid">28161428</pub-id>
</element-citation>
</ref>
<ref id="R274">
<label>274</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tate</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Aghi</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Biology of angiogenesis and invasion in glioma</article-title>
<source/>Neurotherapeutics
          <year>2009</year>
<volume>6</volume>
<fpage>447</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="pmid">19560735</pub-id>
</element-citation>
</ref>
<ref id="R275">
<label>275</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subramanian</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mitroulis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hajishengallis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chavakis</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Regulation of tissue infiltration by neutrophils: role of integrin α3β1 and other factors</article-title>
<source/>Curr Opin Hematol
          <year>2016</year>
<volume>23</volume>
<fpage>36</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">26554893</pub-id>
</element-citation>
</ref>
<ref id="R276">
<label>276</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griner</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Nahta</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion</article-title>
<source/>Biochem Pharmacol
          <year>2013</year>
<volume>85</volume>
<fpage>46</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">23085437</pub-id>
</element-citation>
</ref>
<ref id="R277">
<label>277</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e78618</fpage>
<pub-id pub-id-type="pmid">24236027</pub-id>
</element-citation>
</ref>
<ref id="R278">
<label>278</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segerer</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Rieger</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kapp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dombrowski</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dietl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kämmerer</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>MIC-1 (a multifunctional modulator of dendritic cell phenotype and function) is produced by decidual stromal cells and trophoblasts</article-title>
<source/>Hum Reprod
          <year>2012</year>
<volume>27</volume>
<fpage>200</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="pmid">22064648</pub-id>
</element-citation>
</ref>
<ref id="R279">
<label>279</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Stunff</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Generation and metabolism of bioactive sphingosine-1-phosphate</article-title>
<source/>J Cell Biochem
          <year>2004</year>
<volume>92</volume>
<fpage>882</fpage>
<lpage>899</lpage>
<pub-id pub-id-type="pmid">15258913</pub-id>
</element-citation>
</ref>
<ref id="R280">
<label>280</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maceyka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sankala</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hait</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Le Stunff</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Toman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Satin</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Merrill</surname>
<given-names>AH</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism</article-title>
<source/>J Biol Chem
          <year>2005</year>
<volume>280</volume>
<fpage>37118</fpage>
<lpage>37129</lpage>
<pub-id pub-id-type="pmid">16118219</pub-id>
</element-citation>
</ref>
<ref id="R281">
<label>281</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parham</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Zebol</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Tooley</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Moldenhauer</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Cockshell</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Gliddon</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Moretti</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Tigyi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pitson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Bonder</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate is a ligand for peroxisome proliferator-activated receptor-γ that regulates neoangiogenesis</article-title>
<source/>FASEB J
          <year>2015</year>
<volume>29</volume>
<fpage>3638</fpage>
<lpage>3653</lpage>
<pub-id pub-id-type="pmid">25985799</pub-id>
</element-citation>
</ref>
<ref id="R282">
<label>282</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Van Brocklyn</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Signal transduction of sphingosine-1-phosphate G protein-coupled receptors</article-title>
<source/>ScientificWorldJournal
          <year>2006</year>
<volume>6</volume>
<fpage>946</fpage>
<lpage>966</lpage>
<pub-id pub-id-type="pmid">16906327</pub-id>
</element-citation>
</ref>
<ref id="R283">
<label>283</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gude</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Paugh</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Barbour</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal</article-title>
<source/>FASEB J
          <year>2008</year>
<volume>22</volume>
<fpage>2629</fpage>
<lpage>2638</lpage>
<pub-id pub-id-type="pmid">18362204</pub-id>
</element-citation>
</ref>
<ref id="R284">
<label>284</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Regulation of macrophage function by sphingosine-1-phosphate</article-title>
<source/>Immunobiology
          <year>2009</year>
<volume>214</volume>
<fpage>748</fpage>
<lpage>760</lpage>
<pub-id pub-id-type="pmid">19625101</pub-id>
</element-citation>
</ref>
<ref id="R285">
<label>285</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weichand</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Henke</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mille-Baker</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages</article-title>
<source/>Oncogene
          <year>2013</year>
<volume>32</volume>
<fpage>631</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="pmid">22410777</pub-id>
</element-citation>
</ref>
<ref id="R286">
<label>286</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arlt</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Schwiebs</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Japtok</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rüger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Katzy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kleuser</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Radeke</surname>
<given-names>HH</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate modulates dendritic cell function: focus on non-migratory effects <italic>in vitro</italic> and <italic>in vivo</italic></article-title>
<source/>Cell Physiol Biochem
          <year>2014</year>
<volume>34</volume>
<fpage>27</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">24977479</pub-id>
</element-citation>
</ref>
<ref id="R287">
<label>287</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thuy</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Reimann</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hemdan</surname>
<given-names>NY</given-names>
</name>
<name>
<surname>Gräler</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate in blood: function, metabolism, and fate</article-title>
<source/>Cell Physiol Biochem
          <year>2014</year>
<volume>34</volume>
<fpage>158</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="pmid">24977489</pub-id>
</element-citation>
</ref>
<ref id="R288">
<label>288</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quint</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stiel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Neureiter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schlicker</surname>
<given-names>HU</given-names>
</name>
<name>
<surname>Nimsky</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ocker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Strik</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kolodziej</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas</article-title>
<source/>Tumour Biol
          <year>2014</year>
<volume>35</volume>
<fpage>8979</fpage>
<lpage>8989</lpage>
<pub-id pub-id-type="pmid">24903384</pub-id>
</element-citation>
</ref>
<ref id="R289">
<label>289</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bien-Möller</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lange</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Böhm</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paland</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Küpper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weitmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Havemann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vogelgesang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marx</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>BH</given-names>
</name>
</person-group>
<article-title>Expression of S1P metabolizing enzymes and receptors correlate with survival time and regulate cell migration in glioblastoma multiforme</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>13031</fpage>
<lpage>13046</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.7366">https://doi.org/10.18632/oncotarget.7366</ext-link>
</comment>
<pub-id pub-id-type="pmid">26887055</pub-id>
</element-citation>
</ref>
<ref id="R290">
<label>290</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Furuta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Uchiyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hamada</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients</article-title>
<source/>J Neurooncol
          <year>2010</year>
<volume>98</volume>
<fpage>41</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">19937366</pub-id>
</element-citation>
</ref>
<ref id="R291">
<label>291</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kita</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Uchiyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yachie</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takuwa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hamada</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival</article-title>
<source/>Int J Cancer
          <year>2010</year>
<volume>126</volume>
<fpage>2341</fpage>
<lpage>2352</lpage>
<pub-id pub-id-type="pmid">19810093</pub-id>
</element-citation>
</ref>
<ref id="R292">
<label>292</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Brocklyn</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Pearl</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Kotur</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>TW</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2005</year>
<volume>64</volume>
<fpage>695</fpage>
<lpage>705</lpage>
<pub-id pub-id-type="pmid">16106218</pub-id>
</element-citation>
</ref>
<ref id="R293">
<label>293</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pearl</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Van Brocklyn</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61</article-title>
<source/>Mol Cancer Res
          <year>2009</year>
<volume>7</volume>
<fpage>23</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">19147534</pub-id>
</element-citation>
</ref>
<ref id="R294">
<label>294</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estrada-Bernal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lawler</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Nowicki</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Ray Chaudhury</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Brocklyn</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells</article-title>
<source/>J Neurooncol
          <year>2011</year>
<volume>102</volume>
<fpage>353</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="pmid">20938717</pub-id>
</element-citation>
</ref>
<ref id="R295">
<label>295</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lepannetier</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zanou</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yerna</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Emeriau</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dufour</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Masquelier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Muccioli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tajeddine</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gailly</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate-activated TRPC1 channel controls chemotaxis of glioblastoma cells</article-title>
<source/>Cell Calcium
          <year>2016</year>
<volume>60</volume>
<fpage>373</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="pmid">27638096</pub-id>
</element-citation>
</ref>
<ref id="R296">
<label>296</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fortier</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Labelle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moreau</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Annabi</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Silencing of the MT1-MMP/G6PT axis suppresses calcium mobilization by sphingosine-1-phosphate in glioblastoma cells</article-title>
<source/>FEBS Lett
          <year>2008</year>
<volume>582</volume>
<fpage>799</fpage>
<lpage>804</lpage>
<pub-id pub-id-type="pmid">18267120</pub-id>
</element-citation>
</ref>
<ref id="R297">
<label>297</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Kaye</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Luwor</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>The EGFRvIII variant in glioblastoma multiforme</article-title>
<source/>J Clin Neurosci
          <year>2009</year>
<volume>16</volume>
<fpage>748</fpage>
<lpage>754</lpage>
<pub-id pub-id-type="pmid">19324552</pub-id>
</element-citation>
</ref>
<ref id="R298">
<label>298</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paugh</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Paugh</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Wilczynska</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Kapitonov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rokita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Griswold-Prenner</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kordula</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells</article-title>
<source/>J Biol Chem
          <year>2009</year>
<volume>284</volume>
<fpage>3408</fpage>
<lpage>3417</lpage>
<pub-id pub-id-type="pmid">19074142</pub-id>
</element-citation>
</ref>
<ref id="R299">
<label>299</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gault</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Obeid</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2</article-title>
<source/>J Biol Chem
          <year>2008</year>
<volume>283</volume>
<fpage>3365</fpage>
<lpage>3375</lpage>
<pub-id pub-id-type="pmid">18055454</pub-id>
</element-citation>
</ref>
<ref id="R300">
<label>300</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase</article-title>
<source/>Cell Prolif
          <year>2012</year>
<volume>45</volume>
<fpage>167</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="pmid">22288844</pub-id>
</element-citation>
</ref>
<ref id="R301">
<label>301</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapitonov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Allegood</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hait</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Almenara</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Zipkin</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Dent</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kordula</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts</article-title>
<source/>Cancer Res
          <year>2009</year>
<volume>69</volume>
<fpage>6915</fpage>
<lpage>6923</lpage>
<pub-id pub-id-type="pmid">19723667</pub-id>
</element-citation>
</ref>
<ref id="R302">
<label>302</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<fpage>e19946</fpage>
<pub-id pub-id-type="pmid">21625639</pub-id>
</element-citation>
</ref>
<ref id="R303">
<label>303</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Van Brocklyn</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness</article-title>
<source/>Exp Cell Res
          <year>2007</year>
<volume>313</volume>
<fpage>1615</fpage>
<lpage>1627</lpage>
<pub-id pub-id-type="pmid">17376432</pub-id>
</element-citation>
</ref>
<ref id="R304">
<label>304</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernhart</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Damm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wintersperger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nusshold</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Plastira</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rechberger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Reicher</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wadsack</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Malle</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sattler</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Interference with distinct steps of sphingolipid synthesis and signaling attenuates proliferation of U87MG glioma cells</article-title>
<source/>Biochem Pharmacol
          <year>2015</year>
<volume>96</volume>
<fpage>119</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">26002572</pub-id>
</element-citation>
</ref>
<ref id="R305">
<label>305</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riccitelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giussani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Di Vito</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Condomitti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tringali</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Caroli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Galli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Viani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Riboni</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e68229</fpage>
<pub-id pub-id-type="pmid">23826381</pub-id>
</element-citation>
</ref>
<ref id="R306">
<label>306</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Annabi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lachambre</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Plouffe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sartelet</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Béliveau</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling</article-title>
<source/>Mol Carcinog
          <year>2009</year>
<volume>48</volume>
<fpage>910</fpage>
<lpage>919</lpage>
<pub-id pub-id-type="pmid">19326372</pub-id>
</element-citation>
</ref>
<ref id="R307">
<label>307</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marfia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Campanella</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Navone</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Di Vito</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Riccitelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hadi</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Bornati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Rezende</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Giussani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tringali</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Viani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rampini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Alessandri</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells</article-title>
<source/>Glia
          <year>2014</year>
<volume>62</volume>
<fpage>1968</fpage>
<lpage>1981</lpage>
<pub-id pub-id-type="pmid">25042636</pub-id>
</element-citation>
</ref>
<ref id="R308">
<label>308</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bektas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Poe</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Bigner</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>HS</given-names>
</name>
</person-group>
<article-title>A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells</article-title>
<source/>Cancer Chemother Pharmacol
          <year>2009</year>
<volume>64</volume>
<fpage>1053</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="pmid">19597728</pub-id>
</element-citation>
</ref>
<ref id="R309">
<label>309</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shoda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kurihara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sekino</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kanda</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>4806</fpage>
<pub-id pub-id-type="pmid">25254944</pub-id>
</element-citation>
</ref>
<ref id="R310">
<label>310</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tasić-Dimov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Conić</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Stefanovic</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Glioblastoma multiforme stem cells</article-title>
<source/>ScientificWorldJournal
          <year>2011</year>
<volume>11</volume>
<fpage>930</fpage>
<lpage>958</lpage>
<pub-id pub-id-type="pmid">21516289</pub-id>
</element-citation>
</ref>
<ref id="R311">
<label>311</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gault</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Snider</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Obeid</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis <italic>in vitro</italic></article-title>
<source/>FASEB J
          <year>2010</year>
<volume>24</volume>
<fpage>2727</fpage>
<lpage>2738</lpage>
<pub-id pub-id-type="pmid">20335228</pub-id>
</element-citation>
</ref>
<ref id="R312">
<label>312</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abuhusain</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Matin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kain</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Stringer</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Laaksonen</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Teo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Don</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis</article-title>
<source/>J Biol Chem
          <year>2013</year>
<volume>288</volume>
<fpage>37355</fpage>
<lpage>37364</lpage>
<pub-id pub-id-type="pmid">24265321</pub-id>
</element-citation>
</ref>
<ref id="R313">
<label>313</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lijnen</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>Pleiotropic functions of plasminogen activator inhibitor-1</article-title>
<source/>J Thromb Haemost
          <year>2005</year>
<volume>3</volume>
<fpage>35</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">15634264</pub-id>
</element-citation>
</ref>
<ref id="R314">
<label>314</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Igarashi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Erwin</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Dantas</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>VEGF induces S1P1 receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2003</year>
<volume>100</volume>
<fpage>10664</fpage>
<lpage>10669</lpage>
<pub-id pub-id-type="pmid">12963813</pub-id>
</element-citation>
</ref>
<ref id="R315">
<label>315</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paugh</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Paugh</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kapitonov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wilczynska</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Gopalan</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Rokita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kordula</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells</article-title>
<source/>FASEB J
          <year>2008</year>
<volume>22</volume>
<fpage>455</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="pmid">17855624</pub-id>
</element-citation>
</ref>
<ref id="R316">
<label>316</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bryan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Paugh</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Kapitonov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wilczynska</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kordula</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness</article-title>
<source/>Mol Cancer Res
          <year>2008</year>
<volume>6</volume>
<fpage>1469</fpage>
<lpage>1477</lpage>
<pub-id pub-id-type="pmid">18819934</pub-id>
</element-citation>
</ref>
<ref id="R317">
<label>317</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernhart</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Damm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wintersperger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>DeVaney</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Raynham</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ireson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sattler</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells <italic>in vitro</italic></article-title>
<source/>Exp Cell Res
          <year>2013</year>
<volume>319</volume>
<fpage>2037</fpage>
<lpage>2048</lpage>
<pub-id pub-id-type="pmid">23562655</pub-id>
</element-citation>
</ref>
<ref id="R318">
<label>318</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malchinkhuu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Maehama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mogi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tomura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ishiuchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yoshimoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kurose</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Okajima</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>S1P(2) receptors mediate inhibition of glioma cell migration through Rho signaling pathways independent of PTEN</article-title>
<source/>Biochem Biophys Res Commun
          <year>2008</year>
<volume>366</volume>
<fpage>963</fpage>
<lpage>968</lpage>
<pub-id pub-id-type="pmid">18088600</pub-id>
</element-citation>
</ref>
<ref id="R319">
<label>319</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prosniak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harshyne</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Kenyon</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Bedelbaeva</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Apanasovich</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Heber-Katz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Cotzia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers</article-title>
<source/>Clin Cancer Res
          <year>2013</year>
<volume>19</volume>
<fpage>3776</fpage>
<lpage>3786</lpage>
<pub-id pub-id-type="pmid">23741072</pub-id>
</element-citation>
</ref>
<ref id="R320">
<label>320</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badie</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schartner</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Flow cytometric characterization of tumor-associated macrophages in experimental gliomas</article-title>
<source/>Neurosurgery
          <year>2000</year>
<volume>46</volume>
<fpage>957</fpage>
<lpage>961</lpage>
<pub-id pub-id-type="pmid">10764271</pub-id>
</element-citation>
</ref>
<ref id="R321">
<label>321</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parney</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Waldron</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Parsa</surname>
<given-names>AT</given-names>
</name>
</person-group>
<article-title>Flow cytometry and <italic>in vitro</italic> analysis of human glioma-associated macrophages. Laboratory investigation</article-title>
<source/>J Neurosurg
          <year>2009</year>
<volume>110</volume>
<fpage>572</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="pmid">19199469</pub-id>
</element-citation>
</ref>
<ref id="R322">
<label>322</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mrad</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Imbert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rambow</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Therville</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Carpentier</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ségui</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Levade</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Azar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Marine</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Diab-Assaf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Colacios</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Andrieu-Abadie</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>71873</fpage>
<lpage>71886</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.12380">https://doi.org/10.18632/oncotarget.12380</ext-link>
</comment>
<pub-id pub-id-type="pmid">27708249</pub-id>
</element-citation>
</ref>
<ref id="R323">
<label>323</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schiffmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sekar</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Menrad</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Werno</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Grosch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Geisslinger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype</article-title>
<source/>Int J Cancer
          <year>2009</year>
<volume>125</volume>
<fpage>2114</fpage>
<lpage>2121</lpage>
<pub-id pub-id-type="pmid">19618460</pub-id>
</element-citation>
</ref>
<ref id="R324">
<label>324</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Role of hypoxia in the hallmarks of human cancer</article-title>
<source/>J Cell Biochem
          <year>2009</year>
<volume>107</volume>
<fpage>1053</fpage>
<lpage>1062</lpage>
<pub-id pub-id-type="pmid">19479945</pub-id>
</element-citation>
</ref>
<ref id="R325">
<label>325</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johann</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>von Knethen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geisslinger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate</article-title>
<source/>Blood
          <year>2006</year>
<volume>108</volume>
<fpage>1635</fpage>
<lpage>1642</lpage>
<pub-id pub-id-type="pmid">16690965</pub-id>
</element-citation>
</ref>
<ref id="R326">
<label>326</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tzieply</surname>
<given-names>N</given-names>
</name>
<name>
<surname>von Knethen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johann</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Geisslinger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate</article-title>
<source/>Mol Biol Cell
          <year>2007</year>
<volume>18</volume>
<fpage>3810</fpage>
<lpage>3819</lpage>
<pub-id pub-id-type="pmid">17652460</pub-id>
</element-citation>
</ref>
<ref id="R327">
<label>327</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johann</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eberhardt</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Barra</surname>
<given-names>V</given-names>
</name>
<name>
<surname>von Knethen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pfeilschifter</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Apoptotic cell-derived sphingosine-1-phosphate promotes HuR-dependent cyclooxygenase-2 mRNA stabilization and protein expression</article-title>
<source/>J Immunol
          <year>2008</year>
<volume>180</volume>
<fpage>1239</fpage>
<lpage>1248</lpage>
<pub-id pub-id-type="pmid">18178864</pub-id>
</element-citation>
</ref>
<ref id="R328">
<label>328</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herr</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Werno</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Menrad</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Namgaladze</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dehne</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The supernatant of apoptotic cells causes transcriptional activation of hypoxia-inducible factor-1alpha in macrophages via sphingosine-1-phosphate and transforming growth factor-beta</article-title>
<source/>Blood
          <year>2009</year>
<volume>114</volume>
<fpage>2140</fpage>
<lpage>2148</lpage>
<pub-id pub-id-type="pmid">19549990</pub-id>
</element-citation>
</ref>
<ref id="R329">
<label>329</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>von Knethen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Heme oxygenase-1 contributes to an alternative macrophage activation profile induced by apoptotic cell supernatants</article-title>
<source/>Mol Biol Cell
          <year>2009</year>
<volume>20</volume>
<fpage>1280</fpage>
<lpage>1288</lpage>
<pub-id pub-id-type="pmid">19129475</pub-id>
</element-citation>
</ref>
<ref id="R330">
<label>330</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Mariko</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Dannenberg</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Haka</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Maxfield</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Camerer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Proia</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hla</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Sphingosine kinases are not required for inflammatory responses in macrophages</article-title>
<source/>J Biol Chem
          <year>2013</year>
<volume>288</volume>
<fpage>32563</fpage>
<lpage>32573</lpage>
<pub-id pub-id-type="pmid">24081141</pub-id>
</element-citation>
</ref>
<ref id="R331">
<label>331</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Haxhinasto</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Stefanopoulos</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Fogal</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Adusumalli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Desai</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Patnaude</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Slavin</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Modis</surname>
<given-names>LK</given-names>
</name>
</person-group>
<article-title>Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3</article-title>
<source/>J Immunol
          <year>2013</year>
<volume>190</volume>
<fpage>3533</fpage>
<lpage>3540</lpage>
<pub-id pub-id-type="pmid">23436932</pub-id>
</element-citation>
</ref>
<ref id="R332">
<label>332</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lucke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>von Wnuck Lipinski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gräler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heusch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Levkau</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis</article-title>
<source/>Circ Res
          <year>2011</year>
<volume>108</volume>
<fpage>314</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="pmid">21164103</pub-id>
</element-citation>
</ref>
<ref id="R333">
<label>333</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Awojoodu</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Ogle</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Sefcik</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brayman</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Peirce-Cottler</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Botchwey</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2013</year>
<volume>110</volume>
<fpage>13785</fpage>
<lpage>13790</lpage>
<pub-id pub-id-type="pmid">23918395</pub-id>
</element-citation>
</ref>
<ref id="R334">
<label>334</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate receptor 2 and 3 mediate bone marrow-derived monocyte/macrophage motility in cholestatic liver injury in mice</article-title>
<source/>Sci Rep
          <year>2015</year>
<volume>5</volume>
<fpage>13423</fpage>
<pub-id pub-id-type="pmid">26324256</pub-id>
</element-citation>
</ref>
<ref id="R335">
<label>335</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Debien</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mayol</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Biajoux</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Daussy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>De Aguero</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Taillardet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dagany</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brinza</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kaiserlian</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marvel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Balabanian</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>S1PR5 is pivotal for the homeostasis of patrolling monocytes</article-title>
<source/>Eur J Immunol
          <year>2013</year>
<volume>43</volume>
<fpage>1667</fpage>
<lpage>1675</lpage>
<pub-id pub-id-type="pmid">23519784</pub-id>
</element-citation>
</ref>
<ref id="R336">
<label>336</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahajan-Thakur</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sostmann</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Fender</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Behrendt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Felix</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Schrör</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>BH</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes</article-title>
<source/>J Leukoc Biol
          <year>2014</year>
<volume>96</volume>
<fpage>611</fpage>
<lpage>618</lpage>
<pub-id pub-id-type="pmid">24990321</pub-id>
</element-citation>
</ref>
<ref id="R337">
<label>337</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itsekson-Hayosh</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shavit-Stein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Last</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Goez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bushi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gera</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Zibly</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Mardor</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Harnof</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Thrombin activity and thrombin receptor in rat glioblastoma model: possible markers and targets for intervention?</article-title>
<source/>J Mol Neurosci
          <year>2015</year>
<volume>56</volume>
<fpage>644</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="pmid">25691153</pub-id>
</element-citation>
</ref>
<ref id="R338">
<label>338</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weichand</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grossmann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Levkau</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Apoptotic cells enhance sphingosine-1-phosphate receptor 1 dependent macrophage migration</article-title>
<source/>Eur J Immunol
          <year>2013</year>
<volume>43</volume>
<fpage>3306</fpage>
<lpage>3313</lpage>
<pub-id pub-id-type="pmid">23934754</pub-id>
</element-citation>
</ref>
<ref id="R339">
<label>339</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rashid</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stoller</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Campochiaro</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization</article-title>
<source/>J Cell Physiol
          <year>2009</year>
<volume>218</volume>
<fpage>192</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">18781584</pub-id>
</element-citation>
</ref>
<ref id="R340">
<label>340</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murakami</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tabata</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Controlled release of sphingosine-1-phosphate agonist with gelatin hydrogels for macrophage recruitment</article-title>
<source/>Acta Biomater
          <year>2014</year>
<volume>10</volume>
<fpage>4723</fpage>
<lpage>4729</lpage>
<pub-id pub-id-type="pmid">25038462</pub-id>
</element-citation>
</ref>
<ref id="R341">
<label>341</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuehnel</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Reiss</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Treede</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Holzer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Klapperstueck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Markwardt</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate receptors stimulate macrophage plasma-membrane actin assembly via ADP release, ATP synthesis and P2×7R activation</article-title>
<source/>J Cell Sci
          <year>2009</year>
<volume>122</volume>
<fpage>505</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="pmid">19174470</pub-id>
</element-citation>
</ref>
<ref id="R342">
<label>342</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michaud</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Im</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Hla</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation</article-title>
<source/>J Immunol
          <year>2010</year>
<volume>184</volume>
<fpage>1475</fpage>
<lpage>1483</lpage>
<pub-id pub-id-type="pmid">20042570</pub-id>
</element-citation>
</ref>
<ref id="R343">
<label>343</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3</article-title>
<source/>Biochem Biophys Res Commun
          <year>2007</year>
<volume>355</volume>
<fpage>895</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="pmid">17331465</pub-id>
</element-citation>
</ref>
<ref id="R344">
<label>344</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Völker</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Holtwick</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Al Chahaf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate (S1P) induces expression of E-selectin and adhesion of monocytes via intracellular signalling pathways in vascular endothelial cells</article-title>
<source/>Eur J Cell Biol
          <year>2010</year>
<volume>89</volume>
<fpage>733</fpage>
<lpage>741</lpage>
<pub-id pub-id-type="pmid">20656374</pub-id>
</element-citation>
</ref>
<ref id="R345">
<label>345</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alvarez</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Harikumar</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Hait</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Allegood</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Strub</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Maceyka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kordula</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2</article-title>
<source/>Nature
          <year>2010</year>
<volume>465</volume>
<fpage>1084</fpage>
<lpage>1088</lpage>
<pub-id pub-id-type="pmid">20577214</pub-id>
</element-citation>
</ref>
<ref id="R346">
<label>346</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rho</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction</article-title>
<source/>J Biol Chem
          <year>2015</year>
<volume>290</volume>
<fpage>9660</fpage>
<lpage>9673</lpage>
<pub-id pub-id-type="pmid">25716317</pub-id>
</element-citation>
</ref>
<ref id="R347">
<label>347</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Sphk1 mediates neuroinflammation and neuronal injury via TRAF2/NF-κB pathways in activated microglia in cerebral ischemia reperfusion</article-title>
<source/>J Neuroimmunol
          <year>2017</year>
<volume>305</volume>
<fpage>35</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">28284343</pub-id>
</element-citation>
</ref>
<ref id="R348">
<label>348</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>IT</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate mediates ICAM-1-dependent monocyte adhesion through p38 MAPK and p42/p44 MAPK-dependent Akt activation</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<fpage>e0118473</fpage>
<pub-id pub-id-type="pmid">25734900</pub-id>
</element-citation>
</ref>
<ref id="R349">
<label>349</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolick</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Srinivasan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Hatley</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Clemens</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Whetzel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Tsao</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Hedrick</surname>
<given-names>CC</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2005</year>
<volume>25</volume>
<fpage>976</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="pmid">15761190</pub-id>
</element-citation>
</ref>
<ref id="R350">
<label>350</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yatomi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shimosawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kitayama</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tsuno</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The suppressive effect of sphingosine 1-phosphate on monocyte-endothelium adhesion may be mediated by the rearrangement of the endothelial integrins alpha(5)beta(1) and alpha(v)beta(3)</article-title>
<source/>J Thromb Haemost
          <year>2007</year>
<volume>5</volume>
<fpage>1292</fpage>
<lpage>1301</lpage>
<pub-id pub-id-type="pmid">17403093</pub-id>
</element-citation>
</ref>
<ref id="R351">
<label>351</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment</article-title>
<source/>Cell Mol Immunol
          <year>2015</year>
<volume>12</volume>
<fpage>681</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="pmid">25088224</pub-id>
</element-citation>
</ref>
<ref id="R352">
<label>352</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feuerborn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Potì</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nagel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brodde</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Christoffersen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ceglarek</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Burkhardt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nofer</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression</article-title>
<source/>Atherosclerosis
          <year>2017</year>
<volume>257</volume>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="pmid">28038379</pub-id>
</element-citation>
</ref>
<ref id="R353">
<label>353</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate receptor 2 signaling suppresses macrophage phagocytosis and impairs host defense against sepsis</article-title>
<source/>Anesthesiology
          <year>2015</year>
<volume>123</volume>
<fpage>409</fpage>
<lpage>422</lpage>
<pub-id pub-id-type="pmid">26200183</pub-id>
</element-citation>
</ref>
<ref id="R354">
<label>354</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McQuiston</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Luberto</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Del Poeta</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophages</article-title>
<source/>Microbiology
          <year>2011</year>
<volume>157</volume>
<fpage>1416</fpage>
<lpage>1427</lpage>
<pub-id pub-id-type="pmid">21292747</pub-id>
</element-citation>
</ref>
<ref id="R355">
<label>355</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Srinivasan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Proia</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Ferdek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hedrick</surname>
<given-names>CC</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages</article-title>
<source/>Circ Res
          <year>2008</year>
<volume>102</volume>
<fpage>950</fpage>
<lpage>958</lpage>
<pub-id pub-id-type="pmid">18323526</pub-id>
</element-citation>
</ref>
<ref id="R356">
<label>356</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hammad</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Crellin</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>BX</given-names>
</name>
<name>
<surname>Melton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Anelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Obeid</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages</article-title>
<source/>Prostaglandins Other Lipid Mediat
          <year>2008</year>
<volume>85</volume>
<fpage>107</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">18166496</pub-id>
</element-citation>
</ref>
<ref id="R357">
<label>357</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>YI</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Aladhami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oskeritzian</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Sphingosine-1 phosphate: a new modulator of immune plasticity in the tumor microenvironment</article-title>
<source/>Front Oncol
          <year>2016</year>
<volume>6</volume>
<fpage>218</fpage>
<pub-id pub-id-type="pmid">27800303</pub-id>
</element-citation>
</ref>
<ref id="R358">
<label>358</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brecht</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Popp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fisslthaler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Korff</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Geisslinger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2</article-title>
<source/>FASEB J
          <year>2011</year>
<volume>25</volume>
<fpage>2408</fpage>
<lpage>2417</lpage>
<pub-id pub-id-type="pmid">21450910</pub-id>
</element-citation>
</ref>
<ref id="R359">
<label>359</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenhough</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Smartt</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Paraskeva</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kaidi</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment</article-title>
<source/>Carcinogenesis
          <year>2009</year>
<volume>30</volume>
<fpage>377</fpage>
<lpage>386</lpage>
<pub-id pub-id-type="pmid">19136477</pub-id>
</element-citation>
</ref>
<ref id="R360">
<label>360</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Cyclooxygenase-2 in glioblastoma multiforme</article-title>
<source/>Drug Discov Today
          <year>2017</year>
<volume>22</volume>
<fpage>148</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="pmid">27693715</pub-id>
</element-citation>
</ref>
<ref id="R361">
<label>361</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ören</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mora</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dziumbla</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Popp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grossmann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Lipocalin 2 from macrophages stimulated by tumor cell-derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis</article-title>
<source/>Sci Signal
          <year>2016</year>
<volume>9</volume>
<fpage>ra64</fpage>
<pub-id pub-id-type="pmid">27353364</pub-id>
</element-citation>
</ref>
<ref id="R362">
<label>362</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barra</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>von Knethen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weigert</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brüne</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Apoptotic cell-derived factors induce arginase II expression in murine macrophages by activating ERK5/CREB</article-title>
<source/>Cell Mol Life Sci
          <year>2011</year>
<volume>68</volume>
<fpage>1815</fpage>
<lpage>1827</lpage>
<pub-id pub-id-type="pmid">20949368</pub-id>
</element-citation>
</ref>
<ref id="R363">
<label>363</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grimm</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tischner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Troidl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Albarrán Juárez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sivaraj</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Ferreirós Bouzas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Geisslinger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Binder</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Wettschureck</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>S1P2/G12/13 signaling negatively regulates macrophage activation and indirectly shapes the atheroprotective B1-cell population</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2016</year>
<volume>36</volume>
<fpage>37</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">26603156</pub-id>
</element-citation>
</ref>
<ref id="R364">
<label>364</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>von Bernstorff</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Heidecke</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Schulze</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Differential S1P receptor profiles on M1- and M2-polarized macrophages affect macrophage cytokine production and migration</article-title>
<source/>Biomed Res Int
          <year>2017</year>
<volume>2017</volume>
<fpage>7584621</fpage>
<pub-id pub-id-type="pmid">28367448</pub-id>
</element-citation>
</ref>
<ref id="R365">
<label>365</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Billich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bornancin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dévay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mechtcheriakova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Urtz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Baumruker</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<fpage>47408</fpage>
<lpage>47415</lpage>
<pub-id pub-id-type="pmid">13129923</pub-id>
</element-citation>
</ref>
<ref id="R366">
<label>366</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paugh</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Barbour</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Milstien</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2</article-title>
<source/>FEBS Lett
          <year>2003</year>
<volume>554</volume>
<fpage>189</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="pmid">14596938</pub-id>
</element-citation>
</ref>
<ref id="R367">
<label>367</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Estrada-Hernandez</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Paik</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Venkataraman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brinkmann</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Claffey</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hla</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability</article-title>
<source/>J Biol Chem
          <year>2003</year>
<volume>278</volume>
<fpage>47281</fpage>
<lpage>47290</lpage>
<pub-id pub-id-type="pmid">12954648</pub-id>
</element-citation>
</ref>
<ref id="R368">
<label>368</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allende</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Olivera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>van Echten-Deckert</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hajdu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rosenbach</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Keohane</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Mandala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Proia</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720</article-title>
<source/>J Biol Chem
          <year>2004</year>
<volume>279</volume>
<fpage>52487</fpage>
<lpage>52492</lpage>
<pub-id pub-id-type="pmid">15459201</pub-id>
</element-citation>
</ref>
<ref id="R369">
<label>369</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kharel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Sheasley-O’neill</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Setiady</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zigler</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Burcin</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Ley</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tung</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Engelhard</surname>
<given-names>VH</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>TL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720</article-title>
<source/>J Biol Chem
          <year>2005</year>
<volume>280</volume>
<fpage>36865</fpage>
<lpage>36872</lpage>
<pub-id pub-id-type="pmid">16093248</pub-id>
</element-citation>
</ref>
<ref id="R370">
<label>370</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zemann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kinzel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reuschel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mechtcheriakova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Urtz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bornancin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baumruker</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Billich</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720</article-title>
<source/>Blood
          <year>2006</year>
<volume>107</volume>
<fpage>1454</fpage>
<lpage>1458</lpage>
<pub-id pub-id-type="pmid">16223773</pub-id>
</element-citation>
</ref>
<ref id="R371">
<label>371</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Högenauer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Billich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pally</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Streiff</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Welzenbach</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nussbaumer</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Phosphorylation by sphingosine kinase 2 is essential for <italic>in vivo</italic> potency of FTY720 analogues</article-title>
<source/>ChemMedChem
          <year>2008</year>
<volume>3</volume>
<fpage>1027</fpage>
<lpage>1029</lpage>
<pub-id pub-id-type="pmid">18383466</pub-id>
</element-citation>
</ref>
<ref id="R372">
<label>372</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mechtcheriakova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wlachos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sobanov</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bornancin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zlabinger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Baumruker</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Billich</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3</article-title>
<source/>FEBS Lett
          <year>2007</year>
<volume>581</volume>
<fpage>3063</fpage>
<lpage>3068</lpage>
<pub-id pub-id-type="pmid">17555747</pub-id>
</element-citation>
</ref>
<ref id="R373">
<label>373</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brinkmann</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Heise</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cottens</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hof</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bruns</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Prieschl</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Baumruker</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hiestand</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Zollinger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>KR</given-names>
</name>
</person-group>
<article-title>The immune modulator FTY720 targets sphingosine 1-phosphate receptors</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>21453</fpage>
<lpage>21457</lpage>
<pub-id pub-id-type="pmid">11967257</pub-id>
</element-citation>
</ref>
<ref id="R374">
<label>374</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Menyhart</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Killer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Renault</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Studer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bolli</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Nayler</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gatfield</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling</article-title>
<source/>J Biol Chem
          <year>2013</year>
<volume>288</volume>
<fpage>14839</fpage>
<lpage>14851</lpage>
<pub-id pub-id-type="pmid">23589284</pub-id>
</element-citation>
</ref>
<ref id="R375">
<label>375</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Monnier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Menyhart</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bolinger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Studer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nayler</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Gatfield</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>FTY720 phosphate activates sphingosine-1-phosphate receptor 2 and selectively couples to Gα12/13/Rho/ROCK to induce myofibroblast contraction</article-title>
<source/>Mol Pharmacol
          <year>2015</year>
<volume>87</volume>
<fpage>916</fpage>
<lpage>927</lpage>
<pub-id pub-id-type="pmid">25762025</pub-id>
</element-citation>
</ref>
<ref id="R376">
<label>376</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hajdu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bergstrom</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Quackenbush</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Milligan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shei</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Card</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Keohane</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rosenbach</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hale</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</article-title>
<source/>Science
          <year>2002</year>
<volume>296</volume>
<fpage>346</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="pmid">11923495</pub-id>
</element-citation>
</ref>
<ref id="R377">
<label>377</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gräler</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Goetzl</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors</article-title>
<source/>FASEB J
          <year>2004</year>
<volume>18</volume>
<fpage>551</fpage>
<lpage>553</lpage>
<pub-id pub-id-type="pmid">14715694</pub-id>
</element-citation>
</ref>
<ref id="R378">
<label>378</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaMontagne</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Littlewood-Evans</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schnell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>O’Reilly</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wyder</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Probst</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liau</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Billy</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Theuer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hla</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization</article-title>
<source/>Cancer Res
          <year>2006</year>
<volume>66</volume>
<fpage>221</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="pmid">16397235</pub-id>
</element-citation>
</ref>
<ref id="R379">
<label>379</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mullershausen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zecri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cetin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Billich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guerini</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Seuwen</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors</article-title>
<source/>Nat Chem Biol
          <year>2009</year>
<volume>5</volume>
<fpage>428</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="pmid">19430484</pub-id>
</element-citation>
</ref>
<ref id="R380">
<label>380</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sykes</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Riddy</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Stamp</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>McGuiness</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sattikar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guerini</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Glaenzel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dowling</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Mullershausen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Charlton</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization</article-title>
<source/>Br J Pharmacol
          <year>2014</year>
<volume>171</volume>
<fpage>4797</fpage>
<lpage>4807</lpage>
<pub-id pub-id-type="pmid">24641481</pub-id>
</element-citation>
</ref>
<ref id="R381">
<label>381</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zollinger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Borell</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zimmerlin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Patten</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis</article-title>
<source/>Drug Metab Dispos
          <year>2011</year>
<volume>39</volume>
<fpage>191</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">21045201</pub-id>
</element-citation>
</ref>
<ref id="R382">
<label>382</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kunikata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nagano</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishioka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Akiyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kurita</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Immunosuppressive action of FTY720 for renal allograft a rat model</article-title>
<source/>Transplant Proc
          <year>1999</year>
<volume>31</volume>
<fpage>1157</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="pmid">10083517</pub-id>
</element-citation>
</ref>
<ref id="R383">
<label>383</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Yokota</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fukai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Magata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Omura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kishida</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model</article-title>
<source/>Transplant Proc
          <year>1999</year>
<volume>31</volume>
<fpage>1208</fpage>
<lpage>1209</lpage>
<pub-id pub-id-type="pmid">10083540</pub-id>
</element-citation>
</ref>
<ref id="R384">
<label>384</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XK</given-names>
</name>
<name>
<surname>Funeshima</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Enosawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amemiya</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kitajima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation</article-title>
<source/>Surgery
          <year>2000</year>
<volume>127</volume>
<fpage>47</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">10660758</pub-id>
</element-citation>
</ref>
<ref id="R385">
<label>385</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Long-term effect of FTY720 on lymphocyte count and islet allograft survival in mice</article-title>
<source/>Microsurgery
          <year>2007</year>
<volume>27</volume>
<fpage>300</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="pmid">17477424</pub-id>
</element-citation>
</ref>
<ref id="R386">
<label>386</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopes</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Palma</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Cury</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice</article-title>
<source/>Transplant Proc
          <year>2008</year>
<volume>40</volume>
<fpage>856</fpage>
<lpage>860</lpage>
<pub-id pub-id-type="pmid">18455036</pub-id>
</element-citation>
</ref>
<ref id="R387">
<label>387</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sensken</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gräler</surname>
<given-names>MH</given-names>
</name>
</person-group>
<article-title>Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy</article-title>
<source/>J Pharmacol Exp Ther
          <year>2009</year>
<volume>328</volume>
<fpage>963</fpage>
<lpage>969</lpage>
<pub-id pub-id-type="pmid">19074680</pub-id>
</element-citation>
</ref>
<ref id="R388">
<label>388</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claes</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dhaeze</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fraussen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Broux</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Van Wijmeersch</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stinissen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hupperts</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hellings</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Somers</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e111115</fpage>
<pub-id pub-id-type="pmid">25360562</pub-id>
</element-citation>
</ref>
<ref id="R389">
<label>389</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaudel</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Frink</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Griensven</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schmiddem</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Probst</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bergmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krettek</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Klempnauer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>FTY720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model</article-title>
<source/>Transplant Proc
          <year>2007</year>
<volume>39</volume>
<fpage>493</fpage>
<lpage>498</lpage>
<pub-id pub-id-type="pmid">17362766</pub-id>
</element-citation>
</ref>
<ref id="R390">
<label>390</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yemisci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Alsharif</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brinkmann</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Waeber</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Fingolimod provides long-term protection in rodent models of cerebral ischemia</article-title>
<source/>Ann Neurol
          <year>2011</year>
<volume>69</volume>
<fpage>119</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="pmid">21280082</pub-id>
</element-citation>
</ref>
<ref id="R391">
<label>391</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foster</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Schweitzer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Persohn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hiestand</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Balatoni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Reuschel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Beerli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Billich</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis</article-title>
<source/>J Pharmacol Exp Ther
          <year>2007</year>
<volume>323</volume>
<fpage>469</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="pmid">17682127</pub-id>
</element-citation>
</ref>
<ref id="R392">
<label>392</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arifuzzaman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>YG</given-names>
</name>
</person-group>
<article-title>FTY720 (fingolimod) regulates key target genes essential for inflammation in microglial cells as defined by high-resolution mRNA sequencing</article-title>
<source/>Neuropharmacology
          <year>2017</year>
<volume>119</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">28373076</pub-id>
</element-citation>
</ref>
<ref id="R393">
<label>393</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>HP</given-names>
</name>
</person-group>
<article-title>Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis</article-title>
<source/>Clin Neuropharmacol
          <year>2010</year>
<volume>33</volume>
<fpage>91</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">20061941</pub-id>
</element-citation>
</ref>
<ref id="R394">
<label>394</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabresi</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Radue</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Goodin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jeffery</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rammohan</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Reder</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Vollmer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Agius</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kappos</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stites</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cappiello</surname>
<given-names>L</given-names>
</name>
<name>
<surname>von Rosenstiel</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial</article-title>
<source/>Lancet Neurol
          <year>2014</year>
<volume>13</volume>
<fpage>545</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="pmid">24685276</pub-id>
</element-citation>
</ref>
<ref id="R395">
<label>395</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khatri</surname>
<given-names>BO</given-names>
</name>
</person-group>
<article-title>Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence</article-title>
<source/>Ther Adv Neurol Disord
          <year>2016</year>
<volume>9</volume>
<fpage>130</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">27006700</pub-id>
</element-citation>
</ref>
<ref id="R396">
<label>396</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nayak</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kwang</surname>
<given-names>WX</given-names>
</name>
<name>
<surname>Pushparaj</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Dheen</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia</article-title>
<source/>Neuroscience
          <year>2010</year>
<volume>166</volume>
<fpage>132</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="pmid">20036321</pub-id>
</element-citation>
</ref>
<ref id="R397">
<label>397</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marfia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Navone</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hadi</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Paroni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Berno</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Beretta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gualtierotti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ingegnoli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Levi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Miozzo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Geginat</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fassina</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rampini</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The adipose mesenchymal stem cell secretome inhibits inflammatory responses of microglia: evidence for an involvement of sphingosine-1-phosphate signalling</article-title>
<source/>Stem Cells Dev
          <year>2016</year>
<volume>25</volume>
<fpage>1095</fpage>
<lpage>1107</lpage>
<pub-id pub-id-type="pmid">27217090</pub-id>
</element-citation>
</ref>
<ref id="R398">
<label>398</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Gaire</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Sapkota</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Identification of sphingosine 1-phosphate receptor subtype 1 (S1P1) as a pathogenic factor in transient focal cerebral ischemia</article-title>
<source/>Mol Neurobiol
          <year>2017</year>
</element-citation>
</ref>
<ref id="R399">
<label>399</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase 1/sphingosine-1-phosphate regulates the expression of interleukin-17A in activated microglia in cerebral ischemia/reperfusion</article-title>
<source/>Inflamm Res
          <year>2016</year>
<volume>65</volume>
<fpage>551</fpage>
<lpage>562</lpage>
<pub-id pub-id-type="pmid">27002656</pub-id>
</element-citation>
</ref>
<ref id="R400">
<label>400</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suzumura</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Fingolimod phosphate promotes the neuroprotective effects of microglia</article-title>
<source/>J Neuroimmunol
          <year>2013</year>
<volume>256</volume>
<fpage>13</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">23290828</pub-id>
</element-citation>
</ref>
<ref id="R401">
<label>401</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cipriani</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chara</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Rodríguez-Antigüedad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Matute</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>FTY720 attenuates excitotoxicity and neuroinflammation</article-title>
<source/>J Neuroinflammation
          <year>2015</year>
<volume>12</volume>
<fpage>86</fpage>
<pub-id pub-id-type="pmid">25953296</pub-id>
</element-citation>
</ref>
<ref id="R402">
<label>402</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Czech</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pfeilschifter</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Mazaheri-Omrani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Strobel</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kahles</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Neumann-Haefelin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rami</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huwiler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pfeilschifter</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia</article-title>
<source/>Biochem Biophys Res Commun
          <year>2009</year>
<volume>389</volume>
<fpage>251</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="pmid">19720050</pub-id>
</element-citation>
</ref>
<ref id="R403">
<label>403</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durafourt</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Blain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bar-Or</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Antel</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Differential responses of human microglia and blood-derived myeloid cells to FTY720</article-title>
<source/>J Neuroimmunol
          <year>2011</year>
<volume>230</volume>
<fpage>10</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">20826007</pub-id>
</element-citation>
</ref>
<ref id="R404">
<label>404</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients</article-title>
<source/>Hum Immunol
          <year>2014</year>
<volume>75</volume>
<fpage>1128</fpage>
<lpage>1137</lpage>
<pub-id pub-id-type="pmid">25305034</pub-id>
</element-citation>
</ref>
<ref id="R405">
<label>405</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wurdinger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Deumelandt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van der Vliet</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Wesseling</surname>
<given-names>P</given-names>
</name>
<name>
<surname>de Gruijl</surname>
<given-names>TD</given-names>
</name>
</person-group>
<article-title>Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle</article-title>
<source/>Biochim Biophys Acta
          <year>2014</year>
<volume>1846</volume>
<fpage>560</fpage>
<lpage>575</lpage>
<pub-id pub-id-type="pmid">25453365</pub-id>
</element-citation>
</ref>
<ref id="R406">
<label>406</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huu</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hamaguchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takehara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fujimoto</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin</article-title>
<source/>Arthritis Rheum
          <year>2013</year>
<volume>65</volume>
<fpage>1624</fpage>
<lpage>1635</lpage>
<pub-id pub-id-type="pmid">23508350</pub-id>
</element-citation>
</ref>
<ref id="R407">
<label>407</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Targeting S1P1 receptor protects against murine immunological hepatic injury through myeloid-derived suppressor cells</article-title>
<source/>J Immunol
          <year>2014</year>
<volume>192</volume>
<fpage>3068</fpage>
<lpage>3079</lpage>
<pub-id pub-id-type="pmid">24567529</pub-id>
</element-citation>
</ref>
<ref id="R408">
<label>408</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation</article-title>
<source/>Oncogene
          <year>2017</year>
<volume>36</volume>
<fpage>3760</fpage>
<lpage>3771</lpage>
<pub-id pub-id-type="pmid">28218904</pub-id>
</element-citation>
</ref>
<ref id="R409">
<label>409</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gargett</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Christo</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Hercus</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Abbas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Singhal</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells <italic>in vitro</italic></article-title>
<source/>Clin Transl Immunology
          <year>2016</year>
<volume>5</volume>
<fpage>e119</fpage>
<pub-id pub-id-type="pmid">28090321</pub-id>
</element-citation>
</ref>
<ref id="R410">
<label>410</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thorn</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guha</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cunetta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Espat</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Junghans</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>SC</given-names>
</name>
</person-group>
<article-title>Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases</article-title>
<source/>Cancer Gene Ther
          <year>2016</year>
<volume>23</volume>
<fpage>188</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">27199222</pub-id>
</element-citation>
</ref>
<ref id="R411">
<label>411</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haebich</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mughal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tofazzal</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis</article-title>
<source/>Clin Exp Dermatol
          <year>2016</year>
<volume>41</volume>
<fpage>433</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="pmid">26577239</pub-id>
</element-citation>
</ref>
<ref id="R412">
<label>412</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tashjian</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Golzy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pouratian</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis</article-title>
<source/>J Clin Neurosci
          <year>2016</year>
<volume>30</volume>
<fpage>166</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="pmid">26970935</pub-id>
</element-citation>
</ref>
<ref id="R413">
<label>413</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shrestha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells</article-title>
<source/>Nat Immunol
          <year>2010</year>
<volume>11</volume>
<fpage>1047</fpage>
<lpage>1056</lpage>
<pub-id pub-id-type="pmid">20852647</pub-id>
</element-citation>
</ref>
<ref id="R414">
<label>414</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Jo</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HK</given-names>
</name>
</person-group>
<article-title>CD4+ CD25+ regulatory T cells partially mediate the beneficial effects of FTY720, a sphingosine-1-phosphate analogue, during ischaemia/reperfusion-induced acute kidney injury</article-title>
<source/>Nephrol Dial Transplant
          <year>2011</year>
<volume>26</volume>
<fpage>111</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="pmid">20702533</pub-id>
</element-citation>
</ref>
<ref id="R415">
<label>415</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The sphingosine-1-phosphate receptor agonist FTY720 and its phosphorylated form affect the function of CD4+CD25+ T cells <italic>in vitro</italic></article-title>
<source/>Int J Mol Med
          <year>2012</year>
<volume>30</volume>
<fpage>211</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="pmid">22576630</pub-id>
</element-citation>
</ref>
<ref id="R416">
<label>416</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Eller</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zeiser</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dürr</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>UV</given-names>
</name>
<name>
<surname>Sixt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Markut</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gastl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rosenkranz</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation <italic>in vitro</italic> and <italic>in vivo</italic></article-title>
<source/>J Immunol
          <year>2009</year>
<volume>183</volume>
<fpage>3751</fpage>
<lpage>3760</lpage>
<pub-id pub-id-type="pmid">19692647</pub-id>
</element-citation>
</ref>
<ref id="R417">
<label>417</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Di J Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>FTY720-induced conversion of conventional Foxp3- CD4+ T cells to Foxp3+ regulatory T cells in NOD mice</article-title>
<source/>Am J Reprod Immunol
          <year>2011</year>
<volume>66</volume>
<fpage>349</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="pmid">21623989</pub-id>
</element-citation>
</ref>
<ref id="R418">
<label>418</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geng</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Induced regulatory T cells superimpose their suppressive capacity with effector T cells in lymph nodes via antigen-specific S1p1-dependent egress blockage</article-title>
<source/>Front Immunol
          <year>2017</year>
<volume>8</volume>
<fpage>663</fpage>
<pub-id pub-id-type="pmid">28638384</pub-id>
</element-citation>
</ref>
<ref id="R419">
<label>419</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Priceman</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kujawski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3</article-title>
<source/>Cell Rep
          <year>2014</year>
<volume>6</volume>
<fpage>992</fpage>
<lpage>999</lpage>
<pub-id pub-id-type="pmid">24630990</pub-id>
</element-citation>
</ref>
<ref id="R420">
<label>420</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathinasamy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Domschke</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Böhm</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Dettling</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lasitschka</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Umansky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gräler</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herold-Mende</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schuetz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Beckhove</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1</article-title>
<source/>Cancer Immunol Immunother
          <year>2017</year>
<volume>66</volume>
<fpage>593</fpage>
<lpage>603</lpage>
<pub-id pub-id-type="pmid">28224210</pub-id>
</element-citation>
</ref>
<ref id="R421">
<label>421</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daniel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sartory</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zahn</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Geisslinger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Radeke</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells</article-title>
<source/>J Immunol
          <year>2007</year>
<volume>178</volume>
<fpage>2458</fpage>
<lpage>2468</lpage>
<pub-id pub-id-type="pmid">17277153</pub-id>
</element-citation>
</ref>
<ref id="R422">
<label>422</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zemann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Urtz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Reuschel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mechtcheriakova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bornancin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Badegruber</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Baumruker</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Billich</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Normal neutrophil functions in sphingosine kinase type 1 and 2 knockout mice</article-title>
<source/>Immunol Lett
          <year>2007</year>
<volume>109</volume>
<fpage>56</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">17292973</pub-id>
</element-citation>
</ref>
<ref id="R423">
<label>423</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cuzzocrea</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sabbadini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Salvemini</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-dependent mechanism</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e55255</fpage>
<pub-id pub-id-type="pmid">23372844</pub-id>
</element-citation>
</ref>
<ref id="R424">
<label>424</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Abeynaike</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Escarbe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Pitson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Hickey</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bonder</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent</article-title>
<source/>Am J Pathol
          <year>2012</year>
<volume>180</volume>
<fpage>1740</fpage>
<lpage>1750</lpage>
<pub-id pub-id-type="pmid">22322303</pub-id>
</element-citation>
</ref>
<ref id="R425">
<label>425</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hakomori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Inhibition of chemotactic motility and trans-endothelial migration of human neutrophils by sphingosine 1-phosphate</article-title>
<source/>FEBS Lett
          <year>1997</year>
<volume>420</volume>
<fpage>196</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">9459309</pub-id>
</element-citation>
</ref>
<ref id="R426">
<label>426</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Parinandi</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Zaiman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Usatyuk</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Natarajan</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>30227</fpage>
<lpage>30235</lpage>
<pub-id pub-id-type="pmid">12039947</pub-id>
</element-citation>
</ref>
<ref id="R427">
<label>427</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Usatyuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Irani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Natarajan</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Involvement of phospholipases D1 and D2 in sphingosine 1-phosphate-induced ERK (extracellular-signal-regulated kinase) activation and interleukin-8 secretion in human bronchial epithelial cells</article-title>
<source/>Biochem J
          <year>2002</year>
<volume>367</volume>
<fpage>751</fpage>
<lpage>760</lpage>
<pub-id pub-id-type="pmid">12149127</pub-id>
</element-citation>
</ref>
<ref id="R428">
<label>428</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Sullivan</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Hirota</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>JG</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate (S1P) induced interleukin-8 (IL-8) release is mediated by S1P receptor 2 and nuclear factor κB in BEAS-2B cells</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e95566</fpage>
<pub-id pub-id-type="pmid">24743449</pub-id>
</element-citation>
</ref>
<ref id="R429">
<label>429</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milara</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mauricio</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Donet</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Morcillo</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Cortijo</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate increases human alveolar epithelial IL-8 secretion, proliferation and neutrophil chemotaxis</article-title>
<source/>Eur J Pharmacol
          <year>2009</year>
<volume>609</volume>
<fpage>132</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="pmid">19285497</pub-id>
</element-citation>
</ref>
<ref id="R430">
<label>430</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Alkhouri</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Ammit</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate induces neutrophil chemoattractant IL-8: repression by steroids</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e92466</fpage>
<pub-id pub-id-type="pmid">24647471</pub-id>
</element-citation>
</ref>
<ref id="R431">
<label>431</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Baudhuin</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Lysophospholipids increase interleukin-8 expression in ovarian cancer cells</article-title>
<source/>Gynecol Oncol
          <year>2001</year>
<volume>81</volume>
<fpage>291</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">11330965</pub-id>
</element-citation>
</ref>
<ref id="R432">
<label>432</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bugl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wirths</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Radsak</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Kopp</surname>
<given-names>HG</given-names>
</name>
</person-group>
<article-title>Current insights into neutrophil homeostasis</article-title>
<source/>Ann N Y Acad Sci
          <year>2012</year>
<volume>1266</volume>
<fpage>171</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="pmid">22901268</pub-id>
</element-citation>
</ref>
<ref id="R433">
<label>433</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacKinnon</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chilvers</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Haslett</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sethi</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase: a point of convergence in the action of diverse neutrophil priming agents</article-title>
<source/>J Immunol
          <year>2002</year>
<volume>169</volume>
<fpage>6394</fpage>
<lpage>6400</lpage>
<pub-id pub-id-type="pmid">12444147</pub-id>
</element-citation>
</ref>
<ref id="R434">
<label>434</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schenten</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Melchior</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Steinckwich</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tschirhart</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Bréchard</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Sphingosine kinases regulate NOX2 activity via p38 MAPK-dependent translocation of S100A8/A9</article-title>
<source/>J Leukoc Biol
          <year>2011</year>
<volume>89</volume>
<fpage>587</fpage>
<lpage>596</lpage>
<pub-id pub-id-type="pmid">21233411</pub-id>
</element-citation>
</ref>
<ref id="R435">
<label>435</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>YS</given-names>
</name>
</person-group>
<article-title>Inhibition of neutrophil apoptosis via sphingolipid signaling in acute lung injury</article-title>
<source/>J Pharmacol Exp Ther
          <year>2011</year>
<volume>339</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">21724966</pub-id>
</element-citation>
</ref>
<ref id="R436">
<label>436</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niwa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kozawa</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Matsuno</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kanamori</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Uematsu</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Tumor necrosis factor-alpha-mediated signal transduction in human neutrophils: involvement of sphingomyelin metabolites in the priming effect of TNF-alpha on the fMLP-stimulated superoxide production</article-title>
<source/>Life Sci
          <year>2000</year>
<volume>66</volume>
<fpage>245</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="pmid">10666000</pub-id>
</element-citation>
</ref>
<ref id="R437">
<label>437</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>The effect of sphingosine 1-phosphate/sphingosine 1-phosphate receptor on neutrophil function and the relevant signaling pathway</article-title>
<source/>Acta Haematol
          <year>2015</year>
<volume>134</volume>
<fpage>49</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">25872153</pub-id>
</element-citation>
</ref>
<ref id="R438">
<label>438</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Florey</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Haskard</surname>
<given-names>DO</given-names>
</name>
</person-group>
<article-title>Sphingosine 1-phosphate enhances Fc gamma receptor-mediated neutrophil activation and recruitment under flow conditions</article-title>
<source/>J Immunol
          <year>2009</year>
<volume>183</volume>
<fpage>2330</fpage>
<lpage>2336</lpage>
<pub-id pub-id-type="pmid">19620297</pub-id>
</element-citation>
</ref>
<ref id="R439">
<label>439</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di A Kawamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>XP</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Berdyshev</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bachmaier</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>A novel function of sphingosine kinase 1 suppression of JNK activity in preventing inflammation and injury</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<fpage>15848</fpage>
<lpage>15857</lpage>
<pub-id pub-id-type="pmid">20299461</pub-id>
</element-citation>
</ref>
<ref id="R440">
<label>440</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schulick</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Edil</surname>
<given-names>B</given-names>
</name>
<name>
<surname>El Kasmi</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Barnett</surname>
<given-names>C</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<source/>Cancer-promoting mechanisms of tumor-associated neutrophils
          <year>2017</year>
<volume>214</volume>
<fpage>938</fpage>
<lpage>944</lpage>
</element-citation>
</ref>
<ref id="R441">
<label>441</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Louis</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reifenberger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>von Deimling</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Figarella-Branger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cavenee</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Ohgaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wiestler</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Kleihues</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ellison</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>The 2016 World Health Organization classification of tumors of the central nervous system: a summary</article-title>
<source/>Acta Neuropathol
          <year>2016</year>
<volume>131</volume>
<fpage>803</fpage>
<lpage>820</lpage>
<pub-id pub-id-type="pmid">27157931</pub-id>
</element-citation>
</ref>
<ref id="R442">
<label>442</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orringer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Khatri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zamora-Berridi</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chaudhary</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sagher</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival</article-title>
<source/>J Neurosurg
          <year>2012</year>
<volume>117</volume>
<fpage>851</fpage>
<lpage>859</lpage>
<pub-id pub-id-type="pmid">22978537</pub-id>
</element-citation>
</ref>
<ref id="R443">
<label>443</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verburg</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hänscheid</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dießl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Israel</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Löhr</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vince</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Flentje</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reiners</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Samnick</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Patients with recurrent glioblastoma multiforme. Initial experience with p-[(131)I]iodo-L-phenylalanine and external beam radiation therapy</article-title>
<source/>Nuklearmedizin
          <year>2013</year>
<volume>52</volume>
<fpage>36</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">23303224</pub-id>
</element-citation>
</ref>
<ref id="R444">
<label>444</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imber</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Kanungo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Braunstein</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barani</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Fogh</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Molinaro</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Cabrera</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Sneed</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Aghi</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Indications and efficacy of gamma knife stereotactic radiosurgery for recurrent glioblastoma: 2 decades of institutional experience</article-title>
<source/>Neurosurgery
          <year>2017</year>
<volume>80</volume>
<fpage>129</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="pmid">27428784</pub-id>
</element-citation>
</ref>
<ref id="R445">
<label>445</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Addeo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Caraglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De Santi</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Montella</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Abbruzzese</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Parlato</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vincenzi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Carraturo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Faiola</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Genovese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cennamo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Del Prete</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma</article-title>
<source/>J Neurooncol
          <year>2011</year>
<volume>102</volume>
<fpage>417</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="pmid">20694830</pub-id>
</element-citation>
</ref>
<ref id="R446">
<label>446</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lombardi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bellu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pambuku</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Della Puppa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fiduccia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Farina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>D’Avella</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zagonel</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study</article-title>
<source/>J Neurooncol
          <year>2016</year>
<volume>128</volume>
<fpage>481</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="pmid">27165580</pub-id>
</element-citation>
</ref>
<ref id="R447">
<label>447</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlsson</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Brothers</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Wahlestedt</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Emerging treatment strategies for glioblastoma multiforme</article-title>
<source/>EMBO Mol Med
          <year>2014</year>
<volume>6</volume>
<fpage>1359</fpage>
<lpage>1370</lpage>
<pub-id pub-id-type="pmid">25312641</pub-id>
</element-citation>
</ref>
<ref id="R448">
<label>448</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Champ</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Volek</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Werner-Wasik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme</article-title>
<source/>J Neurooncol
          <year>2014</year>
<volume>117</volume>
<fpage>125</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="pmid">24442482</pub-id>
</element-citation>
</ref>
<ref id="R449">
<label>449</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maroon</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Seyfried</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Donohue</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bost</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The role of metabolic therapy in treating glioblastoma multiforme</article-title>
<source/>Surg Neurol Int
          <year>2015</year>
<volume>6</volume>
<fpage>61</fpage>
<pub-id pub-id-type="pmid">25949849</pub-id>
</element-citation>
</ref>
<ref id="R450">
<label>450</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martuscello</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Vedam-Mai</surname>
<given-names>V</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Schmoll</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Jundi</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Louviere</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Griffith</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Suslov</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Deleyrolle</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma</article-title>
<source/>Clin Cancer Res
          <year>2016</year>
<volume>22</volume>
<fpage>2482</fpage>
<lpage>2495</lpage>
<pub-id pub-id-type="pmid">26631612</pub-id>
</element-citation>
</ref>
<ref id="R451">
<label>451</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winter</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Loebel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Role of ketogenic metabolic therapy in malignant glioma: a systematic review</article-title>
<source/>Crit Rev Oncol Hematol
          <year>2017</year>
<volume>112</volume>
<fpage>41</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">28325264</pub-id>
</element-citation>
</ref>
<ref id="R452">
<label>452</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phuphanich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Rudnick</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Mazer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nuño</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>CG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma</article-title>
<source/>Cancer Immunol Immunother
          <year>2013</year>
<volume>62</volume>
<fpage>125</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">22847020</pub-id>
</element-citation>
</ref>
<ref id="R453">
<label>453</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akasaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Homma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koido</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ohkusa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Komita</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma</article-title>
<source/>Cancer Immunol Immunother
          <year>2016</year>
<volume>65</volume>
<fpage>1499</fpage>
<lpage>1509</lpage>
<pub-id pub-id-type="pmid">27688162</pub-id>
</element-citation>
</ref>
<ref id="R454">
<label>454</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamran</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Calinescu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Candolfi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chandran</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mineharu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Asad</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Koschmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nunez</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Lowenstein</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>MG</given-names>
</name>
</person-group>
<article-title>Recent advances and future of immunotherapy for glioblastoma</article-title>
<source/>Expert Opin Biol Ther
          <year>2016</year>
<volume>16</volume>
<fpage>1245</fpage>
<lpage>1264</lpage>
<pub-id pub-id-type="pmid">27411023</pub-id>
</element-citation>
</ref>
<ref id="R455">
<label>455</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyon</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Mokarram</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Saxena</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Bellamkonda</surname>
<given-names>RV</given-names>
</name>
</person-group>
<article-title>Engineering challenges for brain tumor immunotherapy</article-title>
<source/>Adv Drug Deliv Rev
          <year>2017</year>
<volume>114</volume>
<fpage>19</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">28625831</pub-id>
</element-citation>
</ref>
<ref id="R456">
<label>456</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ning</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wakimoto</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy</article-title>
<source/>Front Microbiol
          <year>2014</year>
<volume>5</volume>
<fpage>303</fpage>
<pub-id pub-id-type="pmid">24999342</pub-id>
</element-citation>
</ref>
<ref id="R457">
<label>457</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foreman</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Cassady</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Markert</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Oncolytic virotherapy for the treatment of malignant glioma</article-title>
<source/>Neurotherapeutics
          <year>2017</year>
<volume>14</volume>
<fpage>333</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="pmid">28265902</pub-id>
</element-citation>
</ref>
<ref id="R458">
<label>458</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Geletneky</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hajda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Angelova</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Leuchs</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Capper</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bartsch</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Schöning</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hüsing</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beelte</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kiprianova</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Roscher</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial</article-title>
<source/>Mol Ther
          <year>2017</year>
</element-citation>
</ref>
<ref id="R459">
<label>459</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jue</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>KL</given-names>
</name>
</person-group>
<article-title>The challenges associated with molecular targeted therapies for glioblastoma</article-title>
<source/>J Neurooncol
          <year>2016</year>
<volume>127</volume>
<fpage>427</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="pmid">26900075</pub-id>
</element-citation>
</ref>
<ref id="R460">
<label>460</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weathers</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Toward personalized targeted therapeutics: an overview</article-title>
<source/>Neurotherapeutics
          <year>2017</year>
<volume>14</volume>
<fpage>256</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="pmid">27995437</pub-id>
</element-citation>
</ref>
<ref id="R461">
<label>461</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warburg</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wind</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Negelein</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The metabolism of tumors in the body</article-title>
<source/>J Gen Physiol
          <year>1927</year>
<volume>8</volume>
<fpage>519</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="pmid">19872213</pub-id>
</element-citation>
</ref>
<ref id="R462">
<label>462</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warburg</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>On respiratory impairment in cancer cells</article-title>
<source/>Science
          <year>1956</year>
<volume>124</volume>
<fpage>269</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="pmid">13351639</pub-id>
</element-citation>
</ref>
<ref id="R463">
<label>463</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Gout</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?</article-title>
<source/>J Pathol
          <year>2013</year>
<volume>230</volume>
<fpage>350</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="pmid">23729358</pub-id>
</element-citation>
</ref>
<ref id="R464">
<label>464</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seyfried</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Mukherjee</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Targeting energy metabolism in brain cancer: review and hypothesis</article-title>
<source/>Nutr Metab (Lond)
          <year>2005</year>
<volume>2</volume>
<fpage>30</fpage>
<pub-id pub-id-type="pmid">16242042</pub-id>
</element-citation>
</ref>
<ref id="R465">
<label>465</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poon</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis</article-title>
<source/>Brain
          <year>2017</year>
<volume>140</volume>
<fpage>1548</fpage>
<lpage>1560</lpage>
<pub-id pub-id-type="pmid">28334886</pub-id>
</element-citation>
</ref>
<ref id="R466">
<label>466</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batich</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Reap</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Archer</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Sanchez-Perez</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Schmittling</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Norberg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Herndon</surname>
<given-names>JE</given-names>
<suffix>2nd</suffix>
</name>
<name>
<surname>Healy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McLendon</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>HS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination</article-title>
<source/>Clin Cancer Res
          <year>2017</year>
<volume>23</volume>
<fpage>1898</fpage>
<lpage>1909</lpage>
<pub-id pub-id-type="pmid">28411277</pub-id>
</element-citation>
</ref>
<ref id="R467">
<label>467</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stupp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Ostermann Kraljevic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pica</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maillard</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Maeder</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Meuli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Janzer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pizzolato</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Miralbell</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Porchet</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Regli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>de Tribolet</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide</article-title>
<source/>J Clin Oncol
          <year>2002</year>
<volume>20</volume>
<fpage>1375</fpage>
<lpage>1382</lpage>
<pub-id pub-id-type="pmid">11870182</pub-id>
</element-citation>
</ref>
<ref id="R468">
<label>468</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanzetta</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Campanella</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rozzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nappa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fedele</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Innocenzi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gagliardi</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Salvati</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Minniti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Frati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Frati</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vecchione</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial</article-title>
<source/>Anticancer Res
          <year>2003</year>
<volume>23</volume>
<fpage>5159</fpage>
<lpage>5164</lpage>
<pub-id pub-id-type="pmid">14981983</pub-id>
</element-citation>
</ref>
<ref id="R469">
<label>469</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athanassiou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Synodinou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maragoudakis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Paraskevaidis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Verigos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Misailidou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Antonadou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Saris</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Beroukas</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Karageorgis</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme</article-title>
<source/>J Clin Oncol
          <year>2005</year>
<volume>23</volume>
<fpage>2372</fpage>
<lpage>2377</lpage>
<pub-id pub-id-type="pmid">15800329</pub-id>
</element-citation>
</ref>
<ref id="R470">
<label>470</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stupp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>van den Bent</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Weller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Taphoorn</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Belanger</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brandes</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Marosi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bogdahn</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Curschmann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Janzer</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Ludwin</surname>
<given-names>SK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title>
<source/>N Engl J Med
          <year>2005</year>
<volume>352</volume>
<fpage>987</fpage>
<lpage>996</lpage>
<pub-id pub-id-type="pmid">15758009</pub-id>
</element-citation>
</ref>
<ref id="R471">
<label>471</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>dos Santos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Pignon</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Blanchard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lefeuvre</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Touat</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Louvel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dhermain</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Soria</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Deutsch</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Le Teuff</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival</article-title>
<source/>J Neurooncol
          <year>2015</year>
<volume>123</volume>
<fpage>307</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="pmid">25975195</pub-id>
</element-citation>
</ref>
<ref id="R472">
<label>472</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noack</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kopp-Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Régnier-Vigouroux</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy</article-title>
<source/>Cell Death Dis
          <year>2014</year>
<volume>5</volume>
<fpage>e1425</fpage>
<pub-id pub-id-type="pmid">25255218</pub-id>
</element-citation>
</ref>
<ref id="R473">
<label>473</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hadaczek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ozawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Soroceanu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Matlaf</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fiallos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>James</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Cobbs</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Cidofovir: a novel antitumor agent for glioblastoma</article-title>
<source/>Clin Cancer Res
          <year>2013</year>
<volume>19</volume>
<fpage>6473</fpage>
<lpage>6483</lpage>
<pub-id pub-id-type="pmid">24170543</pub-id>
</element-citation>
</ref>
<ref id="R474">
<label>474</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stragliotto</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Survival in patients with glioblastoma receiving valganciclovir</article-title>
<source/>N Engl J Med
          <year>2013</year>
<volume>369</volume>
<fpage>985</fpage>
<lpage>986</lpage>
<pub-id pub-id-type="pmid">24004141</pub-id>
</element-citation>
</ref>
<ref id="R475">
<label>475</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stragliotto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Solberg</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Lilja</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Orrego</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bjurman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tammik</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Skarman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Peredo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study</article-title>
<source/>Int J Cancer
          <year>2013</year>
<volume>133</volume>
<fpage>1204</fpage>
<lpage>1213</lpage>
<pub-id pub-id-type="pmid">23404447</pub-id>
</element-citation>
</ref>
<ref id="R476">
<label>476</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells <italic>in vitro</italic> and <italic>in vivo</italic></article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>32930</fpage>
<lpage>32943</lpage>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/oncotarget.5405">https://doi.org/10.18632/oncotarget.5405</ext-link>
</comment>
<pub-id pub-id-type="pmid">26431379</pub-id>
</element-citation>
</ref>
<ref id="R477">
<label>477</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuessler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme</article-title>
<source/>Front Oncol
          <year>2014</year>
<volume>4</volume>
<fpage>275</fpage>
<pub-id pub-id-type="pmid">25340042</pub-id>
</element-citation>
</ref>
<ref id="R478">
<label>478</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuessler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Beagley</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Rehan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Crough</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dasari</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Smalley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>DG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma</article-title>
<source/>Cancer Res
          <year>2014</year>
<volume>74</volume>
<fpage>3466</fpage>
<lpage>3476</lpage>
<pub-id pub-id-type="pmid">24795429</pub-id>
</element-citation>
</ref>
<ref id="R479">
<label>479</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lloyd</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Bui</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Gillies</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Gatenby</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces</article-title>
<source/>Cancer Res
          <year>2016</year>
<volume>76</volume>
<fpage>3136</fpage>
<lpage>3144</lpage>
<pub-id pub-id-type="pmid">27009166</pub-id>
</element-citation>
</ref>
<ref id="R480">
<label>480</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fine</surname>
<given-names>HA</given-names>
</name>
</person-group>
<article-title>New strategies in glioblastoma: exploiting the new biology</article-title>
<source/>Clin Cancer Res
          <year>2015</year>
<volume>21</volume>
<fpage>1984</fpage>
<lpage>1988</lpage>
<pub-id pub-id-type="pmid">25670220</pub-id>
</element-citation>
</ref>
<ref id="R481">
<label>481</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Medema</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Cancer stem cells--important players in tumor therapy resistance</article-title>
<source/>FEBS J
          <year>2014</year>
<volume>281</volume>
<fpage>4779</fpage>
<lpage>4791</lpage>
<pub-id pub-id-type="pmid">25158828</pub-id>
</element-citation>
</ref>
<ref id="R482">
<label>482</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prichard</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>ER</given-names>
</name>
</person-group>
<article-title>The search for new therapies for human cytomegalovirus infections</article-title>
<source/>Virus Res
          <year>2011</year>
<volume>157</volume>
<fpage>212</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="pmid">21095209</pub-id>
</element-citation>
</ref>
<ref id="R483">
<label>483</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kääriäinen</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Hakkarainen</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Jalkanen</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Petsalo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lehtonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peura</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kurkipuro</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Samaranayake</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ylä-Herttuala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rautio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Forsberg</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma</article-title>
<source/>Drug Metab Dispos
          <year>2015</year>
<volume>43</volume>
<fpage>140</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="pmid">25349125</pub-id>
</element-citation>
</ref>
<ref id="R484">
<label>484</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Peredo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Helldén</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wolmer-Solberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pohanka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stragliotto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rahbar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ståhle</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bellander</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Söderberg-Nauclér</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study</article-title>
<source/>BMJ Case Rep
          <year>2015</year>
</element-citation>
</ref>
<ref id="R485">
<label>485</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tanksley</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Mobley</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Ayers</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Moots</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>Valganciclovir and bevacizumab for recurrent glioblastoma: a single-institution experience</article-title>
<source/>Mol Clin Oncol
          <year>2016</year>
<volume>4</volume>
<fpage>154</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="pmid">26893852</pub-id>
</element-citation>
</ref>
<ref id="R486">
<label>486</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crough</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Beagley</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title><italic>Ex vivo</italic> functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme</article-title>
<source/>Immunol Cell Biol
          <year>2012</year>
<volume>90</volume>
<fpage>872</fpage>
<lpage>880</lpage>
<pub-id pub-id-type="pmid">22508289</pub-id>
</element-citation>
</ref>
<ref id="R487">
<label>487</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghazi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ashoori</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hanley</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Brawley</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Kew</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>SZ</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Grada</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Scheurer</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Bollard</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma</article-title>
<source/>J Immunother
          <year>2012</year>
<volume>35</volume>
<fpage>159</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="pmid">22306904</pub-id>
</element-citation>
</ref>
<ref id="R488">
<label>488</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nair</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>De Leon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Boczkowski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schmittling</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Staats</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Weinhold</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Archer</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells</article-title>
<source/>Clin Cancer Res
          <year>2014</year>
<volume>20</volume>
<fpage>2684</fpage>
<lpage>2694</lpage>
<pub-id pub-id-type="pmid">24658154</pub-id>
</element-citation>
</ref>
<ref id="R489">
<label>489</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlsson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giandomenico</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Totterman</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Essand</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein</article-title>
<source/>J Infect Dis
          <year>2005</year>
<volume>192</volume>
<fpage>1912</fpage>
<lpage>1920</lpage>
<pub-id pub-id-type="pmid">16267762</pub-id>
</element-citation>
</ref>
<ref id="R490">
<label>490</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heine</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grünebach</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Holderried</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Appel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Weck</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Dörfel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sinzger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brossart</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Transfection of dendritic cells with <italic>in vitro</italic>-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses</article-title>
<source/>Mol Ther
          <year>2006</year>
<volume>13</volume>
<fpage>280</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">16219490</pub-id>
</element-citation>
</ref>
<ref id="R491">
<label>491</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moody</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Chiles</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Casibang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moody</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>TP</given-names>
</name>
</person-group>
<article-title>SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells</article-title>
<source/>Peptides
          <year>2001</year>
<volume>22</volume>
<fpage>109</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="pmid">11179604</pub-id>
</element-citation>
</ref>
<ref id="R492">
<label>492</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1</article-title>
<source/>Neuropeptides
          <year>2011</year>
<volume>45</volume>
<fpage>151</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="pmid">21272935</pub-id>
</element-citation>
</ref>
<ref id="R493">
<label>493</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells</article-title>
<source/>Mol Cell Biochem
          <year>2014</year>
<volume>389</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">24357116</pub-id>
</element-citation>
</ref>
<ref id="R494">
<label>494</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>García-Garayoa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Allemann-Tannahill</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bläuenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Willmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carrel-Rémy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tourwé</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iterbeke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Conrath</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schubiger</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title><italic>In vitro</italic> and <italic>in vivo</italic> evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors</article-title>
<source/>Nucl Med Biol
          <year>2001</year>
<volume>28</volume>
<fpage>75</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">11182567</pub-id>
</element-citation>
</ref>
<ref id="R495">
<label>495</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Scheunemann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heichert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mäding</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wittrisch</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kretzschmar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rodig</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tourwé</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iterbeke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chavatte</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zips</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Reubi</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Johannsen</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs</article-title>
<source/>Nucl Med Biol
          <year>2002</year>
<volume>29</volume>
<fpage>61</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">11786277</pub-id>
</element-citation>
</ref>
<ref id="R496">
<label>496</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>García-Garayoa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bläuenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bruehlmeier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Blanc</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iterbeke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Conrath</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tourwé</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schubiger</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc</article-title>
<source/>J Nucl Med
          <year>2002</year>
<volume>43</volume>
<fpage>374</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="pmid">11884498</pub-id>
</element-citation>
</ref>
<ref id="R497">
<label>497</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchegger</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bonvin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kosinski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaffland</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reubi</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Bläuenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tourwé</surname>
<given-names>D</given-names>
</name>
<name>
<surname>García Garayoa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bischof Delaloye</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients</article-title>
<source/>J Nucl Med
          <year>2003</year>
<volume>44</volume>
<fpage>1649</fpage>
<lpage>1654</lpage>
<pub-id pub-id-type="pmid">14530481</pub-id>
</element-citation>
</ref>
<ref id="R498">
<label>498</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>García-Garayoa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bläuenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Blanc</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hohn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tourwé</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schubiger</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors</article-title>
<source/>Nucl Med Biol
          <year>2006</year>
<volume>33</volume>
<fpage>495</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="pmid">16720241</pub-id>
</element-citation>
</ref>
<ref id="R499">
<label>499</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>An</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aruva</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13</article-title>
<source/>Nucl Med Biol
          <year>2006</year>
<volume>33</volume>
<fpage>505</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="pmid">16720242</pub-id>
</element-citation>
</ref>
<ref id="R500">
<label>500</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Visser</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Srinivasan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reubi</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Waser</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Erion</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Krenning</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>de Jong</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2003</year>
<volume>30</volume>
<fpage>1134</fpage>
<lpage>1139</lpage>
<pub-id pub-id-type="pmid">12768332</pub-id>
</element-citation>
</ref>
<ref id="R501">
<label>501</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Synthesis and evaluation of 64Cu-DOTA-NT-Cy5.5 as a dual-modality PET/fluorescence probe to image neurotensin receptor-positive tumor</article-title>
<source/>Mol Pharm
          <year>2015</year>
<volume>12</volume>
<fpage>3054</fpage>
<lpage>3061</lpage>
<pub-id pub-id-type="pmid">26162008</pub-id>
</element-citation>
</ref>
<ref id="R502">
<label>502</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wagh</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Brusnahan</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Garrison</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting</article-title>
<source/>Nucl Med Biol
          <year>2015</year>
<volume>42</volume>
<fpage>816</fpage>
<lpage>823</lpage>
<pub-id pub-id-type="pmid">26302836</pub-id>
</element-citation>
</ref>
<ref id="R503">
<label>503</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunetti</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Falciani</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lelli</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Minervini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ravenni</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Depau</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Siena</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tenori</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Menichetti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bracci</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer</article-title>
<source/>Biomed Res Int
          <year>2015</year>
<volume>2015</volume>
<fpage>173507</fpage>
<pub-id pub-id-type="pmid">25984525</pub-id>
</element-citation>
</ref>
<ref id="R504">
<label>504</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falciani</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fabbrini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lozzi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lelli</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pileri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brunetti</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bindi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scali</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bracci</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting</article-title>
<source/>Mol Cancer Ther
          <year>2007</year>
<volume>6</volume>
<fpage>2441</fpage>
<lpage>2448</lpage>
<pub-id pub-id-type="pmid">17766836</pub-id>
</element-citation>
</ref>
<ref id="R505">
<label>505</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navarro-Quiroga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Antonio González-Barrios</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Barron-Moreno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>González-Bernal</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Martinez-Arguelles</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Martinez-Fong</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Improved neurotensin-vector-mediated gene transfer by the coupling of hemagglutinin HA2 fusogenic peptide and Vp1 SV40 nuclear localization signal</article-title>
<source/>Brain Res Mol Brain Res
          <year>2002</year>
<volume>105</volume>
<fpage>86</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">12399111</pub-id>
</element-citation>
</ref>
<ref id="R506">
<label>506</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arango-Rodriguez</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Navarro-Quiroga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gonzalez-Barrios</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Martinez-Arguelles</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Bannon</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Kouri</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Forgez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rostene</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Garcia-Villegas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Martinez-Fong</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Biophysical characteristics of neurotensin polyplex for <italic>in vitro</italic> and <italic>in vivo</italic> gene transfection</article-title>
<source/>Biochim Biophys Acta
          <year>2006</year>
<volume>1760</volume>
<fpage>1009</fpage>
<lpage>1020</lpage>
<pub-id pub-id-type="pmid">16730907</pub-id>
</element-citation>
</ref>
<ref id="R507">
<label>507</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubio-Zapata</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Rembao-Bojorquez</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Arango-Rodriguez</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Dupouy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Forgez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Martinez-Fong</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>NT-polyplex: a new tool for therapeutic gene delivery to neuroblastoma tumors</article-title>
<source/>Cancer Gene Ther
          <year>2009</year>
<volume>16</volume>
<fpage>573</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="pmid">19180142</pub-id>
</element-citation>
</ref>
<ref id="R508">
<label>508</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demeule</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Régina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>É</surname>
<given-names>Besserer-Offroy</given-names>
</name>
<name>
<surname>Murza</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tétreault</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Belleville</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ché</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Larocque</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thiot</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Béliveau</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Longpré</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>É</surname>
<given-names>Marsault</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties</article-title>
<source/>J Clin Invest
          <year>2014</year>
<volume>124</volume>
<fpage>1199</fpage>
<lpage>1213</lpage>
<pub-id pub-id-type="pmid">24531547</pub-id>
</element-citation>
</ref>
<ref id="R509">
<label>509</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leten</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Struys</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dresselaers</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Himmelreich</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title><italic>In vivo</italic> and <italic>ex vivo</italic> assessment of the blood brain barrier integrity in different glioblastoma animal models</article-title>
<source/>J Neurooncol
          <year>2014</year>
<volume>119</volume>
<fpage>297</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="pmid">24990826</pub-id>
</element-citation>
</ref>
<ref id="R510">
<label>510</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Tellingen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Yetkin-Arik</surname>
<given-names>B</given-names>
</name>
<name>
<surname>de Gooijer</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Wesseling</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wurdinger</surname>
<given-names>T</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>HE</given-names>
</name>
</person-group>
<article-title>Overcoming the blood-brain tumor barrier for effective glioblastoma treatment</article-title>
<source/>Drug Resist Updat
          <year>2015</year>
<volume>19</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">25791797</pub-id>
</element-citation>
</ref>
<ref id="R511">
<label>511</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oberoi</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Parrish</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Sio</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Mittapalli</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Elmquist</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Sarkaria</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma</article-title>
<source/>Neuro Oncol
          <year>2016</year>
<volume>18</volume>
<fpage>27</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="pmid">26359209</pub-id>
</element-citation>
</ref>
<ref id="R512">
<label>512</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>XB</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>XR</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>FY</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy</article-title>
<source/>Cancer Sci
          <year>2014</year>
<volume>105</volume>
<fpage>176</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="pmid">24383865</pub-id>
</element-citation>
</ref>
<ref id="R513">
<label>513</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>A sphingosine kinase-1 inhibitor, SKI-II, induces growth inhibition and apoptosis in human gastric cancer cells</article-title>
<source/>Asian Pac J Cancer Prev
          <year>2014</year>
<volume>15</volume>
<fpage>10381</fpage>
<lpage>10385</lpage>
<pub-id pub-id-type="pmid">25556479</pub-id>
</element-citation>
</ref>
<ref id="R514">
<label>514</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>ZX</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>WF</given-names>
</name>
</person-group>
<article-title>SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth <italic>in vitro</italic> and <italic>in vivo</italic></article-title>
<source/>Biochem Biophys Res Commun
          <year>2015</year>
<volume>460</volume>
<fpage>903</fpage>
<lpage>908</lpage>
<pub-id pub-id-type="pmid">25824043</pub-id>
</element-citation>
</ref>
<ref id="R515">
<label>515</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>ZY</given-names>
</name>
</person-group>
<article-title>Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543</article-title>
<source/>Biochem Biophys Res Commun
          <year>2016</year>
<volume>470</volume>
<fpage>728</fpage>
<lpage>734</lpage>
<pub-id pub-id-type="pmid">26775841</pub-id>
</element-citation>
</ref>
<ref id="R516">
<label>516</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>CX</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>He</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>RG</given-names>
</name>
</person-group>
<article-title>SphK1 inhibitor SKI II inhibits the proliferation of human hepatoma HepG2 cells via the Wnt5A/β-catenin signaling pathway</article-title>
<source/>Life Sci
          <year>2016</year>
<volume>151</volume>
<fpage>23</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">26944438</pub-id>
</element-citation>
</ref>
<ref id="R517">
<label>517</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hengst</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sk</surname>
<given-names>UH</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Development of a sphingosine kinase 1 specific small-molecule inhibitor</article-title>
<source/>Bioorg Med Chem Lett
          <year>2010</year>
<volume>20</volume>
<fpage>7498</fpage>
<lpage>7502</lpage>
<pub-id pub-id-type="pmid">21050755</pub-id>
</element-citation>
</ref>
<ref id="R518">
<label>518</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pyne</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bittman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pyne</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules</article-title>
<source/>Cancer Res
          <year>2011</year>
<volume>71</volume>
<fpage>6576</fpage>
<lpage>6582</lpage>
<pub-id pub-id-type="pmid">21940750</pub-id>
</element-citation>
</ref>
<ref id="R519">
<label>519</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickson</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Carvajal</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Merrill</surname>
<given-names>AH</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Gonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cane</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>GK</given-names>
</name>
</person-group>
<article-title>A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors</article-title>
<source/>Clin Cancer Res
          <year>2011</year>
<volume>17</volume>
<fpage>2484</fpage>
<lpage>2492</lpage>
<pub-id pub-id-type="pmid">21257722</pub-id>
</element-citation>
</ref>
<ref id="R520">
<label>520</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>ZX</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>FTY720 for cancer therapy (Review)</article-title>
<source/>Oncol Rep
          <year>2013</year>
<volume>30</volume>
<fpage>2571</fpage>
<lpage>2578</lpage>
<pub-id pub-id-type="pmid">24100923</pub-id>
</element-citation>
</ref>
<ref id="R521">
<label>521</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonoda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aizu-Yokota</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Momoi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kasahara</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells</article-title>
<source/>Biochem Biophys Res Commun
          <year>2001</year>
<volume>281</volume>
<fpage>282</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">11181042</pub-id>
</element-citation>
</ref>
<ref id="R522">
<label>522</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estrada-Bernal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Palanichamy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ray Chaudhury</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Van Brocklyn</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma</article-title>
<source/>Neuro Oncol
          <year>2012</year>
<volume>14</volume>
<fpage>405</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="pmid">22351749</pub-id>
</element-citation>
</ref>
<ref id="R523">
<label>523</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway</article-title>
<source/>Tumour Biol
          <year>2014</year>
<volume>35</volume>
<fpage>10707</fpage>
<lpage>10714</lpage>
<pub-id pub-id-type="pmid">25070489</pub-id>
</element-citation>
</ref>
<ref id="R524">
<label>524</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells</article-title>
<source/>Toxicol Lett
          <year>2015</year>
<volume>236</volume>
<fpage>43</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">25939952</pub-id>
</element-citation>
</ref>
<ref id="R525">
<label>525</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sordillo</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Sordillo</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Helson</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Sphingosine kinase inhibitors as maintenance therapy of glioblastoma after ceramide-induced response</article-title>
<source/>Anticancer Res
          <year>2016</year>
<volume>36</volume>
<fpage>2085</fpage>
<lpage>2095</lpage>
<pub-id pub-id-type="pmid">27127108</pub-id>
</element-citation>
</ref>
<ref id="R526">
<label>526</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montgomery</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Queiroz Lde</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rogerio</surname>
<given-names>F. EGFR</given-names>
</name>
</person-group>
<article-title>p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation</article-title>
<source/>Arq Neuropsiquiatr
          <year>2015</year>
<volume>73</volume>
<fpage>561</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="pmid">26200049</pub-id>
</element-citation>
</ref>
<ref id="R527">
<label>527</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmid</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guba</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ischenko</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Papyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Joka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schrepfer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bruns</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Jauch</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Graeb</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1</article-title>
<source/>J Cell Biochem
          <year>2007</year>
<volume>101</volume>
<fpage>259</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="pmid">17203465</pub-id>
</element-citation>
</ref>
<ref id="R528">
<label>528</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walter</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Rochwalsky</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Reinhold</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Seeger</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Aicher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Urbich</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Spyridopoulos</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brinkmann</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Keul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Levkau</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zeiher</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Dimmeler</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2007</year>
<volume>27</volume>
<fpage>275</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="pmid">17158356</pub-id>
</element-citation>
</ref>
<ref id="R529">
<label>529</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryser</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Ugarte</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bornhäuser</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34+ hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and <italic>in vivo</italic> homing</article-title>
<source/>Mol Immunol
          <year>2008</year>
<volume>46</volume>
<fpage>166</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="pmid">18760838</pub-id>
</element-citation>
</ref>
<ref id="R530">
<label>530</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mierzejewska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Klyachkin</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Ratajczak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abdel-Latif</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kucia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ratajczak</surname>
<given-names>MZ</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate-mediated mobilization of hematopoietic stem/progenitor cells during intravascular hemolysis requires attenuation of SDF-1-CXCR4 retention signaling in bone marrow</article-title>
<source/>Biomed Res Int
          <year>2013</year>
<volume>2013</volume>
<fpage>814549</fpage>
<pub-id pub-id-type="pmid">24490172</pub-id>
</element-citation>
</ref>
<ref id="R531">
<label>531</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma</article-title>
<source/>Mol Cancer Ther
          <year>2005</year>
<volume>4</volume>
<fpage>1430</fpage>
<lpage>1438</lpage>
<pub-id pub-id-type="pmid">16170036</pub-id>
</element-citation>
</ref>
<ref id="R532">
<label>532</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kennedy</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tomsig</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Mathews</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>David</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peyruchaud</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>KR</given-names>
</name>
</person-group>
<article-title>Characterization of a sphingosine 1-phosphate receptor antagonist prodrug</article-title>
<source/>J Pharmacol Exp Ther
          <year>2011</year>
<volume>338</volume>
<fpage>879</fpage>
<lpage>889</lpage>
<pub-id pub-id-type="pmid">21632869</pub-id>
</element-citation>
</ref>
<ref id="R533">
<label>533</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watters</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Sung</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Loughran</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Targeting sphingosine-1-phosphate receptors in cancer</article-title>
<source/>Anticancer Agents Med Chem
          <year>2011</year>
<volume>11</volume>
<fpage>810</fpage>
<lpage>817</lpage>
<pub-id pub-id-type="pmid">21707490</pub-id>
</element-citation>
</ref>
<ref id="R534">
<label>534</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Brien</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Visentin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gentile</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vekich</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shestowsky</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hiraiwa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matteo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cavalli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grotjahn</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies</article-title>
<source/>J Lipid Res
          <year>2009</year>
<volume>50</volume>
<fpage>2245</fpage>
<lpage>2257</lpage>
<pub-id pub-id-type="pmid">19509417</pub-id>
</element-citation>
</ref>
<ref id="R535">
<label>535</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabbadini</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration</article-title>
<source/>Br J Pharmacol
          <year>2011</year>
<volume>162</volume>
<fpage>1225</fpage>
<lpage>1238</lpage>
<pub-id pub-id-type="pmid">21091645</pub-id>
</element-citation>
</ref>
<ref id="R536">
<label>536</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Bullock</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Callea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Visentin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Deutschman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Alsop</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Atkins</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Mier</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Signoretti</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer</article-title>
<source/>Clin Cancer Res
          <year>2015</year>
<volume>21</volume>
<fpage>1925</fpage>
<lpage>1934</lpage>
<pub-id pub-id-type="pmid">25589614</pub-id>
</element-citation>
</ref>
<ref id="R537">
<label>537</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pal</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Drabkin</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hainsworth</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Hazel</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Paggiarino</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Wojciak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Woodnutt</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bhatt</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma</article-title>
<source/>Cancer
          <year>2017</year>
<volume>123</volume>
<fpage>576</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="pmid">27727447</pub-id>
</element-citation>
</ref>
<ref id="R538">
<label>538</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Heese</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Nikas</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Bello</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kraeft</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Seyfried</surname>
<given-names>NT</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Expression of cyclooxygenase 2 (COX-2) in human glioma and <italic>in vitro</italic> inhibition by a specific COX-2 inhibitor, NS-398</article-title>
<source/>Cancer Res
          <year>2000</year>
<volume>60</volume>
<fpage>4926</fpage>
<lpage>4931</lpage>
<pub-id pub-id-type="pmid">10987308</pub-id>
</element-citation>
</ref>
<ref id="R539">
<label>539</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>LZ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>RZ</given-names>
</name>
</person-group>
<article-title>Effect of celecoxib on proliferation, apoptosis, and survivin expression in human glioma cell line U251</article-title>
<source/>Chin J Cancer
          <year>2010</year>
<volume>29</volume>
<fpage>294</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="pmid">20193113</pub-id>
</element-citation>
</ref>
<ref id="R540">
<label>540</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kohanbash</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fellows-Mayle</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Komohara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Decker</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Ohlfest</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells</article-title>
<source/>Cancer Res
          <year>2011</year>
<volume>71</volume>
<fpage>2664</fpage>
<lpage>2674</lpage>
<pub-id pub-id-type="pmid">21324923</pub-id>
</element-citation>
</ref>
<ref id="R541">
<label>541</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braganhol</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tamajusuku</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wink</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Battastini</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Ecto-5’-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line</article-title>
<source/>Biochim Biophys Acta
          <year>2007</year>
<volume>1770</volume>
<fpage>1352</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="pmid">17643826</pub-id>
</element-citation>
</ref>
<ref id="R542">
<label>542</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bavaresco</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Braganhol</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cappellari</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Rockenbach</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Farias</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Wink</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Delgado-Cañedo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Battastini</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>The role of ecto-5’-nucleotidase/CD73 in glioma cell line proliferation</article-title>
<source/>Mol Cell Biochem
          <year>2008</year>
<volume>319</volume>
<fpage>61</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">18636315</pub-id>
</element-citation>
</ref>
<ref id="R543">
<label>543</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>QQ</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>QB</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XG</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas</article-title>
<source/>Neuro Oncol
          <year>2013</year>
<volume>15</volume>
<fpage>1160</fpage>
<lpage>1172</lpage>
<pub-id pub-id-type="pmid">23737488</pub-id>
</element-citation>
</ref>
<ref id="R544">
<label>544</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blacher</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ben Baruch</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Geva</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Garneau-Tsodikova</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fridman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Inhibition of glioma progression by a newly discovered CD38 inhibitor</article-title>
<source/>Int J Cancer
          <year>2015</year>
<volume>136</volume>
<fpage>1422</fpage>
<lpage>1433</lpage>
<pub-id pub-id-type="pmid">25053177</pub-id>
</element-citation>
</ref>
<ref id="R545">
<label>545</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Szep</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Garzuly</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Post</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Epidermal growth factor receptor as a therapeutic target in glioblastoma</article-title>
<source/>Neuromolecular Med
          <year>2013</year>
<volume>15</volume>
<fpage>420</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="pmid">23575987</pub-id>
</element-citation>
</ref>
<ref id="R546">
<label>546</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padfield</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Kurian</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma</article-title>
<source/>Front Oncol
          <year>2015</year>
<volume>5</volume>
<fpage>5</fpage>
<pub-id pub-id-type="pmid">25688333</pub-id>
</element-citation>
</ref>
<ref id="R547">
<label>547</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sepúlveda-Sánchez</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>MÁ</surname>
<given-names>Vaz</given-names>
</name>
<name>
<surname>Balañá</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gil-Gil</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reynés</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ó</surname>
<given-names>Gallego</given-names>
</name>
<name>
<surname>Martínez-García</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vicente</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Quindós</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Luque</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ruano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pérez-Segura</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phase II trial of dacomitinib, a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification</article-title>
<source/>Neuro Oncol
          <year>2017</year>
<volume>19</volume>
<fpage>1522</fpage>
<lpage>1531</lpage>
<pub-id pub-id-type="pmid">28575464</pub-id>
</element-citation>
</ref>
<ref id="R548">
<label>548</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Rho</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Seol</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<fpage>e103327</fpage>
<pub-id pub-id-type="pmid">25084005</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>